Pd-catalysed synthesis of functionalised adenosine analogues and their characterisation as base-discriminating fluorescent probes by De Ornellas, Sara
  
Pd-catalysed synthesis of functionalised 
adenosine analogues and their 
characterisation as base-discriminating 
fluorescent probes 
 
 
Sara De Ornellas 
 
PhD Thesis 
 
 
Department of Chemistry 
University of York 
 
September 2012 
 ii 
 
Abstract 
 
A novel class of 7-modified 7-deazaadenosine nucleosides has been synthesised containing 
diarylacetylene groups at C7.  Diarylacetylene boronate esters were synthesised by 
chemoselective Sonogashira cross-coupling.  The boronate esters were then coupled to 7-
iodo-7-deazaadenine nucleosides using aqueous Suzuki-Miyaura cross-coupling in good to 
excellent yields (68%->99%).  The modified nucleosides showed very promising UV-vis 
absorption and fluorescence emission properties in DMSO, with high quantum yields and 
UV absorbance maxima bathochromically shifted with respect to intrinsic biomolecular 
absorption bands.  In water, the parent compound 20a had a decreased quantum yield 
(0.15) and the absorbance maximum occurred at a lower wavelength (302 nm).  The 
protected phosphoramidite of 20a was synthesised, and the fluorescent nucleoside was 
incorporated at a central position in a series of 13-base deoxyoligonucleotides, covering a 
range of neighbouring DNA sequence contexts.  The oligonucleotides had absorbance 
maxima similar to the nucleoside in DMSO (ca. 322 nm), and quantum yields comparable to 
the nucleoside in water (0.024-0.237).  Melting curve analysis of the oligonucleotide 
duplexes showed some destabilisation due to the fluorescent substituent, but less than 
expected for a completely mismatched base pair.  Circular dichroism spectra highlighted 
the range of ordered, helix-like structures present in the single-strand oligonucleotides, and 
confirmed that the duplexes formed a B-type DNA helix.  An investigation of base-pair 
mismatch discrimination showed a clear fluorescence quenching effect for c7A∙C mismatch 
pairs.  Other mismatches did not show discriminatory fluorescence quenching or 
enhancement.  Investigation of the pH dependence of the oligonucleotide fluorescence 
emission showed high sensitivity to changes in pH, with acidic conditions causing significant 
quenching.  The evidence strongly suggests that mismatched base-pair discrimination is 
due to formation of a protonated wobble pairing between the 7-deazaadenosine and 
cytidine, as previously proposed by Seela and co-workers.  This base-pair mismatch causes 
an increase in the pKa of the 7-deazaadenosine heterocycle, so the mismatch acts as a 
template for protonation.  Potential applications for the 7-modified 7-deazaadenosine 
nucleoside analogues are discussed. 
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 1 
 
1 Introduction 
 
1.1 Nucleic acids 
 
Since the 1940s it has been thought that DNA (deoxyribonucleic acid) was the carrier of 
genetic information.  However, it was not until the structure of DNA was determined by 
Watson and Crick in 1953 that its role and mechanism began to be understood.1  DNA is a 
macromolecule consisting of polymerised nucleotides.  Nucleotides consist of a nitrogen 
heterocycle (the nucleobase), a deoxyribose sugar moiety and a phosphate, and the 
structure of DNA is a sequence of nucleobases joined by a sugar-phosphate backbone.  
Each DNA macromolecule is paired by hydrogen bonding (through the nucleobases) with a 
complementary strand, and the two strands run in opposite directions around a central axis 
to form a double helix (Figure 1.1).  There are actually two types of nucleic acids found in 
cells; DNA and RNA.  DNA differs from RNA in that the ribose sugar contains one less 
hydroxyl, and DNA is double stranded, whereas RNA usually consists of a single strand.  In 
organisms DNA is the storage form of the genetic code, while the transcription of DNA into 
RNA is required for translation of the genetic code into protein.2,3   
 
Figure 1.1 Structure of DNA double helix.3 
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DNA and RNA each consist of four nucleotides which differ in their nucleobases, three of 
which are found in both nucleic acids, and one of which is different.  The nucleobases can 
be either purine or pyrimidine heterocycles, and in each case a purine base forms a 
complementary pairing with a pyrimidine base.  DNA generally contains the bases adenine 
(A), guanine (G), cytosine (C) and thymine (T), whilst in RNA the thymine base is replaced by 
uracil (U), although other more unusual bases are also found in nature, e.g. in transfer RNA.  
There is specificity in the base pairing (termed Watson-Crick base pairing); adenine pairs 
with thymine and guanine with cytosine in DNA, with uracil replacing thymine and pairing 
with adenine in RNA.  The base pairs are formed by hydrogen bonding; the A∙T/U base-pair 
has two hydrogen bonds and the G∙C base-pair has three hydrogen bonds.  The sequence of 
bases carries the genetic information, and this precise base pairing is crucial to DNA 
replication, DNA transcription and RNA translation into protein.  Nucleobases joined via a 
glycosidic bond to a ribose or deoxyribose sugar are referred to as nucleosides, whilst 
nucleotides are nucleosides which have been phosphorylated with one or more phosphate 
esters at the 5′-hydroxyl (Figure 1.2).  
 
Figure 1.2 Structure of nucleobases, nucleosides and nucleotides. 
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1.1.1 Nucleic acid secondary structure 
 
Nucleic acids can adopt a variety of helical structures.  The most common structure 
associated with DNA is the B-type double helix, which is shown above.  In this structure, the 
antiparallel strands form a right-handed helix where the stacked base-pairs lie 
perpendicular to the axis of the helix.  The A-type double helix is also a right handed helix, 
but differs in the geometry of the bases and the conformation of the sugars.  In A-type 
structures, the base-pairs are tilted with respect to the helical axis, and the helix is wider 
and shorter.  A-type helices bind less water than B-type structures, so can be observed 
crystallographically in dehydrated nucleic acids.  RNA double helices do not generally form 
B-type structures due to steric clashes between the C2′-OH and the closest phosphate 
group, so double-stranded RNA tends to adopt an A-type structure, where the change in 
sugar conformation means the C2′-OH projects outwards.  A third (and less common) 
biologically relevant structure is the Z-type helix.  Unlike A- and B-type nucleic acids, Z-type 
structures are left-handed helices.  Z-type structures are generally formed by duplexes of 
alternating guanosines and cytidines.  The nucleotide conformations are also very different 
from A- and B-type structures; rather than all the nucleotides adopting the anti 
conformation, the nucleotides alternate between anti and syn, with the purines generally 
adopting the syn conformation (Figure 1.1).  The key features of these nucleic acid 
structures are summarised in Table 1.1. 
 
 
Figure 1.3 Anti/syn nucleoside equilibrium, which defines the position of the purine relative to the sugar ring 
system. 
 
 
Figure 1.4 C2′-endo/C3′-endo sugar pucker equilibrium. 
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 Table 1.1 Key structural features of common nucleic acid secondary structures. 
 Helix structure 
 A B Z 
Helix sense Right-handed Right-handed Left-handed 
Glycosyl bond anti anti Alternating syn and 
anti 
Rise per base pair /Å 2.3 3.4 3.8 
Base-pair tilt with 
respect to helix axis 
19° 1° 9° 
Sugar pucker C3′-endo (N) C2′-endo (S) Alternating C2′-endo 
and C3′-endo 
 
The factors which affect the nucleic acid secondary structure formed are diverse.  As 
previously mentioned, hydration of the helix can play an important role, as can the 
sequence of nucleotides.  The environment of the nucleic acid is also key: high salt 
environments stabilise B-type structures, while addition of less polar solvents such as 
ethanol or trifluoroethanol can cause transition to A-type structures in which the 
hydrophobic nucleobases are more exposed.  The conformation of the sugar is also very 
important (Figure 1.4), as well as steric accommodation of any structural modifications. 
Other base-pairing modes are also known, which give rise to more varied secondary and 
tertiary structures.4  These non-Watson-Crick base-pairs are most commonly observed in 
RNA structures.  Hoogsteen base-pairs are formed along the major groove edge of nucleic 
acid duplexes, and do not interfere with normal Watson-Crick base-pairs (Figure 1.5).  This 
means that where both Watson-Crick and Hoogsteen base-pairs are present, RNA triplex 
structures can be formed.  In some cases, such as shown in the C∙G*A+ structure in Figure 
1.5, the nucleobase must be protonated in order to form a Hoogsteen base-pair. 
 
Figure 1.5 Examples of Hoogsteen base-pairing. 
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1.2 Modified nucleosides and nucleotides 
 
Modified nucleosides have been the subject of much research due to the wide range of 
biological activity observed in many derivatives.5  Analogues of the naturally occurring 
nucleosides, in particular sugar-modified nucleosides, have been developed for medicinal 
purposes.6  They have been widely used as antiviral agents, for example as treatment 
against HIV (Zidovudine and Stavudine) and herpes virus (Acyclovir and Famciclovir) (Figure 
1.6).7  Nucleoside analogues have also been used in the treatment of some cancers.6 
 
 
Figure 1.6 Examples of modified nucleosides used as antiviral drugs. 
 
1.2.1 Fluorescence labelling for biochemical applications 
 
Nucleosides and nucleotides can be chemically-modified so that they can be used as probes 
of biological systems.  A variety of spectroscopic labels are commonly used to study 
biological systems, depending on the specific requirements of the system being 
investigated and the information required.  These include spin-labelling (NMR8 and EPR9), 
radiolabelling,10 electrochemical-labelling11 and fluorescence-labelling.12,13  Fluorescence-
labelling is probably the most widely used, as it is a safe and extremely versatile technique.  
Fluorescence spectroscopy can be applied to a number of different techniques to 
determine both structural and dynamic information about a biological system.  Both 
ensemble and single-molecule fluorescence techniques can be used.  Ensemble methods 
look at fluorescence signals averaged over a large population of molecules.  One of the 
great advantages of fluorescence spectroscopy is its high sensitivity, allowing for the 
detection of a single fluorophore with appropriate excitation and detection methods.  
Advanced techniques such as FRET (Förster Resonance Energy Transfer) are powerful tools 
 6 
 
for investigating 3D structure and molecular dynamics.14  FRET is where the emitted photon 
of one fluorophore (the donor) is absorbed by a second fluorophore (the acceptor), giving 
information about the relative distance of the fluorophores. 
Another valuable property of many fluorophores is the dependence of their fluorescence 
emission on their chemical environment.  Environmental sensitivity is usually dependent on 
the polarity or pH of the location of the fluorophore – for example, a nucleic acid labelled 
with an environmentally sensitive fluorophore will show different fluorescent emission 
depending whether or not it is bound to a protein.  In this way, fluorophore-labelled 
biomolecules are powerful tools for biochemical analysis. 
 
1.2.2 Fluorescent nucleotides 
 
It is generally desirable that the functionalised-nucleotides exhibit the same biological 
properties as the natural compounds.13  This usually includes base-pairing and duplex 
stability, but is dependent on the desired application.  The fluorescent properties of the 
modified nucleotide are also important – the introduced fluorophore must absorb light at 
wavelengths shifted away from the background absorbances of nucleic acids (260 nm) and 
proteins (280 nm).  It is also important that the emission spectra be distinct from the 
intrinsic fluorescence emission of tryptophan in proteins (300-350 nm).  Another 
consideration when choosing a fluorescent label is the linker which attaches it to the 
substrate.  Fluorophores may be directly attached to nucleotides, or linkers (usually alkyl 
chains) can be used.  The length and nature of the linker can significantly affect how 
sensitive the probe is to changes in the environment of the nucleotide.  
Modifications can be made at almost every position, but can be divided into three main 
categories: base-modified, sugar-modified and phosphate-modified (Figure 1.7).15,16   
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Figure 1.7 Possible positions for structural modification of nucleotides.* 
 
Nucleosides and nucleotides can be labelled at either the 2′- or 3′-OH on the sugar, coupled 
directly or through a linker.  These compounds are useful for studying systems where the 
nucleotide can bind even with large groups on the sugar moiety (for example, where the 
NTP interacts with proteins through the base, and the sugar points away from the binding 
site).17  Modifications at the 3′-OH are not suitable for incorporation into nucleic acids, as 
the nucleotide is linked to its adjacent nucleotide through the 3′-O position (Figure 1.8).  As 
deoxyribonucleotides do not contain a 2′-hydroxyl, modifications cannot be made directly 
at this position in DNA systems.  It is also important to ensure that modifications at the 2′-H 
or 2′-OH position do not interfere with the conformation of the ribose 5-membered ring.  
The sugar conformation determines the secondary structure of the nucleic acid, and 
substitutions at this position can influence the ratio of conformations both sterically and 
electronically.18  
 
 
Figure 1.8 Examples of commercially available sugar-modified fluorescent ATP analogues.16 
 
                                                          
* Purine numbering used throughout main text. 
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Phosphate-modified nucleotides have also been used extensively, particularly for single-
molecule DNA sequencing,19 and can be functionalised in a similar manner (Figure 1.9).  
However, as γ-phosphate labels are cleaved upon nucleotide incorporation into 
oligonucleotides, they are less suitable for studying nucleic acids. 
 
Figure 1.9 Examples of commercially available phosphate-modified fluorescent ATP analogues.16 
 
Many base-modified fluorescent nucleotides are also known, and many are commercially 
available.  Generally, the disadvantage of this strategy is the possible interference with 
Watson-Crick base-pairing.  For adenine nucleotides, there are three main positions for 
attachment of a fluorophore.  Labels can be introduced on the C2 position of the 
nucleobase, however this will interfere with the Watson-Crick edge.  There are many 
applications where this is not problematic; however these modified nucleotides are not 
suitable for studying DNA duplexes or many RNA systems with secondary structures based 
on Watson-Crick base-pairing.  Labels can also been introduced by substitution at the 
exocyclic amine.  Even labels with long linker groups at this position can influence the 
Watson-Crick base-pair by altering the electronic properties of the amine proton.  Other 
modifications at this position can block the Watson-Crick base-pairing face altogether, or 
reduce base-pairing specificity (Figure 1.10).   
 9 
 
 
Figure 1.10 Examples of commercially available base-modified fluorescent ATP analogues.16 
 
Therefore, an advantageous position for labelling purine nucleotides is at the 8-position, 
which is removed from the Watson-Crick base-pairing edge; many 8-modified purine 
nucleosides are also known.  However, there is also a major disadvantage to modification 
at this position.  Large groups at C8 (for example phenyl or phenylethynyl, see Section 1.4) 
cause a switch from the sugar being predominantly in the anti-position, to almost 
exclusively in the syn-conformation.20  This switch is accompanied by a change in the ratio 
of 2′-endo (S) to 3′-endo (N), favouring the 2′-endo conformation (Figure 1.11). 
 
 
Figure 1.11 Conformational changes which are induced by substitution at C8 of adenosine. 
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1.2.3 7-Deazapurine nucleosides 
 
The conformational changes observed with 8-modified purines led to the development of 
labelling at C7 of 7-deazapurines.  7-Modified-7-deazapurine nucleotides have been shown 
to be enzymatically-incorporated into nucleic acids, and show high duplex stability.  The 7-
substituent is located in the major groove of DNA and therefore does not interfere with 
stability or base-pairing.  Unlike the 8-modified purines, 7-modified-7-deazapurines 
preferentially adopt the anti-conformation. 
Naturally occurring 7-deazapurine nucleosides such as tubercidin,21 sangivamycin22 and 
toyocamycin23 have been of interest for many years due to their biological activity and 
potential pharmaceutical applications (Figure 1.12).  Tubercidin (7-deazaadenosine) was 
first isolated from Streptomyces tubercidicus in 1957, and the structure confirmed as 4-
amino-7-D-ribofuranosyl-7H-pyrrolo[2,3-d]pyrimidine in 1963. 24   14C labelling studies 
suggest that tubercidin is biosynthetically derived from adenosine.25  C2 of adenosine is 
conserved in tubercidin, but C8 of adenosine does not become C8 in tubercidin.  Instead, it 
appears that the carbon atoms which make up the pyrrole ring of tubercidin originate from 
C1 and C2 of ribose (Scheme 1.1). 
 
 
Figure 1.12 Examples of naturally occurring 7-deazapurine nucleosides. 
 
One of the most important naturally-occurring 7-deazapurine nucleosides is the 7-
deazaguanosine-derived queuosine (Q) which is found in nearly all prokaryotes and 
eukaryotes.26  It replaces the first anticodon position in the tRNAs of histidine, asparagine, 
aspartic acid and tyrosine; it is thought to enhance translation accuracy, amongst other 
purposes. 
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Scheme 1.1 Proposed key step in the biosynthesis of tubercidin. 
 
7-Deazapurine nucleosides can be easily functionalised at the 7-position, and because of 
their high duplex stability and similar properties to the natural purines, they have become 
popular choices for the synthesis of labelled purine nucleosides.  However, there are 
surprisingly few examples of usefully fluorescent 7-modified-7-deazapurine nucleotides, i.e. 
those with appropriate absorbance and emission wavelengths and high quantum yields.  
The Seela group has published a range of fluorescent 7-deazapurine nucleotides with 
various organic groups connected by alkynyl linkers.27  However the quantum yields tend to 
be very low and the absorbance maxima not sufficiently shifted away from those of 
biomolecules.  The examples shown in Figure 1.13 show the analogue with the highest 
quantum yield (recorded in water), and the analogue with the highest absorbance 
maximum.  Generally, these analogues have fluorescence emission too weak for most 
applications in biological systems. 
 
 
Figure 1.13 Examples of fluorescent 7-modified-7-deazapurine nucleosides reported by the Seela group. 
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Kaufmann et al. published an alternative fluorescently-labelled 7-deazaadenosine, 
containing a stilbene fluorophore with a PEG (polyethylene glycol) linker (Figure 1.14).28  
They attached an aminopropynyl group to the 7-deazadenosine, to which the fluorophore 
with PEG tether could be covalently attached using amide chemistry, to give the 
fluorescent nucleoside which was then phosphorylated.  The 7-deazaadenosine 
triphosphate could be incorporated into DNA by a variety of DNA polymerase enzymes, 
although the rate of incorporation was quite low.  A study by Famulok and co-workers 
showed that similar modifications to these are better tolerated by family B polymerase 
enzymes than family A polymerases.29 
 
 
Figure 1.14 7-Deazaadenosine triphosphate with PEG-tethered stilbene fluorophore. 
 
Another example of 7-deazapurine nucleotides containing various fluorophores was 
reported by Ju et al. in 2006.30  They used alkyne linkers, once again, but this time the 
fluorophore was connected by a cleavable linker (Figure 1.15).  The added flexibility gained 
by using a long linker allows for the addition of a large fluorophore, giving extremely 
fluorescent nucleotides (in this case for DNA sequencing applications).  The fluorophores 
(and 3′-O-allyl protecting groups) are cleavable using a Pd catalyst.  These fluorescent 
nucleotides have been shown to be tolerated by DNA polymerase enzymes, and have 
applications in DNA sequencing using PCR.  The disadvantage of attaching a fluorophore 
through a long linker is that the reporter part of the molecule is distant from the 
biologically active centre, meaning it will most likely not be sensitive to the 
microenvironment of the nucleobase.  It is also possible for planar fluorophores attached to 
nucleotides through long linkers to intercalate DNA helices, which is sometimes desired, 
but may cause fluorescence quenching.31 
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Figure 1.15 Fluorescently-labelled 7-deazapurine nucleotides for DNA sequencing. 
 
Other types of labels for 7-deazapurines have been reported.  The Hocek group has 
reported a variety of nucleosides and nucleotides with electrochemical labels, including 7-
deazapurines.  The electrochemical labels include Ru-bipy complexes, 32  ferrocene 
substituents33 and m-nitro- and m-aminophenyl labels (Figure 1.16).34  The compounds 
utilise both alkynyl and phenylene linkers. 
 
 
Figure 1.16 Representative electrochemically-labelled 7-deazaadenosine nucleosides and nucleotides reported 
by the Hocek group. 
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1.3 Fluorescent nucleotides for base mismatch discrimination 
 
1.3.1 Single nucleotide polymorphism 
 
Single nucleotide polymorphisms (SNPs) are site-specific mutations within a gene resulting 
from replacement of a single nucleotide with a different base.  Polymorphisms can be 
between individuals of a species, or between paired chromosomes of an individual.  SNPs 
are more often found within non-coding sequences of genome, and even within coding 
regions do not necessarily result in the coding of an incorrect amino acid (due to the 
degeneracy of the genetic code).  Despite this, SNPs (or combinations of SNPs) have been 
implicated in many human diseases, such as osteoporosis,35 cardiovascular disease,36 and 
primary (idiopathic) hypertension,37 amongst others.  SNPs can also indicate an individual’s 
response to drugs, and therefore may hold the key to future developments in personalised 
medicine.38 
 
1.3.2 Methods for genotyping SNPs 
 
There are numerous methods available for the identification of known SNPs.  They can be 
divided into four main categories: detection of hybridisation, primer extension, ligation and 
invasive cleavage.39  Assays can either be carried out in solution (homogeneous) or on a 
solid support.  Invasive cleavage involves the application of the enzyme Flap endonuclease 
(FEN) which is a very sensitive enzyme for structure-specific cleavage.40  The Invader® assay 
involves two oligonucleotide probes which complement different parts of the target 
sequence – one labelled with a fluorescence quencher on one side of the cleavage site and 
a fluorophore on the opposite side, and an Invader oligonucleotide.  The two 
oligonucleotide sequences overlap at the single-nucleotide polymorphism site.  If the target 
sequence is fully complementary with the probe strand, cleavage can occur and the 
fluorophore-containing oligonucleotide is released, giving fluorescence emission (Figure 
1.17). 
 
 15 
 
 
Figure 1.17 Representation of the Invader® assay for SNP genotyping.40 
 
The oligonucleotide ligation assay (OLA) also uses two oligonucleotide probes which 
complement the target sequence.41  In this case there is no overlap – the two sequences 
anneal to the target strand and are joined by DNA ligase.  Two capture oligonucleotides are 
used, labelled with different fluorophores, and with different nucleotides at the 3′ end, 
representing the two genotypes.  The fluorophore which is successfully ligated represents 
the allele which is present, and so can be used to identify the genotype. 
Primer extension methods involve the use of polymerase enzymes which can extend a 
primer sequence to incorporate a nucleotide complementary to the SNP.39  The synthesised 
sequence can then be detected using a variety of techniques such as mass spectrometry or 
melting curve analysis.  Alternatively, the primer sequence can contain the SNP.  In this 
case, a PCR reaction is used where the sequence is only amplified if the primer is fully 
complementary to the target sequence. 
Hybridisation methods directly detect whether a specific nucleotide is base-paired by the 
introduction of a reporter molecule (generally a fluorescent label).  Detection of 
hybridisation is fast and direct, and can be carried out on a solid support or 
homogeneously. 
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1.3.3  Fluorescent nucleotides for base mismatch discrimination 
 
There are several general strategies for spectroscopic detection of SNPs using modified 
nucleotides.  Modified nucleotides can be introduced at the position opposite the SNP site, 
so that the modified nucleotide is at the base-pair of interest (Figure 1.18, top).  This can 
lead to a change in fluorescent properties upon hybridisation, giving either an increase in 
fluorescence intensity or a fluorescence quenching effect upon formation of a base-pair. 
 
 
Figure 1.18 Diagram showing possible strategies for base mismatch discrimination. 
 
An alternative strategy uses a fluorescent probe placed at an adjacent site to the base-pair 
of interest (Figure 1.18, bottom).  It is expected that structural changes associated with a 
fully base-paired duplex (or the structural distortions caused by a mismatch) will influence 
the fluorescence intensity of the probe.  Oligonucleotides which can form hairpins can also 
be used, where one end of the sequence is labelled with a fluorophore, and the other is 
labelled with a quencher.  If a base-pair mismatch is present, the oligonucleotide will 
preferentially stay in the hairpin form, with the fluorophore quenched.  If the fully 
complementary strand is present, the hairpin will unfold and the strands will anneal, 
separating the fluorophore and quencher and leading to fluorescence emission. 
The Saito group has contributed extensively to the development of base-discriminating 
fluorescent nucleosides.  The base-discriminating fluorescent nucleosides they have 
designed can be divided into two main categories: size expanded nucleosides and pyrene-
labelled nucleosides, and include both purine and pyrimidine bases.31 The size-expanded 
cytosine analogues BPP42 and NPP43 were reported by Saito and co-workers in 2003 (Figure 
1.19).  An oligonucleotide containing BPP (benzopyridopyrimidine) was hybridised with its 
 17 
 
complementary strand.  When the complementary strand contained guanosine opposite 
the BPP nucleotide instead of adenosine, a strong fluorescence quenching effect was 
observed.  It was found to be suitable for identifying an A/G SNP which is known to occur in 
the human interferon-γ gene (IFNG).44  Due to the very low quantum yields displayed by 
BPP, NPP was developed as a base-discriminating nucleotide with similar properties but 
slightly increased fluorescence.  Both nucleotides showed intermediate fluorescence when 
opposite a pyrimidine base.  Although they were very effective for particular sequences, 
these base-discriminating nucleosides were found to be unsuitable when in sequences 
adjacent to G/C pairs due to the fluorescence quenching observed. 
Purine-based, size-expanded nucleosides were also developed by Saito and co-workers 
(Figure 1.19).45  Methoxybenzoadenine (MDA) and methoxybenzoinosine (MDI) were found to 
be efficient for identifying pyrimidine SNPs, showing significant fluorescence quenching 
when an incorrect pyrimidine is opposite.  However, once again the probes are quenched 
by G/C pairs, so are only suitable for identifying SNPs were the varying nucleotide is next to 
A/T pairs. 
 
 
Figure 1.19 Size-expanded base-discriminating nucleosides. 
 
Due to the sequence specificity of the size-expanded base-discriminating fluorescent 
nucleosides, the Saito group developed nucleosides containing pyrene fluorophores which 
are not in conjugation with the nucleobase.  The design of these nucleosides was based on 
the principle that with an appropriate linker chain, the pyrene group can intercalate the 
DNA when the nucleoside is not base-paired, but when the correct base-pair is formed, it is 
suitably constrained so the fluorophore points into solution.  Intercalation is known to 
quench pyrene fluorescence, so a quenching effect will be observed if the base-pair is 
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mismatched.46  Pyrene derivatives are also known to be highly solvatochromic,47 so changes 
in the polarity of the local environment will cause changes in fluorescence.  
Uridine and cytidine nucleosides-bearing pyrene fluorescent labels were synthesised by 
Saito and co-workers (Figure 1.20).48   
 
 
Figure 1.20 Pyrene-labelled uridine and cytidine nucleosides. 
 
The pyrenecarboxyamide-containing nucleosides were found to be strongly fluorescent 
only when opposite A in oligonucleotides.  In the sequence 5′-d(CGCAATuTAACGC)-3′ with 
its fully complementary strand, the quantum yield was 20.3%, a significant improvement on 
the size-expanded nucleosides.31  Even in a sequence where the modified nucleotide is 
between cytidines, the quantum yield was still good (15.1%), unlike the size-expanded 
nucleotides which were strongly quenched when near G-C pairs.  The labels with amino 
groups were only weakly fluorescent, and did not show base-discriminating properties.  
This supports their hypothesis that the observed solvatochromism is similar to that 
observed for pyrene-1-carboxaldehyde, where the solvent-dependent relative positions of 
the n→π* and π→π* energy levels accounts for the dramatic impact of solvent polarity on 
its fluorescent properties.47  Molecular modelling (AMBER* force field in water) of the 
system indicated that the pyrene fluorophore was not intercalating in the DNA helix, but 
that in a mismatched base-pair the pyrene was bound to the DNA along the minor groove.  
In matched base-pairs, the pyrene fluorophore is exposed to the solvent, giving rise to the 
differences in fluorescence intensity. 
Saito and co-workers also developed a purine analogue of the pyrene-labelled nucleosides 
based on 2′-deoxy-7-deazaadenosine. 49   Although the purine analogues were also 
synthesised with an alkyne linker, unlike the pyrimidine analogues the alkyne was removed 
by hydrogenation to the more flexible alkane (Figure 1.21, left).  A fully complementary 
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duplex containing the fluorescent adenosine was found to be extremely stable – the 
melting temperature was found to be higher than for the unmodified duplex.  The modified 
nucleotide was found to be highly quenched when base-paired with thymidine, but still 
fluorescent when base-paired with any other nucleotide.  Saito and co-workers propose 
that the quenching effect is due to intercalation of the pyrene group, which may be 
possible in this case because of the more flexible propyl linker.  A molecular model of a 
short duplex containing this nucleotide indicates that this intercalated structure is the 
possible cause of the base-discrimination effect (Figure 1.21, right). 
 
 
Figure 1.21 Pyrene-labelled 7-deazaadenosine analogue (left) and calculated model of matched duplex showing 
pyrene intercalation (right).49 
 
Saito and co-workers also reported a base-discriminating fluorescent guanosine analogue,50 
similar to compounds reported by our groups.51  Introduction of an aryl ethynyl group at C8 
induces strong fluorescence in purine analogues, but also causes conformational changes 
(Section 1.2.1).  The fluorescence brightness of the three analogues investigated by Saito 
and co-workers was dependent on solvent, with the dimethylamino analogue showing the 
highest solvent dependence.  This analogue was investigated for its base-discriminating 
properties in two different duplexes and showed moderate base-discrimination, thought to 
be due to the dependency of the fluorescence emission on local polarity.  Investigations in 
York indicate that no base-pair is formed by 8-modified purines in short duplexes.52 
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Figure 1.22 Fluorescent 8-modified-2′-deoxyadenosines investigated by Saito and co-workers. 
 
The Tor group have also developed some fluorescent nucleosides capable of identifying 
base-pair mismatches.  They have developed two different size-expanded analogues of 
uridine, based on thieno[3,4-d]pyrimidine53 and quinazoline (benzopyrimidine).54  The 
thieno[3,4-d]pyrimidine analogue (Figure 1.23, left) was phosphorylated and enzymatically 
incorporated into oligonucleotides by T7 RNA polymerase (RNAP).  In the duplex of 5′-
d(GCGCCGuGCA)-3′, the nucleotide was found to be strongly fluorescent when base-paired 
with cytidine, and showed significant quenching when opposite adenosine.  However, it 
seems possible that if the base-discrimination is due to subtle changes in local polarity of 
the environment of the nucleotide rather than a specific base interaction, the identification 
of mismatches may be sequence dependent.  The quinazoline analogue (Figure 1.23, right) 
has different properties, with increased fluorescence intensity when opposite a G 
mismatch, although again this has only been tested in one sequence.  Both nucleosides 
were shown to form stable duplexes, with melting temperatures very similar to the 
unmodified duplexes. 
 
 
Figure 1.23 Size-expanded fluorescent base-discriminating nucleosides developed by Tor and co-workers. 
 
Another base-discriminating, size-expanded nucleoside has been reported by Cekan and 
Sigurdsson. 55   A nitroxide-labelled cytidine analogue was incorporated into an 
oligonucleotide, and then reduced to give the amine compound which was highly 
fluorescent (Scheme 1.2).  This fluorescent label shows moderate mismatch discrimination, 
with different amounts of fluorescence quenching observed for the single-stranded 
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oligomer depending on which base is opposite the modified base.  The base-discrimination 
also showed sequence specificity, with better differentiation observed when the 
fluorescent probe was adjacent to pyrimidine bases. 
 
 
Scheme 1.2 Synthesis of fluorescent cytidine analogue by reduction of nitroxide label in oligonucleotides. 
 
Recently, a size-expanded nucleoside based on 7-dezaadenosine was synthesised by 
Wilhelmsson and co-workers (Figure 1.24).56  This simple system, consisting of a 7-phenyl-
7-deazaadenosine conformationally locked by cyclisation onto the exocyclic amine, is 
moderately fluorescent (φ = 6.8% in water).  The nucleoside was incorporated into short 
oligonucleotides with a wide range of sequences (twelve different sequences of decamers).  
The range of oligomers investigated allowed them to fully investigate the effect of 
sequence on the properties of the fluorescent nucleotide.  This is more thorough than 
many reported examples, but is particularly important as the base-discriminating 
properties of some fluorescent nucleotides have been shown to be sequence dependent.31  
 
 
Figure 1.24 Wilhelmsson size-expanded fluorescent nucleoside. 
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Melting temperatures of the duplexes containing the quadracyclic adenosine are the same 
or higher than the melting temperatures of the unmodified duplexes, with the stabilisation 
observed being sequence specific.  Significant destabilisation was observed for base-pair 
mismatches, suggesting specific thymidine base-pairing.  The fluorescence quantum yields 
were also found to be sequence dependent, ranging from 5.8% to 0.2% for the single 
stranded oligonucleotides, with neighbouring pyrimidine bases causing the greatest 
quenching effect.  In most cases, further quenching was observed upon formation of a 
duplex with a correctly matching base-pair.  However, the presence of a base mismatch led 
to an increase in quantum yield being observed.  This means that the modified base can be 
used to identify a base-pair mismatch; however the effectiveness of the base 
discrimination is sequence dependent. 
An alternative approach has been developed jointly by the Tucker, Vyle and Bassani 
groups.57  Rather than modifying the nucleoside which has a mismatch, they introduced a 
fluorescent probe at an adjacent site to the base pair of interest.  Their method also differs 
because it uses a non-nucleosidic fluorescent probe (Figure 1.25, left). 
 
 
Figure 1.25 Tucker/Vyle/Bassani non-nucleosidic fluorescent probes. 
 
The anthracene-based fluorescent probe was incorporated into an oligonucleotide which 
was annealed with complementary strands containing one or two mismatches at positions 
adjacent to the probe.  Interestingly, when the modified oligomer was annealed with a fully 
matched complementary strand only a very small decrease in melting temperature was 
observed (2 °C), indicating that the anthracene may be intercalating in the duplex.  This was 
associated with a significant drop in fluorescence intensity, also expected from 
intercalation of the anthracene probe (cf. Saito pyrene fluorescent labels).  When a base 
mismatch (C∙A) was present adjacent to the fluorescent probe, a much larger decrease in 
melting temperature was observed (12.5 °C), and an increase in fluorescence intensity was 
observed.  This suggests that the anthracene is no longe
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Although only one mismatch has been investigated, this probe shows potential for SNP 
identification. 
Tucker and co-workers have also reported a similar but chiral anthracene probe, where the 
sugar unit is synthesised from D-threoninol and the linker is either methylene (like the 
previous example) or butylene (Figure 1.25, right).  In this case, the fluorescent label was 
incorporated into duplexes and used to probe the base opposite the modification.  The 
longer linker was found to have less impact on the melting temperature than the 
methylene linker, suggesting that it is better able to intercalate the duplex.  The methylene-
linker probe showed only very poor discrimination between different bases for both 
melting temperature and fluorescence methods.  However, the butylene linked probe 
showed varying fluorescence spectra and melting temperatures for each base, suggesting 
that the degree of anthracene intercalation is dependent on the base opposite.  
Interestingly, the duplex containing this probe was also able to differentiate between 
cytidine and 5-methylcytidine (a common DNA methylation).  Cytidine caused a small 
increase in fluorescence intensity compared with the single strand, while 5-methylcytidine 
caused an equivalent decrease in fluorescence.  This highlights the high sensitivity of this 
fluorescent probe, although further investigation is required to determine if this is a 
general phenomenon.   
During the preparation of this work, Hocek and co-workers reported nucleosides with 
fluorescent biaryl labels (Figure 1.26). 58   The modifications also contain fluorine 
substituents so that the labels can be used as NMR probes. 
 
 
 
Figure 1.26 Some of the fluorine-labelled fluorescent nucleosides synthesised by Hocek and co-workers. 
 24 
 
 
The fluorescent nucleotides were based on 2′-deoxy-7-deazaadenosine and 2′-
deoxyuridine.  The nucleotide triphosphates were generally found to be highly fluorescent, 
with quantum yields up to 28% in water.  The fluorescence of the nucleotide analogues was 
found to be dependent on pH.  The biphenyl and benzofuran-based 7-deazaadenosine 
analogues showed fluorescence quenching at acidic pH values, which they propose is due 
to protonation of the amino group.  The aminobenzoxazole and benzoxazole 7-
deazaadenosine analogues’ fluorescence emission peaks (565 nm and 496 nm, 
respectively) were quenched with decreasing pH, but a second fluorescence emission (at 
443 nm and 429 nm) was observed, giving a gradient of blue to yellow emission as pH 
varies.  The uridine analogues generally showed an increase in fluorescence intensity upon 
increasing pH, as the nucleotide heterocycle is deprotonated.  The modified nucleotide 
triphosphates were incorporated into oligonucleotides using primer extension (PEX), and 
their base mismatch discrimination investigated.  The modified 7-deazaadenosine 
nucleotides showed some base discrimination, with moderate quenching observed when 
they were opposite other purines, and a larger quenching effect seen when a pyrimidine 
mismatch (C) was present.  The uridine nucleotides showed highly sequence-dependent 
mismatch discrimination, with neighbouring guansoine nucleotides causing quenching of 
the benzofuran and benzoxazole and aminobenzoxazole-labelled uridines. 
 
1.4 Pd-catalysed functionalisation of nucleosides and nucleotides 
 
1.4.1 Pd-catalysed cross-coupling reactions 
 
Palladium catalysis has become an invaluable tool for the efficient synthesis and 
functionalisation of complex organic compounds; moreover, palladium catalysed cross-
coupling is an essential tool in the synthesis of modified nucleosides.  Palladium-catalysed 
cross-coupling is generally used for the synthesis of sp2-sp2 or sp-sp2 bonds, making it ideal 
for the synthesis of those fluorescent nucleosides with aryl, alkenyl or alkynyl groups 
directly bonded to the nucleobase heterocycle.  Cross-coupling reactions require a 
halogenated (or pseudohalogen) species, which can be coupled to an organometallic 
reagent with the use of a transition metal catalyst.  Typically palladium is used, but nickel 
and other metals are also suitable.59  The organohalide oxidatively adds to the Pd0 catalyst 
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to give a PdII species.  This complex can then undergo transmetallation with the 
organometallic reagent, followed by reductive elimination to give the coupled product, and 
regenerate the Pd0 catalyst (Scheme 1.3).  Either the complex must isomerise to the cis-
isomer for reductive elimination to occur, or ligand dissociation (to form a 14e- species) 
must precede reductive elimination to form the product.  Often other additives, such as 
bases and ligands, are required.  
 
 
Scheme 1.3 General mechanism of palladium-catalysed cross-coupling.   
The species undergoing oxidative addition, transmetallation and reductive elimination are presumed to be 
ligated (based on stability arguments 16-electron Pd0 and PdII species are likely), although ligand dissociation is 
required to facilitate catalytic coupling, which is not specified for simplicity. 
 
A wide variety of organometallic reagents have been used in these reactions, including 
organostannanes (Stille), 60  organoboronic acids (Suzuki-Miyuara), 61  Grignard reagents 
(Kumada),62 organozinc compounds (Negishi)63 and organocuprates (Sonogashira).64  As 
previously mentioned, palladium-catalysed cross-coupling reactions have traditionally been 
used for coupling sp2 (or sp) carbons, due to the problems associated with β-hydride 
elimination.  However, recent catalyst systems and reaction condition development 
facilitate the cross-coupling of sp3 centres.65 
 
1.4.2 Pd-catalysed cross-coupling of halogenated nucleosides and nucleotides 
 
Palladium catalysis has been extensively used in the C- and N-functionalisation of 
nucleosides.66  Cross-coupling chemistry has been used for the functionalisation of all five 
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canonical bases as well as many unnatural or uncommon bases.  The most commonly used 
cross-coupling reactions for nucleosides and nucleotides are Sonogashira, Suzuki and Stille 
cross-couplings.  Traditionally, cross-coupling of nucleosides has involved protection of the 
sugar moiety and nucleobase before reaction to improve solubility and avoid possible side 
reactions.  However, this is inefficient and adds extra protection and deprotection steps to 
the synthesis.  A significant advancement was made in 1990 by Casalnuovo and Calabrese, 
who published a variety of cross-coupling reactions on unprotected nucleosides and 
nucleotides under aqueous conditions.67  They reported conditions for both Sonogashira 
and Suzuki cross-couplings using the water-soluble catalyst Pd(tppms)3 (TPPMS = sodium 
triphenylphosphine monosulfonate) in water/acetonitrile or water/methanol mixtures.  
These conditions could even be used for cross-coupling reactions on highly unstable 
nucleotide triphosphates, albeit in moderate yield (Scheme 1.4). 
 
 
Scheme 1.4 Sonogashira cross-coupling of 5-iodo-dideoxyuridine 5′-triphosphate to give T-505. 
 
These conditions were developed further and optimised by Shaughnessy and co-workers in 
2003.68  8-Bromopurine and 5-iodopyrimidine nucleosides were coupled with arylboronic 
acids under aqueous conditions by using water soluble phosphine ligands such as TPPTS 
(sodium triphenylphosphine trisulfonate) to solubilise the palladium catalyst (Scheme 1.5).  
Although the functionalisation of 8-bromoadenosine was found to proceed readily, 
guanosine was found to be a more challenging substrate due to the readily ionisable amine 
group and multiple binding modes to palladium.  Shaughnessy and Western have 
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subsequently shown the inhibitory effect guanosine may have on palladium catalysed 
cross-coupling reactions.69  They also found that TXPTS (trisodium tri(4,6-dimethyl-3-
sulfonatophenyl)phosphine) was a more effective ligand for nucleoside cross-coupling than 
TPPTS, giving quantitative yields at room temperature in 30 min.  
 
 
Scheme 1.5 Aqueous Suzuki-Miyaura cross-coupling of 8-Br-adenosine with phenylboronic acid. 
 
Collier and Wagner improved the synthesis of 8-arylguanosine mono- and triphosphates by 
using a pyridine additive and acetonitrile solvent in the phosphorylation of 8-
bromoguanosine.70  8-Bromo-ATP and AMP could then be used in cross-coupling reactions 
using similar conditions to Shaughnessy and co-workers.  Their process is an efficient two 
step synthesis of 8-substituted guanosine triphosphates or nucleotides from 8-
bromoguanosine.  They also applied Suzuki-Miyaura cross-coupling chemistry to the 
synthesis of modified NAD+ analogues.71  NAD+ was brominated and then directly cross-
coupled in situ to give 8-aryl-NAD+ derivatives (Scheme 1.6) 
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Scheme 1.6 One-pot synthesis of 8-aryl-NAD+ from NAD+. 
 
The chemistry developed by Casalnuovo and Calabrese, and by Shaughnessy and co-
workers, has been applied to a range of nucleoside and nucleotide substrates, to introduce 
a wide array of substituents.  Some of these nucleoside analogues will be discussed in later 
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sections, but notable contributions have come from the Hocek group, who in particular 
have investigated the metal:ligand ratio and developed microwave conditions for this 
chemistry.72  They have also optimised the conditions for the Suzuki cross-coupling of 
halogenated nucleotide triphosphates, for an efficient and significantly less divergent route 
to functionalised nucleotides (Scheme 1.7).73 
 
 
Scheme 1.7 An example of cross-coupling on an unprotected nucleotide triphosphate using Hocek conditions. 
 
One of the most remarkable applications of Shaughnessy’s conditions reported to date is 
the cross-coupling of a brominated nucleobase incorporated into an oligonucleotide.  
Manderville and co-workers incorporated 8-bromoguanosine into short oligonucleotides 
(up to 15mers), which were then subjected to Pd-catalysed cross-coupling using conditions 
based on those reported by Shaughnessy (Scheme 1.8).74  A large excess of arylboronic acid 
was required to give the arylated-oligonucleotides, which were isolated in good yields 
(45%). 
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Scheme 1.8 Manderville conditions for cross-coupling of brominated oligonucleotides. 
 
A few examples of Sonogashira cross-coupling of unprotected 8-bromoadenosine with 
terminal acetylenes were reported by Cristalli and co-workers in 2001, although no 
characterisation of the products was given.75  Liebscher and co-workers also synthesised a 
variety of lipophilic 8-substituted adenosines by Sonogashira cross-coupling, however 
synthesis of the 8-substituted guanosine analogues required protection of the sugar 
hydroxyls and the exocyclic amine.76   
Previously in the Baumann and Fairlamb groups, Firth investigated the Sonogashira cross-
coupling of unprotected purine nucleosides, including the first Sonogashira cross-coupling 
of unprotected 8-bromoguanosine.51 A library of 8-substituted adenosines and guanosines 
was synthesised by Sonogashira cross-coupling, including thienylacetylene- and 
ferrocenylacetylene-substituted products (Scheme 1.9).  The effect of the Pd:Cu ratio in the 
Sonogashira cross-coupling of guanosines was investigated.  The optimal conditions were 
found to require 2 mol% Cu and 1 mol% Pd.   
 
 
Scheme 1.9 Sonogashira cross-coupling of adenosine with phenylacetylene. 
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Similar aqueous conditions to those used by Shaughnessy for Suzuki-Miyaura cross-
couplings have also been applied to Sonogashira cross-couplings.  Some of the first 
examples of this type were published by Hocek and co-workers for the cross-coupling of 
halogenated nucleotide triphosphates (Scheme 1.10).77  Shaughnessy and co-workers 
subsequently optimised the conditions for the unprotected 8-bromopurine and 5-
iodopyrimidine nucleosides, finding that, as for Suzuki cross-couplings, TXTPS was the most 
efficient water-soluble phosphine ligand.78 
 
 
Scheme 1.10 Aqueous Sonogashira cross-coupling of halogenated nucleotide triphosphates. 
 
Another earlier application of Pd-catalysed cross-coupling to the modification of 
oligonucleotides was published by Richert and co-workers in 2004.79  Their application of 
Sonogashira cross-coupling to halogenated oligonucleotides is similar to that published 
later by Manderville and co-workers, but Richert’s method differs in that the 
oligonucleotides are protected and still bound to the solid-phase support used for synthesis 
of the oligonucleotides.  This is advantageous as it makes purification of the products much 
easier.  The conditions are also quite different from Manderville’s; rather than using an 
aqueous Pd-catalyst such as Pd(OAc)2 with TPPTS, more traditional Sonogashira cross-
coupling conditions are used (Scheme 1.11). 
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Scheme 1.11 Richert Sonogashira alkynylation of 5-I-U in an oligonucleotide bound to a solid support. 
 
 
1.4.3 Pd-catalysed C-H functionalisation of nucleosides 
 
Direct arylation is the coupling of an aryl halide with a C-H bond, often a heterocycle 
(Scheme 1.12).  Direct arylation methodology has become more widely applicable to a 
range of heterocycles in recent years.80  It is advantageous over traditional cross-coupling 
routes as it avoids the pre-functionalisation of the heterocycle, does not require the use of 
expensive (arylboronic acids) or toxic (organotin) coupling partners, and often increases 
atom-efficiency.  
 
 
Scheme 1.12 Direct arylation methodology. 
 
The direct arylation of N-benzylpurines was reported by Hocek and co-workers in 2006.  
2,6-Dichloropurines were substituted at C8-H by cross-coupling with aryl halides using a Pd 
catalyst and excess copper(I) iodide and base.81  Hocek developed the direct arylation of 
unprotected adenosine nucleosides simultaneously with the Fairlamb group.82,83  Both 
processes employ a palladium catalyst and excess copper(I) iodide.  The Fairlamb 
conditions require an excess of caesium carbonate (Scheme 1.13), whereas Hocek uses 
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piperidine as a base.  In both cases, diarylated products, where both the 8-position and the 
exocyclic amine group were arylated, were by-products, however this was more 
problematic under the Hocek conditions (Fairlamb – 4 %, Hocek – 18 %).  The higher 
temperatures used by Hocek also led to increased deglycosylation, and therefore lower 
yields.  The Fairlamb group also investigated the reaction mechanism.  Although Pd0 
nanoparticles were formed under the reaction conditions, a negative mercury drop test 
suggested the reaction to be homogenous.  However, the efficacy of this test as a probe for 
the homogeneity of a reaction has not been fully determined, particularly in very polar 
solvents such as DMF.84,85  The role of copper(I) iodide was not fully understood despite 
these investigations.  A Sonogashira-like mechanism was proposed, however this does not 
account for the requirement for three equivalents of copper iodide (Scheme 1.14).  Further 
investigation into this reaction within the Fairlamb group has suggested that coordination 
of the nucleobase to CuI plays a key role in this reaction, and may account for the need for 
an excess of copper iodide.86 
 
 
Scheme 1.13 Direct arylation of adenosine under Fairlamb conditions. 
 
 
Scheme 1.14 Proposed mechanism for Pd/Cu mediated direct arylation of adenine nucleosides. 
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Some insight into the mechanism may be gained from looking at simpler systems 
previously reported in the literature.  Pd/Cu systems were first developed by Miura and co-
workers in the 1990s for the direct arylation of heterocycles.87  They found that the 
selectivity of Pd-catalysed arylations was affected by the presence of CuI salts.  When 
Pd(OAc)2 was used as the sole catalyst, the arylation of N-methylimidazole with 
iodobenzene was selective for C-5, however when a stoichiometric amount of CuI was 
added, the selectivity was pushed towards C-2 arylation (Scheme 1.15) 
 
 
Scheme 1.15 Effect of CuI on direct arylation of N-methylimidazole. 
 
Bellina, Rossi and co-workers reported an investigation into the effects of additives on the 
palladium-catalysed direct arylation of imidazoles, which led to the optimisation of 
conditions for selective C-2 arylation (Scheme 1.16).88  They proposed that the switch in 
selectivity is due to a change in mechanism; arylation at C-5 occurs via electrophilic 
aromatic substitution by the ‘ArPdIIX’ species, whereas arylation at C-2 occurs via cupration 
at C-2, followed by transmetallation to Pd. 
 
 
Scheme 1.16 Direct arylation of imidazole at C2. 
 
The Fairlamb group then developed the direct arylation of 2′-deoxyadenosine.86 This is a 
more challenging substrate due to the increased instability of the glycosyl bond (102 times 
more unstable than adenosine).89  Lowering the reaction temperature from 120 to 80 °C 
was required to prevent deglycosylation (Scheme 1.17).  It was found that the reaction at 
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this temperature gave unreliable yields depending on how the solvent was purified.  On 
further investigation, it was found that this was due to decomposition products of DMF 
which were not formed at the lower temperature.  DMF can decompose on heating to form 
dimethylamine and carbon monoxide.90  After screening of a variety of amines, it was found 
that sub-stoichiometric piperidine (40 mol%) was an adequate ‘dimethylamine mimic’, 
giving good, repeatable yields.86  It may aid the reduction of Pd(OAc)2 (i.e. the secondary 
amine lowers the reduction potential at PdII), via [Pd(HNC5H10)2(OAc)2], to Pd
0 under these 
more mild reaction conditions. 
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Scheme 1.17 Direct arylation of 2′-deoxyadenosine. 
 
Nucleosides with extended aryl systems can be synthesised by carrying out the direct 
arylation reaction on 2′-deoxyadenosine with 3- or 4-chloro- or bromo- iodobenzene, 
selectively functionalising the iodide over the other halogens.91  Further Suzuki-Miyaura 
cross-coupling of the second halogen gives biphenyl products with extended π-systems 
(Scheme 1.18).  If a third halogen is incorporated during the Suzuki cross-coupling step, a 
third aryl group can be added in a second Suzuki arylation step. 
 
 
Scheme 1.18 Synthesis of 8-biaryl-2′-deoxyadenosines by sequential direct arylation and Suzuki-Miyaura cross-
coupling. 
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1.5 Aims and Objectives 
 
The central aim of this project is the design and synthesis of a novel class of base-modified 
fluorescent nucleosides and nucleotides.  Whilst there are many commercially available 
fluorescent nucleosides, there is a scarcity of fluorescently labelled purine analogues with 
biochemical properties similar to the natural nucleosides.  Fluorescently labelled purine 
nucleosides and nucleotides generally contain fluorescent groups with long linker groups, 
such that the label is distant from the nucleobase.  This is useful for some applications, but 
often it is preferable to have a fluorescent label which is less bulky and can act as a 
reporter of the local chemical environment. 
The development of fluorescent adenosine analogues, with properties similar to the 
natural nucleoside, which can act as probes of local environment, is highly desirable.  There 
are many potential applications for fluorescently labelled nucleosides and nucleotides.  This 
project will focus on their applications as base-discriminating fluorescent nucleotides for 
identification of single-nucleotide polymorphisms.  Currently reported base-discriminating 
fluorescent nucleotides often have limitations, such as limited sequence specificity or 
quenching by neighbouring bases.  A fluorescent nucleotide with the fluorophore in 
conjugation with the nucleobase should have fluorescence which is sensitive to base-pair 
formation.  Crucially, the base-discriminating properties of the nucleotide will be less 
affected by subtle geometry changes which are imparted by sequence variation. 
Modification at C7 of 7-deazaadenosines has been shown to be a useful way of introducing 
fluorescent labels to adenosine nucleotides.  7-Modified-7-deazaadenosines exhibit high 
duplex stability with little duplex distortion, and high DNA melting temperatures.  Alkynyl-
substituted 7-deazaadenosines, where the conjugated alkynyl group acts as the 
fluorophore (Panel A, Figure 1.27) generally possess low quantum yields and/or absorbance 
maxima overlapping with the intrinsic absorbances of other biomolecules.   
Previous experience with 8-modified-purines has shown that the introduction of relatively 
small substituents (such as phenyl and phenylethynyl) groups at C8 is adequate to 
introduce significant fluorescence.  In these systems, conjugation between the π electrons 
in the C8 substituent group and the purine nucleobase occurs readily.  However, the π 
electron systems of chemical substituents at C7 are less likely to conjugate with the 
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nucleobase.  This is the likely explanation for the aforementioned poor fluorescent 
properties of phenyl- and phenylethynyl-substituted 7-deazapurines.  For this reason, a 
novel organic rigid rod system based on a phenylethynylbenzene motif, or a phenylethynyl 
group linked to a terminal hetero-aromatic group, will be synthesised to induce adequate 
fluorescence (Panel B, Figure 1.27).  The purine nucleobase at one end of the system will 
likely influence its intrinsic fluorescent properties.  Previous experience in the 8-modified 
series has shown that substitution of the terminal phenyl group (located at the other end 
of the rigid rod system) with electron withdrawing or donating groups can then be used to 
tune the fluorescence properties of the analogue.  Therefore a series of 7-deazapurines 
containing electron donating and electron withdrawing rigid-rod fluorophores at C7 will be 
synthesised. 
 
 
Figure 1.27 Rigid-rod fluorescent labels for 7-deazapurine nucleosides. 
 
A related area of interest is the development of methodology for the synthesis of C-
modified nucleosides.  This work was initiated previously with the optimisation of 
Sonogashira coupling conditions for application to purine nucleosides,51 and then with the 
development of C-H functionalisation methodology for direct arylation at C8 of 
adenosine,86 which employed a Pd catalyst and stoichiometric Cu additive.  C-H 
functionalisation is advantageous as it avoids the need for pre-functionalisation 
(halogenation) of the nucleoside substrates.  Direct arylation potentially allows for 
functionalisation of the unmodified nucleoside in a biological setting, e.g. for in situ 
labelling of nucleic acids.  Because of the inaccessibility of the C8-H position of adenosine 
when the nucleoside is base-paired, only exposed adenine residues (such as in mismatches 
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and hairpins) could be functionalised.  However, for this to be a practical and compatible 
methodology, milder conditions must first be developed.  Understanding the reaction 
mechanism is central to improving this catalytic methodology. 
 
In summary, the aims of the project are: 
• Design and synthesis of a novel class of 7-deazaadenine nucleosides with 
fluorescent substituents at C7. 
• Incorporation of 7-deazaadenine nucleosides with appropriate photophysical 
properties into oligonucleotides and determine their suitability as base 
discriminating fluorescent probes. 
• Improvement and extension of C-H functionalisation methodologies for accessing 
fluorescent nucleosides and nucleic acids. 
 
 
The following objectives will be key to achieving these aims: 
• Characterisation of the fluorescent nucleosides by UV-Vis spectroscopy, including 
solvatochromic studies. 
• Characterisation of the fluorescent nucleosides by fluorescence spectroscopy, 
including both steady-state and time-resolved measurements. 
• Incorporation of the fluorescent nucleosides into oligonucleotides using solid-
phase phosphoramidite chemistry. 
• Determine if incorporation of the fluorescent nucleoside alters the secondary 
structure of the oligonucleotide using circular dichroism spectroscopy. 
• Assessment of the base-discriminating properties of the fluorescent nucleotide 
within the oligonucleotides by examination of the effect of base-pair mismatches 
on secondary structure, duplex stability and the fluorescence properties of the 
labelled nucleotides. 
• Further investigation into the mechanism of the Pd-catalysed direct arylation of 2′-
deoxyadenosine, in particular the role of CuI. 
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2 Synthesis of nucleoside analogues 
 
2.1 Introduction 
 
In the 1960s, Davoll synthesised a series of pyrrolo[2,3-d]pyrimidines (7-deazapurines) 
using a relatively simple procedure, making 7-deazapurine nucleosides more accessible.92  
The total synthesis of tubercidin and related nucleosides and deoxyribonucleosides has 
been achieved by stereospecific nucleobase anion glycosylation of 6-chloro-7-deazapurine, 
3 (Scheme 2.1).93,94  The stereoselectivity in this reaction is controlled by the temperature 
of synthesis of the 1-chloro-ribofuranose, producing either the thermodynamic (2β) or 
kinetic (2α) product. 
 
 
Scheme 2.1 Synthesis of tubercidin from 6-chloro-7-deazapurine. 
 
A similar route can also be used to synthesise the 2′-deoxyribose analogue,95 using Hoffer’s 
chlorosugar, 6 (Scheme 2.2).96  Hoffer’s chlorosugar is often used in the synthesis of 2-
deoxyribose-containing compounds as it is simple to prepare, and a single anomer of the 
sugar can be produced with >99% selectivity.  The selectivity observed with 6 suggests that 
the reaction proceeds via an SN2 mechanism (I, Figure 2.1), rather than via dissociation of 
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the chloride to form an oxonium intermediate (II, Figure 2.1).  The formation of only β-
nucleosides from reactions with tri-O-benzyl-α-D-arabinofuranosyl chloride showed that 
steric effects do not play a role in this reaction, and the selectivity was rationalised by the 
presence of a close ion-pair intermediate (III, Figure 2.1).97 
 
 
Scheme 2.2 Synthesis of 2′-deoxytubercidin from Hoffer's chlorosugar. 
 
 
Figure 2.1 Possible intermediates in the glycosylation of 6-chloro-7-deazapurine. 
 
Glycosylation of nucleobases under Vorbrüggen conditions (also known as the silyl-Hilbert-
Johnson reaction) is a versatile method for accessing new nucleoside analogues in a one-
pot process.98,99  Vorbrüggen glycosylation requires silylation of the nucleobase NH and 
activation of a sugar protected with acyl groups and activated by addition of a Lewis acid 
(Scheme 2.3).100  The α/β selectivity is determined by the configuration at the 2-position of 
the sugar by neighbouring group participation, i.e. where the 2-hydroxyl is protected as an 
acyl group.  In most recent examples, the nucleobase is silylated using N,O-
bis(trimethylsilyl)acetamide (BSA), and trimethylsilyl triflate is used as the Lewis acid.101  
The reaction is therefore catalytic in BSA and TMSOTf, although stoichiometric amounts are 
often used to achieve shorter reaction times. 
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Scheme 2.3 Vorbrüggen glycosylation of uracil. 
 
The reaction has a wide substrate scope and can be used for the glycosylation of both 
purine and pyrimidine bases.  However, the pyrrole nitrogen of 7-deazapurines is inert 
under these conditions.  Instead, 7-deazapurines will either react at C7 or at one of the 
pyrimidine nitrogens, or give no product.102  Surprisingly, the 7-halogenated analogues 
readily undergo glycosylation under identical conditions.  This may be due to the electronic 
influence of the halogen or the increased thermal stability of the product at higher reaction 
temperatures (Scheme 2.4).103  The reactivity of N-9 may also be increased by the reactive 
C-7 position being blocked in these 7-substituted derivatives. 
 
 
Scheme 2.4 Glycosylation of 7-substituted-7-deazapurines. 
 
Glycosylation of 7-halogenated-7-deazapurines is useful because it facilitates access to a 
wide range of 7-substituted derivatives.  The halogen substituents allow for further 
substitution, either by traditional organic chemistry, or by palladium-catalysed cross-
coupling reactions (See Section 1.4.1).  
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2.2 Synthesis of 7-iodo-7-deazaadenosine – a versatile starting material 
for synthetic elaboration 
 
A three-step synthesis of 7-iodo-7-deazaadenosine from the commercially available 
reagent 6-chloro-7-deazapurine has been previously published.103  Firstly, the purine 
heterocycle is iodinated, then the protected ribose sugar can be attached using Vorbrüggen 
glycosylation, and finally a global deprotection reaction with ammonia gives the 
deprotected nucleoside and installs the exocyclic amine.103  This is the synthetic route 
followed in this work, although optimisation was necessary (Scheme 2.5) 
 
 
Scheme 2.5 Synthetic route to 7-iodo-7-deazaadenosine. 
 
The synthesis of 6-chloro-7-iodo-7-deazapurine, 13, reported by Seela and co-workers uses 
N-iodosuccinimide (NIS) as the iodinating agent, followed by recrystallisation from 
methanol to give the product.27  However, it was found that several recrystallisations were 
required to achieve high purity and good yields (>70%) and a by-product was observed in 5-
10% yield, resulting from nucleophilic aromatic substitution of the chlorine substituent by 
methanol, to give 6-methoxy-7-iodo-7-deazapurine.  As this by-product is undesired and 
difficult to separate from the product, a new method for the iodination reaction was 
required.  Iodine in DMF has been used previously for the iodination of indoles.104  This 
procedure was applied to 6-chloro-7-deazapurine, and the iodinated product was isolated 
in 74% yield (Scheme 2.6).  This procedure has been used to carry out the synthesis of 13 
on a multigram scale (17 mmol).  
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Scheme 2.6 Synthesis of 6-chloro-7-iodo-7-deazapurine. 
 
Glycosylation could then be carried out under Vorbrüggen conditions, using TMSOTf and 
BSA (Scheme 2.7).  The glycosylation reaction was carried out according to the procedure 
reported by Seela et al.103  With these conditions, the glycosylated product was isolated in 
64 % yield.  Optimisation of this step was undertaken in an attempt to reduce the quantity 
of BSA and TMSOTf required, and to increase the yield (Table 2.1). 
 
 
Scheme 2.7 Glycosylation of 6-chloro-7-iodo-7-deazapurine. 
 
Table 2.1 Effect of reagent stoichiometry on glycosylation reaction. 
a After chromatography on silica gel.  b Isolated as 1:1 mixture of protected sugar and product. 
 
It was found that a sub-stoichiometric amount of both reagents marginally increased yield 
(71%), but decreasing the ratio to 0.1 equivalents resulted in a significant drop in yield 
(33%). 
BSA TMSOTf Yield
a
 /% 
1.2 eq 1.1 eq 64 (59 lit.103)  
0.5 eq 0.5 eq 71 
0.1 eq 0.1 eq 33b  
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As previously mentioned, the deprotection/nucleophilic aromatic substitution step 
reported by Seela et al. was carried out in an autoclave with methanolic ammonia at 
120 °C.  The reaction was attempted at 80 °C in a sealed tube and gave 45% yield, along 
with some of the 6-methoxy analogue (formed via competing reaction of the chloro 
compound with methanol).  Due to the practical difficulties encountered repeating these 
conditions without access to an ammonia-resistant autoclave, milder conditions were 
required.  As previously reported, in cases where substitution by methanol is problematic, 
aqueous ammonia/dioxane at 60 °C can be used as an alternative.103  This approach proved 
more successful, eliminating the problems encountered using ammonia under high 
pressure.  After 3 days, the product was isolated in 87% yield (Scheme 2.8).  The 7-iodo 
nucleoside product was formed as a single diastereomer, with NMR characterisation 
consistent with the literature. 
 
 
Scheme 2.8 Deprotection/nucleophilic aromatic substitution. 
 
2.3 Synthesis of 7-modified fluorescent nucleosides 
 
2.3.1 Initial cross-coupling reactions 
 
As discussed previously, palladium-catalysed cross-coupling is a powerful tool for the 
synthesis of arylated and alkynylated nucleosides from the corresponding halogenated 
substrates.  Sonogashira cross-coupling of 15 with phenylacetylene, using the conditions 
developed by Firth et al.51, resulted in formation of the product in 65% yield.  However the 
product was contaminated with a mixture of unknown by-products which could not be 
separated by column chromatography on silica gel.  Lowering the reaction temperature 
from 80 °C to room temperature (ca. 13-23 °C) gave a cleaner reaction, giving 16 in 83% 
yield (Scheme 2.9).   
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Scheme 2.9 Sonogashira cross-coupling of 7-iodo-7-deazaadenosine with phenylacetylene. 
 
7-(1-Naphthyl)-7-deazaadenosine, 17 was also synthesised by this method.  The product 
was isolated as a yellow solid in 89% yield following chromatography on silica gel.  7-
Phenyl-7-deazaadenosine was synthesised by Suzuki-Miyaura cross-coupling, using the 
conditions developed by Hocek and co-workers.105  The reaction was carried out under 
aqueous conditions, using TPPTS as the water soluble ligand, and 18 was isolated in 72% 
yield (Scheme 3.5). 
 
 
Scheme 2.10 Suzuki cross-coupling of 7-iodo-7-deazaaenosine with phenyl boronic acid. 
 
Although these methods proved successful, the poor fluorescent properties of these 
analogues (see Chapter 3) emphasised the requirement for 7-deazaadenosine systems with 
extended π-systems. 
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2.3.2 Arylethynylphenyl-modified 7-deazaadenosines 
 
Arylethynylarylene-substitued systems were identified as potentially useful “second-
generation” fluorescent nucleosides.  The extended π-system is expected to improve the 
fluorescence properties of the nucleoside (see Chapter 3).  Two possible routes were 
identified for synthesising the target 7-[4-(arylethynyl)-phenyl]-7-deazaadenosine 
compounds (Scheme 2.11). 
 
 
Scheme 2.11 Cross-coupling approaches to 7-arylethynylaryl-7-deazaadenosines. 
 
7-(4-Bromophenyl)-7-deazaadenosine, 19, was synthesised by Suzuki-Miyaura cross-
coupling, in order to produce an advanced intermediate which could be further 
functionalised using Sonogashira cross-coupling (Scheme 2.12). 
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Scheme 2.12 Synthesis of 7-(4-bromophenyl)-7-deazaadenosine. 
 
Further functionalisation of the modified nucleoside was attempted by Sonogashira cross-
coupling, using the conditions developed by Firth et al. (Scheme 2.13).51  
 
 
Scheme 2.13 Sonogashira coupling to synthesise target compound. 
 
However, under these conditions the Sonogashira coupling reaction did not go to 
completion and the product was inseparable from the starting material by column 
chromatography on silica gel.  The reaction was repeated using an aqueous catalyst system 
with tri(4,6-dimethyl-3-sulfonatophenyl)phosphine trisodium salt  (TXTPS) as the ligand, 
and a lower temperature (80 °C), similar to the conditions developed by Shaughnessy and 
Western for Suzuki coupling of nucleosides,68 and applied to the Sonogashira coupling of 
halogenated nucleoside triphosphates by Hocek and co-workers.106  Subsequent to this 
work, Shaughnessy published a more detailed investigation of this ligand applied to the 
aqueous Sonogashira coupling of halogenated nucleosides, albeit with higher catalyst 
loadings.107  
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Under these conditions the reaction was found to be capricious, and precipitation of the 
catalyst as palladium black occurred on several occasions, possibly due to trace oxygen.  
Under strictly anaerobic conditions, the reaction proceeded to 95% completion (by NMR 
conversion), however as the product could not be separated from the starting material by 
column chromatography on silica gel this was not adequate. 
Due to the difficulties encountered in the separation of this product from the 7-(4-
bromophenyl)-7-deazaadenosine starting material, the second approach was attempted.  
This utilised Suzuki coupling to attach the arylethynylaryl fluorophore in one step.  As each 
differently substituted boron reagent must be synthesised separately, this approach is 
more divergent. 
Arylethynylaryl trifluoroborates have been recently synthesised by Ham and Kim, using 
either Sonogashira or Heck alkynylations.108  The same conditions were applied to the 
synthesis of a series of arylethynylaryl trifluoroborates, 22a-e, from the corresponding 
alkynes and 4-bromophenyl potassium trifluoroborate, 21 (Scheme 2.14).  21 was 
synthesised from the corresponding boronic acid using KHF2, according to the procedure 
described by Molander and co-workers.109   
   
 
Scheme 2.14 Synthesis of Suzuki coupling partner by Heck alkynylation (yields calculated from 1H NMR 
spectroscopic analysis). 
 
The arylethynylaryl trifluoroborates were coupled with 7-iodo-7-deazaadenosine using Pd-
catalysed Suzuki-Miyaura coupling, similar to the Shaughnessy conditions (Scheme 2.15).68 
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Scheme 2.15 Synthesis of target compounds by Suzuki coupling. 
 
Although separation of the product from the starting material and organoboronic acid 
formed in the reaction was not trivial, the products could be isolated in moderate to good 
yields.  This approach was used to successfully synthesise the parent (Z = H), 4-methoxy 
and 4-methylsulfanyl analogues.  However, there are several limitations with this 
methodology.  The major limitation is in purifying the synthesised trifluoroborate salts if 
the alkynylation reaction does not go to complete conversion, due to the high polarity of 
organotrifluoroborates and their instability to silica gel.110  This was the case with the 
synthesis of the 3-thienyl and 4-trifluoromethylphenyl- substituted 4-ethynylphenyl 
trifluoroborates, which gave yields of 65% and 60% respectively.  It was possible to couple 
the impure trifluoroborate products with the 7-iodo-7-deazaadenosine to give mixtures of 
20 and the desired product.  The mixed products could then be separated by preparative 
thin layer chromatography, however obviously this is far from ideal. 
Due to the difficulties encountered when expanding the range of arylated nucleosides, an 
alternative approach was attempted.  Another useful way to protect organoboronic acids is 
to use organoboronate esters.  Following procedures published by Zheng et al.,111 4-
bromophenyl boronic acid neopentylglycol ester was synthesised (Scheme 2.16) and the 
bromide chemoselectively coupled to phenylacetylene to give 27a (Scheme 2.17). 
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Scheme 2.16 Synthesis of neopentylglycol-protected 4-bromophenylboronic acid. 
 
 
Scheme 2.17 Sonogashira coupling of 4-bromophenyl boronic acid neopentyl ester with phenylacetylene. 
 
The bromide undergoes a Sonogashira coupling with the arylacetylene, with no observed 
Suzuki by-products (arising from activation of the boronate ester group).  This is probably 
because the use of an anhydrous solvent with an amine base favour Sonogashira coupling.  
Although no water or aqueous base was added, and dry DMF used, no particularly rigorous 
air/moisture free conditions were employed in this reaction.  It is thought that an aqueous 
base is required to activate organoboronic acids,112 although there are some examples of 
Suzuki-Miyaura couplings under apparently anhydrous conditions.113   
To develop a slightly less divergent route, 4-ethynylphenyl boronic acid neopentyl glycol 
ester 29 was synthesised using similar conditions.  This can then be coupled to aryl halides 
to give the same arylethynylphenyl- products without the need to individually synthesise 
each arylacetylene (Scheme 2.18).  The arylethynylaryl boronate esters were synthesised 
using one of these two routes in moderate to excellent yields (Scheme 2.19 and Table 2.2).  
There does not appear to be a pattern in the variation in yields, however the lower yields 
(Table 2.2, entries 2 and 3) may be due to these reactions being carried out on a smaller 
scale. 
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Scheme 2.18 Synthesis of phenylethynylphenyl boronate ester. 
 
This slightly altered strategy allows for the synthesis of a wider range of fluorescent 
nucleosides, through greater variation of the aryl substituents.  Changing the base from 
potassium phosphate to caesium carbonate and adjusting the metal to ligand ratio from 
1:5 to 1:2.5 led to a significant improvement in the yield.  A number of analogues have 
been synthesised in this way (Scheme 2.20 and Table 2.2). 
  
 
Scheme 2.19 Synthesis of arylethynylaryl nucleoside analogues. 
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Scheme 2.20 Cross-coupling of 7-modified-7-deazaadenosines with organoboronate esters. 
 
Table 2.2 Yields of synthesised modified nucleosides.   
 Ar Route Yield of boronate ester
a
 /% Nucleoside Product Yield
a
 /% 
1 Ph- A 88 20a 74 
2 4-MeO-C6H4- A 62 20b >99 
3 4-MeS-C6H4- B 63 20c 71 
4 3-Thienyl- A 68 20d 77 
5 4-CF3-C6H4- B 92 20e 68 
a Isolated yield after column chromatography on silica gel. 
 
2.3.3 Synthesis of 2′-deoxyadenosine analogues 
 
7-Iodo-7-deaza-2′-deoxyadenosine was synthesised according to published procedures 
(Scheme 2.21).114,115  Hoffer’s chlorosugar (6) was synthesised exclusively as the α-anomer 
from 2-deoxyribose in three steps (42%).  It was then coupled with 6-chloro-7-iodo-7-
deazapurine in a stereospecific-anion-glycosylation employing the solid-liquid phase-
transfer agent TDA-1 (tris(dioxa-3,6-heptyl)amine).116  As with the ribose analogue, a one-
pot deprotection/nucleophilic aromatic substitution with aqueous ammonia and dioxane 
gives the product in high yield after column chromatography on silica gel. 
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Scheme 2.21 Synthesis of 7-iodo-7-deaza-2′-deoxyadenosine. 
 
7-Iodo-7-deaza-2′-deoxyadenosine, 34, was then coupled with 27a using Suzuki-Miyaura 
cross-coupling conditions as described above to give 35 quantitatively (Scheme 2.22). 
 
2
2
2
2 3
2
34 27a 35  
Scheme 2.22 Synthesis of the 2′-deoxyribose analogue. 
 
The fluorescent nucleosides were comprehensively characterised using standard 
techniques, including NMR spectroscopy and ESI mass spectrometry, as well as 
photophysically by UV/vis and fluorescence spectroscopy (See Chapter 3). 
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2.3.4 NMR spectroscopic analysis of nucleoside products, including conformational 
aspects 
 
NMR spectra of all the novel nucleosides showed a single diastereomer, consistent with the 
β-anomer.  NMR spectra were recorded in CD3OD or (CD3)2SO, depending on compound 
solubility.  In particular, 20c was found to be only partially soluble in methanol.  A good 13C 
spectrum could not be obtained for 20c in DMSO-d6, so HSQC was used to determine 
13C 
NMR chemical shifts.  The ribose compounds were expected to display coupling between 
all adjacent protons on the sugar ring (additional coupling to the hydroxyls is also observed 
in (CD3)2SO).  This would give rise to C1′-H (d, J = 6.4 Hz), C2′-H (dd, J = 6.4, 5.3 Hz), C3′-H 
(dd, J = 5.3, 2.8 Hz), C4′-H (ddd, J = 2.8, 2.8, 2.8 Hz), C5′-H (dd, J = 12.4, 2.8, 2.8 Hz), C5′′-H 
(dd, J = 12.4, 2.8, 2.8 Hz).  In all cases, the C4′-H was observed as an ‘apparent’ quartet 
(Figure 2.2).  This would be expected if the three coupling constants (to C3′-H, C5′-H and 
C5′′-H) were identical, however it can be deduced from the other signals that this is not the 
case.  Instead, the observed quartet has a coupling constant equivalent to the average of 
the expected coupling constants.  Use of a high field spectrometer did not improve the 
resolution of these coupling constants.  The averaged signal may be the result of 
conformational changes occurring at room temperature.  In some cases, the C2′-H is 
similarly observed as an apparent triplet, with an averaged coupling constant. 
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Figure 2.2 Partial 1H NMR (700 MHz, CD3OD) spectrum of 20a at 298 K with inset expansion of the C4′-H signal 
at δ 4.13. 
 
NMR spectroscopy is a useful tool for determining structural information about 
nucleosides.117  As described previously, the ribose (or 2′-deoxyribose) sugar can adopt a 
number of conformations, and these can be an indicator of how similar the modified 
nucleoside will be to the natural nucleoside in biological systems.  Sugar conformation 
contributes to the secondary structure of nucleic acids, so the similarity of the modified 
nucleoside conformation to the natural nucleoside will give an indication of any distortion 
of nucleic acid secondary structure caused by the fluorescent label. 
The torsion angle around the nucleoside glycosyl bond χ(O4′-C1′-N9-C4) gives rise to the 
syn and anti conformers.  The anti conformer (90° < χ < 270°) is the preferred conformer of 
the natural nucleosides at room temperature, and is the conformer that occurs in both A-
type and B-type nucleic acid secondary structures.  However, as discussed previously, 
modifications to the nucleoside can cause a switch in the preferred conformer from anti to 
syn.86  Whether a compound is anti or syn can be deduced from 1H and 13C NMR 
spectroscopy by examining the sugar chemical shifts.  Generally, a switch from anti to syn is 
associated with an upfield shift of δ(C2′) and a downfield shift of δ(C1′), δ(C3′) and δ(C4′).  
The chemical shift of C2′-H can also be used to determine the syn/anti ratio. 118  Although 
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this method does not take into account the impact of other conformational changes on 
δ(C2′-H), it is still an indication of the predominant species.  Examination of the 
spectroscopic data for the novel 7-deazaadenosine nucleosides, and comparison with the 
natural nucleosides, the unmodified 7-deazaadenosines and some 8-modified adenosines 
suggests that the compounds 20a and 35 both preferentially adopt the anti conformation 
at 298K in (CD3)2SO (Table 2.3). 
 
Table 2.3 Comparison of NMR chemical shifts of natural and modified nucleosides, including the novel 
fluorescent 7-deazaadenosine nucleosides in DMSO-d6. 
Compound Solvent 
δ Major 
conformer C1′ C2′ C3′ C4′ C2′-H 
A119 DMSO-d6 86.7 74.3 71.4 88.8 4.64 anti 
dA120 DMSO-d6 83.8 39.7 71.8 88.7 2.73 anti 
8-Ph-A83 DMSO-d6 86.7 71.2 71.1 89.0 5.18 syn 
8-Ph-dA86 DMSO-d6 85.7 37.2 71.4 88.4 3.30 syn 
c7A121 DMSO-d6 87.6 73.7 70.8 85.1 4.42 anti 
c7dA122 DMSO-d6 85.8 40.2 70.8 87.8  anti 
20a 
DMSO-d6 89.7 74.3 71.2 85.9 4.71 anti 
MeOH-d4 89.9 75.6 72.5 87.3 4.67 anti 
35 MeOH-d4 86.5 41.5 73.0 89.1 2.72 anti 
 
The second important conformational variation is the pucker of the ribose ring.  There are 
twenty possible sugar conformations which can be described by a pseudorotational cycle 
(Figure 2.3).117,123  The conformers can be divided into S-type or N-type structures.  The 
most commonly observed and biologically important conformers are C2′-endo (2E) and C3′-
endo (3E) conformations.  C2′-endo conformations are associated with B-type DNA, whereas 
C3′-endo conformations are associated with A-type nucleic acid structures.  By applying the 
Karplus equation, the ratio of C2′-endo:C3′-endo can be determined from the 1H coupling 
constants of the nucleosides (Equation 2.1).123  This method assumes that only C2′-endo 
and C3′-endo conformations are present.  The coupling constants relevant to the sugar 
pucker are J3′4′ and J1′2′.  As the C4′-H signal does not have resolved coupling constants (see 
above), J3′4′ was measured from the C3′-H signal.  The novel fluorescent 7-deazaadenosines 
have C2′-endo:C3′-endo ratios close to those observed for the natural adenosines and 
unmodified 7-deazaadenosines.  This is a good indicator that the modifications introduced 
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will not significantly disrupt the secondary structure of duplexes containing these 
nucleosides or change their biological properties through changes in sugar conformation. 
 
%C2'-endo	 
 	100

 	
 
Equation 2.1 Determination of the percentage of C2′-endo conformation. 
 
 
Figure 2.3 Pseudorotational cycle highlighting the commonly observed sugar puckers. 
 
Table 2.4 Coupling constants and ratio of C2′-endo to C3′-endo for novel 7-deazaadenosines and comparison 
with other adenosine compounds. 
Compound Solvent J1′2′ J3′4′ %C2′-endo %C3′-endo 
A DMSO-d6 6.2 3.0 67 33 
dA DMSO-d6 7.9 2.6 75 25 
7-I-c7A DMSO-d6 6.4 m n.d. n.d 
7-I-c7dA DMSO-d6 8.2 2.6 76 24 
20a 
DMSO-d6 6.2 m n.d. n.d. 
MeOH-d4 6.4 2.8 70 30 
35 MeOH-d4 7.1 2.7 72 28 
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2.4 Phosphoramidite synthesis 
 
2.4.1 Introduction 
 
A common method for incorporating unnatural nucleosides into oligonucleotides is by 
chemical solid-phase synthesis.124,125  This has the advantage of tolerating many highly 
modified nucelobases and sugars which would not normally be tolerated by nucleic acid 
polymerase enzymes. 126   The presence of only one secondary hydroxyl in 
deoxyribonucleosides makes the synthesis of the 3′-phosphoramidite significantly more 
straightforward for DNA than RNA. 127   Modern fully-automated systems mean 
oligonucleotides can be synthesised with very little error.  
A 3′-phosphoramidite (generally derived from 2-cyanoethyl-N,N-
diisoproylchlorophosphoramidite) of the nucleoside is synthesised which acts as a 
precursor to the phosphate group.  Appropriate protecting groups are also required for 
each nucleoside; usually the 5′-hydroxyl is protected with a 4,4′-dimethoxytrityl group 
which can be removed orthogonally from common amino and hydroxyl protecting groups 
such as benzoyl and silyl groups; the method is selective for primary hydroxyls.125   
Nucleic acids are synthesised from the 3′-end to the 5′-end.  First, the 3′-hydroxyl of the 
first nucleoside is attached to a solid-support (usually through a non-nucleoside linker such 
as succinyl, attached to the 3′-O position of the first nucleoside).  The trityl protecting group 
on the 5′-position is then removed under acidic conditions (Scheme 2.23, I).  The free 
hydroxyl can then couple to another nucleoside phosphoramidite (II).  Any unreacted 5′-
hydroxyls can be capped using acetic acid and 1-methylimidazole to prevent reaction in the 
next cycle of the synthesis (III), and to allow easy removal of these shorter oligonucleotides 
at the end of the synthesis.  The PIII phosphoramidite is then oxidised to the P
V phosphate 
that makes up the backbone of nucleic acids (IV). 
The cycle of detritylation, coupling, capping and oxidation is repeated until all the desired 
nucleobases have been incorporated.  The oligonucleotide can then be cleaved from the 
solid-support. 
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Scheme 2.23 Solid-phase synthesis of oligonucleotides. 
 
2.4.2 Synthesis of fluorescent nucleoside phosphoramidite monomer 
 
The parent compound, containing the 4-(phenylethynyl)phenyl group at C7 (35), was 
chosen for incorporation into oligonucleotides due to its simple structure and promising 
fluorescent properties.  The most commonly used protecting group for the exocyclic amine 
of adenosine nucleosides prior to solid phase synthesis is benzoyl, however other groups 
are also sometimes used.  For incorporation of the parent compound into oligonucleotides 
using solid-phase synthesis, the amine was protected as a dimethyl formamidine by 
reaction with dimethylformamide dimethyl acetal (DMF-DMA).  This protecting group was 
chosen as it has been used previously with 7-modified-7-deazaadenosines;128,129 recently it 
has been shown to impart greater stability to unnatural adenine nucleoside 
phosphoramidites.130  It is also easy to install, does not require prior protection of the sugar 
hydroxyls, and can be removed under standard oligonucleotide deprotection conditions 
(i.e. aqueous ammonia).  The formamidine was formed quantitatively, which allowed the 
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crude product (after removal of the solvent) to be used without further purification.  The 
second protection step, installation of the 5′-hydroxyl with DMTrCl, was also successful, 
giving 36 in 73% yield over two steps (Scheme 2.24). 
 
 
Scheme 2.24 Protection of 35 for solid-phase synthesis. 
 
The protected nucleoside was then converted to the phosphoramidite, 37, by reaction with 
2-cyanoethyl-N,N-diisoproylchlorophosphoramidite to give a mixture of diastereomers 
(Scheme 2.25).  Unusually for nucleoside phosphoramidites of this type, the diastereomers 
have similar resonances in the 31P NMR spectrum and are thus virtually indistinguishable 
(Figure 2.4).  An unknown impurity which was present in the 2-cyanoethyl-N,N-
diisoproylchlorophosphoramidite starting material (31P NMR δ 14.5) was also present in the 
product, but did not have any impact on the solid-phase synthesis. 
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Scheme 2.25 Synthesis of nucleoside phosphoramidite 37. 
 
 
Figure 2.4 
31P NMR (212 MHz, CD2Cl2) spectra of 37. 
 
The synthesised phosphoramidite was incorporated into a single position of five different 
13-base oligomers (ODN1→ODN5) by BioTeZ Berlin-Buch GmbH.  The purity of the 
synthesised oligonucleotides was gauged by positive-mode MALDI-TOF-MS (Table 2.5). 
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Table 2.5 Synthesised oligonucleotides calculated and found MALDI-TOF-MS. 
 Sequencea 
Calculated 
MW [M+H] 
Found MW 
(MALDI)b 
Error 
/ppm 
% GC 
content 
ODN1 5′d(CGCTTGaGTTCGC)3′ 4115.76 4115.8227 16.15 62 
ODN2 
5′
d(CGCTTCaCTTCGC)
3′
 4035.74 4035.8191 18.62 62 
ODN3 5′d(CGCAAGaGAACGC)3′ 4151.80 4151.8688 15.98 62 
ODN4 5′d(CGCAACaCAACGC)3′ 4071.79 4071.8898 24.46 62 
ODN5 5′d(CGCAATaTAACGC)3′ 4101.79 4101.8589 16.92 46 
a a = 35 residue  b 3-Hydroxypicolinic acid (3-HPA) in 1:1 MeCN:H2O (0.5 M) was used as the matrix and mixed 
1:1 with the oligonucleotide dissolved in water (ca. 500 μM) 
 
These sequences were selected to investigate the effect of the local environment on the 
modified base by varying the neighbouring bases.  Purine-rich (ODN3) and pyrimidine-rich 
(ODN1 and ODN2) sequences, and the effect of GC rich (ODN1→4) and AT rich (ODN5) 
oligomers were chosen.  The properties of the oligonucleotides are discussed in Chapter 4. 
 
2.5 Phosphorylation 
 
2.5.1 Introduction 
 
Triphosphorylation of modified nucleosides is required prior to incorporation into nucleic 
acids by polymerase enzymes.  Nucleotide triphosphates are extremely unstable, even at 
low temperatures, which makes their synthesis, storage and handling problematic.131  
Although much research has been conducted into the synthesis of nucleotide 
triphosphates, from the corresponding nucleosides, no general synthetic method has yet 
been developed.   
Routes to nucleotide triphosphates usually require reaction of the nucleoside with an 
electrophilic phosphorous centre.  If this is a monophosphate precursor (such as POCl3), it is 
then reacted further with a nucleophilic pyrophosphate.  One of the most widely applicable 
routes to nucleotide triphosphates was developed independently by Ludwig132 and Ruth 
and Cheng.133  Building on work by Yoshikawa and co-workers,134 they developed a one-pot 
synthesis of nucleotide triphosphates from the corresponding unprotected nucleosides 
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(Scheme 2.26).  This methodology has been found to be one of the most widely applicable 
phosphorylation strategies, particularly for the synthesis of unnatural nucleosides.135 
 
 
Scheme 2.26 Ludwig's one-pot synthesis of ATP from unprotected adenosine. 
 
It was found that the use of trialkylphosphate solvents was key to the selectivity for 5′-
triphosphates, suggested to be due to the formation of a complex between the solvent and 
the nucleoside which activates the 5′-position (Figure 2.5).136  However, recently an 
example of a phosphorylation procedure which gives high selectivity for the 5′-position in a 
more conventional organic solvent, acetonitrile, has been published.137 
 
 
Figure 2.5 Proposed complex formed between triethylphosphate and guanosine. 
 
Another problem with the POCl3-based syntheses is the formation of the Vilsmeier reagent 
(Scheme 2.27, I) from POCl3 and DMF.
138  This activated reagent can go on to form 2′,3′-
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bicyclic phosphate nucleotides (III) or inorganic triphosphate (II).  2′,3′-Bicyclic phosphates 
can also be formed from the decomposition of 2′- or 3′-triphosphates.132 
 
 
Scheme 2.27 Byproducts formed during phosphorylation. 
 
A common alternative route to nucleotide triphosphates was developed by Ludwig and 
Eckstein. 139   This approach uses salicyl chlorophosphite (2-chloro-1,3,2-
benzodioxaphosphorin-4-one, 39) as the α-phosphorus component, which is coupled to the 
nucleoside before addition of pyrophosphate and oxidation of the α-phosphorus to PV 
(Scheme 2.28). 
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Scheme 2.28 Ludwig-Eckstein synthesis of ATP from salicyl chlorophosphite. 
 
This route is advantageous because it allows synthesis of the α-thiophosphate (NTPαS) by 
oxidation with sulfur instead of iodine/water.  It also gives very good selectivity for the 
triphosphate product over mono- or diphosphates, however protection of the 2′- and 3′-
hydroxyls is usually necessary as selectivity for the primary hydroxyl over the secondary 
hydroxyls is poor.  Recently, this synthesis has been improved upon by Huang and co-
workers for the synthesis of ribonucleotides 140  and deoxyribonucleotide. 141   Their 
modification improves the selectivity for triphosphates over mono- and diphosphates by 
pre-forming the triphosphate reagent (42) by reaction of salicyl chlorophosphite with 
pyrophosphate prior to introduction to the nucleoside (Scheme 2.29).  Another benefit is 
the use of unprotected nucleosides in this chemistry.  The ratio of 5′-phosphorylated 
products to 2′- and 3′-triphosphorylated products was found to be ca. 85:15 for ATP and ca. 
90:10 for dATP (although the crude yield of ATP was only 10%).  The nucleotide 
triphosphates can be used crude or further purified by HPLC, but unlike the POCl3-based 
syntheses the products do not require an FPLC purification step. 
 
 65 
 
 
Scheme 2.29 Synthesis of triphosphitylating reagent from salicyl chlorophosphite. 
 
2.5.2 Phosphorylation using Ludwig conditions 
 
The phosphorylation of the parent compound 20a was attempted using both methods 
described above.  The phosphorylation was carried out using a procedure developed in-
house based on the Ludwig conditions (Scheme 2.30).142   
 
 
Scheme 2.30 Attempted synthesis of nucleotide triphosphate using Ludwig conditions. 
 
The crude reaction mixture was dried under vacuum and then purification by FPLC (DEAE 
Sephadex) was attempted.  Several problems were encountered at this stage of the 
synthesis.  Elution of the triphosphate from the ion-exchange column using a gradient up to 
1 M TEAB (Et3NH2CO3 buffer, pH = 8.0) was not very successful due to the extremely long 
retention time and poor separation of the triphosphate from higher phosphates (Figure 
2.6).  8-Phenyladenosine triphosphate elutes at ca. 0.6 M TEAB on a similar gradient, 
suggesting that the increased lipophilicity of these modified nucleosides may be the cause 
of the problems with the elution and separation by FPLC.142  The buffer concentration was 
increased to 1.2 M but this did not lead to a significant improvement in the retention time 
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or peak breadth.  The very broad peaks may be an indication that the modified nucleotide 
is too non-polar, and therefore close to precipitation. 
 
 
Figure 2.6 Example of an FPLC trace from the purification of NTP 43, the final peak (still eluting at the end of the 
run) is thought to be the triphosphate. 
 
Another problem encountered at this stage of the synthesis was the decomposition of the 
product during purification.  Due to the large volumes of product-containing fractions 
collected after FPLC purification, lyophilisation was not a practical option for obtaining the 
solid product.  Therefore, the product-containing fractions were dried using a rotary 
evaporator, keeping the water bath at <50 °C.  Whilst this ensures that the triphosphate 
product is not completely destroyed, it does result in some decomposition.  At this stage, 
the product could be identified by mass spectrometry.  The product must then be purified 
further by HPLC, at which stage further decomposition can occur, and indeed no product 
was successfully identified after HPLC purification and solvent removal. 
 
2.5.3 Phosphorylation using Huang conditions 
 
Phosphorylation of the parent nucleoside compound was also attempted using Huang’s 
conditions.140  Although Huang and co-workers showed that selectivity for the 5′-position 
 67 
 
was very good, even at room temperature, the selectivity using the 7-modified nucleoside 
was only moderate when the reaction was carried out at 0 °C (Scheme 2.31). 
 
 
Scheme 2.31 Phosphorylation using Huang conditions. 
 
 
2.6 Conclusions 
 
A novel class of 7-deazaadenine nucleosides, both ribo- and deoxyribo-analogues, were 
synthesised using Pd-catalysed cross-coupling chemistry.  4-(Arylethynyl)phenyl boronate 
ester reagents were synthesised using chemoselective Pd-catalysed Sonogashira coupling 
of 4-bromophenyl boronic acid neopentyl glycol ester with terminal acetylenes.  The 4-
(arylethynyl)phenyl boronate esters were then coupled with 7-iodo-7-deazaadenine 
nucleosides under aqueous Suzuki-Miyaura conditions, using the water-soluble phosphine 
ligand TPPTS.  Cs2CO3 was found to be a superior base to K3PO4 or Na2CO3, and the ligand to 
metal ratio was also found to be key in achieving good yields.  The nucleosides were 
isolated in good to excellent yields (68% to quant.). 
The parent deoxyribo-compound (35) was prepared for solid-phase oligonucleotide 
synthesis, with the exocyclic amine protected as a dimethyl formamidine group, and the 5′-
hydroxyl protected with a 4,4′-dimethoxytrityl (DMTr) group.  Phosphitylation of the 
protected nucleoside gave the nucleoside 3′-phosphoramidite, which was commercially 
incorporated into a series of oligonucleotides. 
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Attempts to synthesise the nucleoside 5′-triphosphate were largely unsuccessful due to the 
difficulties encountered in purifying the product.  Using Huang and co-workers’ 
methodology resulted in the formation of triphosphate product, but this was not 
successfully separated from the other nucleoside phosphate products formed. 
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3 Photophysical characterisation of modified nucleosides 
 
3.1  Introduction 
 
3.1.1 Principles of photophysics 
 
Of key importance in the synthesis of fluorescent biological probes are their photophysical 
properties.  To be useful in the study of biochemical and biophysical interactions, the 
compounds must have appropriate spectral properties.  Both the UV-Vis and fluorescence 
properties must be evaluated to determine the effectiveness of the fluorophore.  The 
absorption properties of the chromophore are governed by the Beer-Lambert Law 
(Equation 3.1).  The molar absorption (or extinction) coefficient (ε) (a measure of how 
efficiently the compound absorbs light) can be calculated by measuring the absorbance (A) 
over a range of concentrations (c). 
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Equation 3.1 Beer-Lambert Law.   
I0 = intensity of incident light, I = intensity of transmitted light, l = path length. 
 
The absorption wavelength must be shifted away from the protein and nucleic acid 
absorptions at 280 nm and 260 nm so the fluorophore can be selectively excited.  The 
emission wavelength must then also be shifted away from the emissions of the aromatic 
amino acids (295-350 nm) so the fluorophore can be easily detected.   
UV-Vis absorption occurs when an electron is excited from the HOMO (S0) to the LUMO (S1) 
by a photon.  The absorbance wavelength of a chromophore is therefore dependent on the 
energy gap between the HOMO and LUMO.  The higher the energy of the transition 
between the HOMO and the LUMO, the shorter the wavelength of light required for the 
transition.  UV-Vis transitions can occur between any symmetry allowed combination of 
orbitals, for example, π→π*, n→π* or n→σ*.  Intramolecular charge transfer (ICT) 
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transitions can also occur, whereby the excitation induces a change in charge distribution 
across the molecule.143  These usually occur when the chromophore contains electron 
donor and electron acceptor groups which are in conjugation with each other.  The 
electronic transitions which can occur can be illustrated using a Jablonski diagram (Figure 
3.1).144 
 
 
Figure 3.1 Jablonski diagram showing electronic transistions. 
A = absorbance, F = fluorescence, P = phosphorescence, ISC = intersystem crossing, IC = internal conversion. 
 
If some of the vibrational levels of the ground and excited states overlap, the excited 
electron can decay through non-luminescent (non-radiative) processes (internal 
conversion).  Solvent interactions can then dissipate the energy through collisions with the 
chromophore, or the energy can be lost through vibrational relaxation.  Luminescent 
emission occurs when an electron excited to S1 relaxes by emitting a photon (Figure 3.2).   
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Figure 3.2 Diagram showing radiative and non-radiative decay of electronic excited states. 
 
Luminescent emission can be either fluorescence (decay from a singlet state) or 
phosphorescence (decay from a triplet state, following intersystem crossing).  Luminescent 
emission is generally bathochromically shifted with respect to the absorbance wavelength.  
The difference between the absorbance and emission wavelengths is called the Stokes 
shift, and is due to energy loss through internal conversion (usually to a lower vibrational 
energy level).  The Stokes shift is generally measured in wavenumbers, as this is 
proportional to energy. 
Two key properties of any fluorophore are the quantum yield and the fluorescence lifetime.  
Quantum yield (Φ) is a measure of the efficiency of a fluorophore, i.e., it is a measure of 
what percentage of the photons absorbed are emitted as fluorescence.  It can be expressed 
in terms of the emissive rate (Γ) and the rate of non-emissive decay (knr) (Equation 3.2).
145  
Fluorophores with higher quantum yields are more efficient, and many commercial 
fluorophores have quantum yields close to 1. 
 
Φ 
	
Γ
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Equation 3.2 Equation governing quantum yield. 
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The lifetime of a fluorophore (#) is the average time it spends in the excited state before 
decay to the ground state.  It can also be described as the time taken for the intensity to 
decay to 1/e of the initial value (I0).  The lifetime of the excited state can be used to 
differentiate between fluorescent and phosphorescent emission.  Fluorescence lifetimes 
are short (ca. 10-8 s), whereas phosphorescent lifetimes are usually much longer 
(milliseconds to seconds) due to the forbidden transition between the triplet excited state 
and the singlet ground state.  The fluorescent lifetime is also dependent on the rates of 
both emissive and non-emissive decay (Equation 3.3). 
 
# 
 	
1
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Equation 3.3 Equation governing fluorescence lifetime. 
 
The time-dependence of fluorescence decay can be described by an exponential (or multi-
exponential) decay (Equation 3.4).  Fluorescence lifetimes can therefore be calculated by 
plotting log[I(t)] against t. 
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Equation 3.4 Function for a single exponential fluorescence decay. 
I(t) = Intensity at time t. 
 
3.1.2 Fluorescent probes 
 
Fluorescent probes can be divided into two categories: intrinsic fluorophores and extrinsic 
fluorophores.  Intrinsic fluorophores are those arising from naturally occurring fluorescence 
present in the system being studied.  In biological systems, this is often due to tryptophan 
residues in proteins.  Extrinsic fluorophores are fluorescent probes which are introduced in 
to a system in order to study it.  Extrinsic fluorophores can be covalently or non-covalently 
bonded to the system they are being used in.  When studying biological systems using an 
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extrinsic fluorophore, it is important to know whether the fluorescent label influences the 
system being studied, as attaching large or bulky groups may affect the biological activity. 
Fluorophores generally contain extended conjugated π-systems, as the energy gap 
between the ground and excited states lowers as the conjugation increases.  The 
relationship between conjugation and absorbance maxima was quantified for conjugated 
dienes by Woodward and Fieser in the 1940s.146  Lowering the energy gap increases the 
absorption wavelength, which helps shift the absorbance away from the background amino 
acid and nucleotide absorbances. 
Most commonly used organic fluorophores are based around aromatic cores, such as 
naphthalene and pyrene, or heteroaromatic cores, such as coumarin and pyrrole (Figure 
3.3). 
 
 
Figure 3.3 Examples of common extrinsic fluorophores. 
 
Previous work in the group on 8-modified-adenosines has shown that analogues with 
directly linked aromatic groups such as 8-thienyl- and 8-phenyl-adenosines show increased 
fluorescence (higher quantum yields) compared with arylethynyl substituted analogues.91  
However, the analogues with ethynyl-linked aryl groups showed bathochromically shifted 
absorption and emission maxima compared with their directly linked counterparts, due to 
the extended π-system, often making them more effective for use in real systems. 
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3.2 UV-Vis spectroscopy 
 
UV-Vis spectra of the 7-modified-7-deazaadenosines were recorded in DMSO over five 
concentrations between ca. 1x10-6 M and 1x10-4 M, and the Beer-Lambert law used to 
calculate the molar absorption coefficients (Table 3.1).  DMSO was selected as a solvent for 
comparison to the previously synthesised 8-modified purine nucleosides, and because of 
the good solvation of nucleosides in DMSO.  The UV-Vis spectra show, as expected, that 
increasing the size of the conjugated system causes a bathochromic shift in the absorption 
wavelength.  So 7-phenyl-7-deazaadenosine absorbs at a lower wavelength than 7-(4-
[phenylethynyl]phenyl)-7-deazaadenosine (286 nm and 321 nm respectively).  The 
nucleosides with diphenylacetylene-based substituents (entries 4-6, 8) also exhibit a 
second peak (as a shoulder) in the UV spectrum which is hypsochromically shifted with 
respect to the main peak.  The two peaks in the UV spectrum may be due to two different 
electronic transikons, most likely π→π* and intramolecular charge transfer (ICT).  The UV 
spectrum of the thienyl-containinly compound (entry 7) is more complex, with several 
other peaks present at shorter wavelengths.  The same is true of the napthylethynyl-
substituted nucleoside, which also exhibits a complex absorbance spectrum with peaks at 
287, 298 and 307 nm, in addition to the main bands given in Table 3.1.  These extra 
transitions may be due to vibrational structure which is not resolved in the other 
compounds. 
7-Phenyl-7-deazaadenosine has a similar λmax to an equivalent 8-modified nucleoside, 8-
phenyl-2′-deoxyadenosine, which absorbs at 289 nm in DMSO.91  Their molar absorption 
coefficients are also similar.  However, the differences between 7-phenylethynyl-7-
deazaadenosine and 8-phenylethynyladenosine are more pronounced.  In this case, the 7-
modified compound has a much shorter absorbance wavelength than the 8-modified 
compound (302 nm and 330 nm respectively).51  Investigations into the effect of 
substitution patterns in phenylacetylene dendrimers147 and bis(phenylacetylene)benzene 
systems148 have shown that meta substitution of the phenyl ring leads to interruption of 
the conjugation and isolation of one phenylacetylene unit from the other.  It has been 
observed that 1,3-di(phenylethynyl)benzene has a UV spectrum similar to phenylacetyene, 
however 1,2- and 1,4-di(phenylethynyl)benzene have UV spectra consistent with an 
extended π-system.  Moving the phenylacetylene substituents from the 8-position in 8-
(phenylethynyl)adensoine, to the 7-position in 7-(phenylethynyl)-7-deazaadenosine has a 
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similar effect, disrupting conjugation through the purine ring.  The 8-modified nucleoside 
therefore has a larger conjugated system because it includes the pyrimidine ring (Figure 
3.4). 
 
Table 3.1 UV-Vis spectra of modified nucleosides in DMSO. 
 
 R 
 
λmax /nm λshoulder /nm ε /mol
-1
dm
3
cm
-1
 
1 
 
16 302 322 18300 
2 
 
17 337 353 12900 
3 
 
18 286 - 12400 
4 
 
20a 321 297 21500 
5 
 
20b 321 306 22600 
6 
 
20c 331 309 25400 
7 
 
20d 313 315 21400 
8 
 
20e 328 321 14900 
 
The absorbance spectrum of diphenylacetylene in DMSO has not been reported, however 
its spectra in a variety of other solvents (such as acetonitrile,149 dichloromethane,150 
cyclohexane and ethanol 151 ) are very different from those observed for the 
diphenylacetylene-functionalised nucleosides.  In ethanol, diphenylacetylene has peaks at 
298, 289, 280, 273 and 265 nm.151  The majority of these peaks are due to vibrational 
transitions, and all the peaks are significantly blue-shifted with respect to the absorbances 
observed for the diphenylacetylene-decorated nucleosides.  This suggests that rather than 
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the diphenylacetylene moiety acting as an extrinsic fluorescent label, the nucleobase is 
extending the conjugation and is part of the chromophore.  This is further evidence that, as 
shown in Figure 3.4, the nucleobase is part of the chromophore. 
 
 
Figure 3.4 Differences in conjugation between 8-(phenylethynyl)adenosine and 7-(phenylethynyl)-7-
deazaadenosine. 
 
In general, changing the substituent on the terminal position of the diphenylacetylene 
moiety appears to have a relatively small effect on the UV spectrum.  Examples with 
electron-donating (MeO- and MeS-, Table 3.1, entries 5 and 6) and electron-withdrawing 
(F3C-, entry 8) substituents were synthesised; however there does not appear to be any 
pattern to the UV absorbance maxima.  This may be because the heterocycle can act as an 
electron-donating or electron-withdrawing group, depending on the substituents on the 
chromophore.  This pattern was previously observed in both the 8-phenylethynyl- and 8-
phenyladenosine series. 152   A similar effect was also reported for 2,5-
bis(phenylethynyl)thiophenes.153  However, in this case, there are not enough examples to 
definitively know if this pattern is being followed. 
The 3-thienylethynylphenyl-substituted nucleoside was investigated because 3-
thienylethynylphenyl-substituted heterocycles have shown bathochromically shifted UV 
and emission spectra, compared with phenylethynylphenyl-substituted analogues.154  The 
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thienylethynylphenyl-substituted nucleoside, however, did not show red-shifted UV 
absorbance. 
Overall, the modified nucleosides showed promising UV spectral properties.  The 4-
(phenylethynyl)phenyl-subsituted 7-deazaadenosines have absorbance wavelengths above 
320 nm, suitably shifted away from the natural nucleic acid absorbances (260 nm) and 
tryptophan residue absorbances (280 nm).  Their molar absorption coefficients are also 
high (ca. 20x103 mol-1dm3cm-1) suggesting they are effective chromophores. 
 
3.3 Fluorescence spectroscopy 
 
The fluorescence emission spectra of the modified nucleosides were also recorded in 
DMSO.  The spectra were recorded at concentrations which give a UV absorbance of ca. 0.1 
A.U., in order to minimise inner filter effects.  Quantum yields were measured using an 
integrating sphere.  An integrating sphere reflects >99.9% of the photons emitted and 
allows a steady-state fluorimeter to be used for a direct (primary) measurement of 
quantum yield.  It is also much faster and more efficient than the traditional ratiometric 
(secondary) method.155  The integrating sphere and method used is similar to that 
described by Beeby and co-workers.156  Measurements are made to determine the number 
of photons absorbed by the sample (after subtraction of the background solvent) by 
measuring the emission over a range at the excitation wavelength ±10 nm.  The number of 
photons emitted is then measured by subtracting the emission spectrum of the background 
solvent from the emission spectrum of the sample.  These numbers can be used to give a 
ratio of photons absorbed to photons emitted, provided the spectrometer response is 
accounted for. 
Unlike the analogous 8-modified adenosines, the 7-modified-7-deazaadenosines with small 
substitutions (Table 3.2, entries 1-3) show only weak fluorescence.  As described in Section 
3.3, this is probably due to the reduced conjugation when the substituent is on the 7-
position.  These nucleosides had low quantum yields (less than 2%), compared with the 
high quantum yields seen for 8-phenyl- and 8-phenylethynyladenosines (0.81 and 0.55 
respectively) in DMSO.  The arylethynylphenyl-labelled nucleosides, however, show more 
promising fluorescent properties. 
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Table 3.2 Fluorescence spectroscopy of the modified nucleosides in DMSO. 
 
 R 
 λem 
/nm 
Stokes’ shift 
/cm
-1
 
Φ τ /ns 
1 
 
16 weak - <0.01 4.1 (87%), 0.5 (13%) 
2 
 
17 432 6438 0.02 1.5 (60%), 0.5 (40%) 
3 
 
18 363 7663 <0.01 n.d.† 
4 
 
20a 428 7788 0.74 2.2 (92%), 0.5 (8%) 
5 
 
20b 405 6461 0.78 1.6 (90%), 0.5 (10%) 
6 
 
20c 431 7009 0.76 2.0 (92%), 0.5 (8%) 
7 
 
20d 404 7196 0.32 1.5 (88%), 0.5 (12%) 
8 
 
20e 491 10121 0.41 2.1 (87%), 0.8 (12%) 
 
All the arylethynylphenyl-substituted analogues have high quantum yields, in particular 
compounds 20a, 20b and 20c (Table 3.2, entries 4-6) which all have quantum yields over 
70%.  The thiophene-containing analogue 20d (entry 7) had a lower quantum yield (32%), 
as did the CF3-compound 20e (entry 8, 41%).  The variation in the wavelength of the 
emission maxima for these compounds was much larger than the variation in their 
absorbance maxima.  This gives rise to a large variation in Stokes’ shift.  In particular, the 
CF3-compound has a large Stokes’ shift of 10x10
3 cm-1.  Although fluorescence emission 
spectra generally mirror the absorbance spectra of the fluorophore, in this case the 
emission spectra have only one peak, and do not exhibit the shoulder peaks seen in the 
                                                          
† A good fit could not be obtained for the data collected (see Appendix I). 
 79 
 
absorbance spectra.  This means that although there are two electronic absorbance 
transitions, there is only one fluorescence emission transition.  There are two possible 
explanations for this: either only one absorbance is emissive, or one of the excited states 
converts into the other, before emission from this excited state. 
Fluorescence lifetimes were measured in collaboration with Dr. A Beeby (Durham) using 
Time-Correlated Single Photon Counting (TCSPC).  All the 7-modified-7-deazaadenosines 
were found to have bi-exponential decays, with a major component which varied according 
to the substituent at the 7-position, and a minor component (ca. 10%) which was generally 
around 0.5 ns.  A representative decay spectrum is shown in Figure 3.5.  The fluorescence 
lifetimes of the deoxyribo-analogue 35 (2.3 ns (88%), 0.6 ns (12%)) were very similar to 
those measured for 20a.  Changing the solvent from DMSO to water gave quite different 
lifetime measurements for 35.  Like in DMSO, a double exponential decay gave the best fit, 
but in this case the shorter lifetime component is the dominant pathway (0.4 ns (62%), 0.9 
ns (38%)), and both lifetimes are significantly shorter than the 2.3 ns measured in DMSO.  
The presence of two lifetimes could be due to the fluorophore being in two different 
environments – this could be indicative of aggregation, although no other evidence for this 
was observed.  Alternatively, it could be due to the presence of a second fluorophore, as 
simple substitutions at C7 (such as iodide) give rise to weak fluorescence emission from the 
heterocycle.  In this case, the disconnection between the aromatic systems gives rise to 
two separate fluorescent emissions (Figure 3.4). 
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Figure 3.5 Fluorescence decay spectrum of 20a in DMSO. 
 
3.4 Solvatochromism 
 
Solvatochromism of fluorophores can be informative about the nature of the excited state 
and the electronic transitions giving rise in the absorbance and emission spectra.  The 
effects of solvent on the absorbance and emission spectra of 7-[4-(phenylethynyl)-phenyl]-
7-deazaadenosine (20a) were therefore investigated (Table 3.3).  Solvatochromism also has 
implications for biological applications – solvatochromic fluorescent probes can be used to 
gain insight into the polarity of the local environment.  As water is the “biological solvent”, 
the way the fluorophore behaves in aqueous conditions is very important.  These results 
show that there is a significant drop-off in quantum yield in water, as compared to DMSO.  
Although this is not ideal, the quantum yield of 15% is still useful,157 and is an order of 
magnitude better than the analogues with simple phenyl- or phenylethynyl- substitutions, 
as well as other reported compounds of this type.27 
  
 
 
Table 3.3 The effect of solvent on the spectroscopic properties of 20a. 
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Solvent λmax /nm ε /mol
-1
dm
3
cm
-1
 λem /nm Stokes’ shift /cm
-1
 Quantum Yield 
DMSO 321 21531 428 7788 0.74 
H2O
a 302 19764 429 9802 0.15 
MeOH 306 24875 407 8110 0.46 
CH2Cl2
a 312 25286 394 6670 0.61 
MeCN 308 24313 409 8017 0.62 
EtOH 304 26312 393 7449 0.31 
iPrOH 304 31101 396 7642 0.29 
EtOAca 311 23944 389 6447 0.33 
DMF 318 26630 420 7637 0.78 
a Solutions made from stocks of 20a in DMSO. 
There are relatively small changes in the absorbance and emission spectra for the modified 
nucleoside as the solvent polarity changes.  The absorbance maximum varies between 302 
nm (water) and 321 nm (DMSO), while the emission maximum varies between 393 nm 
(ethanol) and 428 nm (DMSO).  When these changes in absorbance and emission maxima 
are plotted against solvent dielectric, there appears to be only a weak correlation (Figure 
3.6).  Other measures of solvent polarity, such as ET(30),
158 also give very weak correlations 
(Figure 3.7).  If the transikon seen is π→π*, very linle change in the λmax should be observed 
on changing the solvent, however if the UV band is due to intramolecular charge transfer 
(ICT), a significant bathochromic shift would be expected.145  In this case, there is no clear 
correlation between the absorbance wavelength and the solvent polarity, suggesting that 
the observed UV transitions are not due to ICT.  There may be other competing factors, 
such as preferential solvation of the ground or excited electronic states. 
Although there are only poor correlations between the absorbance and emission 
wavelengths, the results do show a strong correlation between the Stokes’ shift and the 
solvent dielectric (Figure 3.8).  This shows that the fluorophore is sensitive to its 
environment, and can detect changes in its local polarity. 
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Figure 3.6. Changes in λmax and λem against solvent dielectric for 20a. 
 
Figure 3.7 Correlation between ET(30) and wavenumber for 20a. 
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Figure 3.8 Correlation between solvent dielectric and Stokes shift for 20a. 
 
3.5 Effect of pH 
 
The effect of changing pH on the UV-Vis and fluorescence spectra can also be informative 
about the nature of the electronic transitions observed.159  To probe the observed spectra 
further, the effect of pH on the UV-Vis spectra has been investigated for 20a in DMSO by 
addition of aqueous 1 M HCl (Figure 3.9).  It has been previously shown that addition of 
acid to a compound exhibiting ICT bands has a dramatic effect on the UV-Vis spectrum.160  
This is generally due to protonation of a lone pair which is then no longer able to donate 
into the ICT system.  In this case, it does appear that a similar, if less pronounced, effect is 
seen.  The main band and the shoulder peak appear to give an “averaged” peak upon 
addition of acid.  Although this could point to the presence of an ICT band it is not 
conclusive.  Rosemeyer and Seela have previously shown by 15N NMR spectroscopy that 
protonation of 7-deazaadenosine nucleosides occurs at the N-1 position.161  They also 
noted that the 7-deaza-nucleoside was more basic than adenosine. 
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Figure 3.9 Effects of decreasing pH on 20a in DMSO. 
 
This initial result shows a clear change in the UV spectrum upon protonation.  To 
investigate this further, buffered solutions were used to probe the effect of pH on the 
fluorescence emission spectra of 20a and 35.  The fluorescence emission spectrum showed 
pronounced quenching on protonation of the nucleoside.  As protonation is known to occur 
on the N-1 position, this suggests that the pyrimidine heterocycle is heavily involved in the 
fluorescence emission.  The dependence of the fluorescence spectra of 35 on pH is shown 
in Figure 3.10.  The intensity at the emission maximum was measured as a function of pH 
and displayed a sigmoidal transition indicative of a single ionisable group being titrated.  
This pH titration curve was fitted with a sigmoidal function (using OriginLab) to determine 
the pKa.  The pKa was found to be 4.35, which is 0.95 pH units less than 2′-deoxytubercidin, 
and 0.85 pH units more than 2′-deoxyadenosine.  The difference in pKa between the 
substituted and unsubstituted 7-deazaadenosines has been previously observed for other 
7-modified 7-deazaadenosines.  7-halo-7-deazadenosines have pKa values between 4.24 (7-
bromo) and 4.42 (7-fluoro), measured by UV-Vis spectroscopy.162  This is thought to be due 
to the electron-withdrawing effect of the halogens, however there does not appear to be a 
direct correlation between the electronegativity of the substituent and the pKa of the 
heterocycle.  7-(1-Propynyl)-7-deazaadenosine also has a lower pKa than the unsubstituted 
heterocycle (pKa = 4.50), which is quite similar to the pKa measured for 35. 
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Figure 3.10 Changes in fluorescence intensity of compound 35 at λ429 in buffered solution with varying pH at 
2.5 μM. 
 
 
3.6 Ab-initio calculations 
 
In an attempt to better understand the differences in the photophysical properties of the 
first- and second-generation 7-modified-7-deazaadenosines, some calculations on model 
systems (N-methyl-7-modified-7-deazaadenines) were carried out by Dr J. Slattery 
(Department of Chemistry, University of York).  
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HOMO: -4.98 eV HOMO: -5.02 eV 
  
  
LUMO: -2.25 eV LUMO: -2.53 eV 
  
  
Figure 3.11 BP86/def2-TZVPP optimised structures for N-methyl-7-phenylethynyl-7-deazaadenine (left) and N-
methyl-7-[4-(phenylethynyl)-phenyl]-7-deazaadenine (right). 
 
The calculations suggest that the HOMO and LUMO of N-methyl-7-phenylethynyl-7-
deazaadenine are distributed quite evenly across the compound, with the HOMO slightly 
more on the nucleobase, and the LUMO weighted towards the phenylethynyl substituent 
(Figure 3.11).  Conversely, the HOMO and LUMO of N-methyl-7-[4-(phenylethynyl)-phenyl]-
7-deazaadenine show a greater separation, with the HOMO on the nucleobase, and the 
LUMO predominantly on the diphenylacetylene subsituent.  This suggests that the modified 
nucleoside could act as a donor-acceptor system, indicating ICT is theoretically possible.  
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Although the wavelengths of the transitions determined from the ab initio calculations do 
not match the measured UV spectra, the calculated values are qualitatively similar.  The 
phenylethynyl- system was found to have the higher energy transition, as observed 
experimentally. 
 
3.7 Conclusions 
  
The photophysical properties of the 7-modified-7-deazaadenosines with simple phenyl- or 
arylethynyl- groups were found to be insufficient for applications in biological systems, 
mainly due to their low quantum yields.  However, the novel nucleosides with 
arylethynylaryl-moieties exhibited promising UV and fluorescence properties, with the UV 
absorbance maxima shifted away from the regions associated with the aromatic amino acid 
residues.  The quantum yields were high in DMSO, and although the quantum yield of the 
parent compound decreased in water (to 15%), this is still an order of magnitude more 
than simple derivatives, such as the phenyl- and phenylethynyl-substituted compounds.  
The changes in the absorbance and emission wavelengths on changing the solvent were 
not consistent with a classical ICT push-pull system, however the Stokes’ shift was found to 
be sensitive to changes in polarity.  Although there is not a clear correlation between local 
polarity and the absorbance and emission maxima, the Stokes’ shift correlations may be 
useful as a probe of local environment in biological systems.  
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4 Oligonucleotide properties 
 
4.1 Introduction 
 
Incorporation of modified nucleotides into nucleic acids can result in a variety of changes, 
to both the properties of the nucleic acid, and the properties of the modified nucleotide.  
For fluorescent nucleotides, this can mean that the fluorescent modification can impact on 
the structure of the nucleic acid.  Many fluorescent base-modifications can affect Watson-
Crick base-pairing, for adenine nucleotides this generally means modifications to the 
exocyclic amine or the C2 position.  Disruption to Watson-Crick base-pairing will decrease 
duplex stability, particularly for shorter oligonucleotides.  Other base-modifications, such as 
8-modified purines, have been shown to interfere with duplex stability by inducing changes 
in sugar conformation.163  It is equally as important to know what impact the environment 
of the nucleic acid has on the modification which has been introduced.  This is particularly 
important for fluorescent nucleotides, which often show significant changes upon 
incorporation.  For example, 2-aminopurine, a commonly used fluorescent nucleobase, 
shows significant quenching (about 2 orders of magnitude) upon incorporation into nucleic 
acids.164 
A variety of techniques can be used to determine the impact of the modified nucleotide on 
the oligonucleotide structure in both the single strands and the duplexes.  Changes in the 
UV/Vis and fluorescence spectra can be informative, particularly for fluorophores sensitive 
to microenvironment.   
 
4.1.1 Melting temperatures 
 
Duplex destabilisation is generally measured by comparing the melting temperature of the 
duplex containing the modification with the unmodified duplex.  This gives an indication of 
whether the modified nucleotide is forming a stable base-pair.  DNA shows a hyperchromic 
change in absorbance upon melting (denaturing).  When the DNA duplex is heated slowly, 
an increase in UV absorbance is observed (usually measured at 260 nm).  The transition 
observed is cooperative; as the duplex begins to melt, the melting becomes more facile.  
This is shown by the characteristic sigmoidal melting curve (Figure 4.1).  The melting 
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temperature (Tm) is defined as the temperature at which half the duplex has melted.  It is 
measured as the point half way between the minimum and maximum UV absorbances.  
Alternatively, the melting curve can be differentiated to give a characteristic first-derivative 
curve, where the melting temperature is the temperature at the maximum of the curve 
(the maximum gradient of the melting curve and mid-point of the melting transition).  
Melting temperatures can also be used to assess base-discrimination with mismatched 
base pairs, by examining the change in melting temperature when a base mismatch is 
present.  Usually, a significant decrease in melting temperature is observed when a base-
pair mismatch is present as compared to the fully complementary sequence.  Many 
frequently used methods for identification of SNPs rely on changes in melting 
temperatures, but using techniques which can differentiate between double-stranded and 
single-stranded DNA.    
 
 
Figure 4.1 Representative sigmoidal melting curve. 
 
4.1.2 Circular dichroism spectroscopy 
 
Circular dichroism (CD) is a useful technique for discerning information about the 
secondary structure of chiral biomolecules such as proteins and nucleic acids.  This 
technique measures the difference between a sample’s absorbance of left and right 
circularly polarised light, which is dependent on the secondary structure of the nucleic 
acid.165  Circular dichroism absorbances are generally converted to extinction coefficients, 
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to give a concentration-independent value.  For biopolymers, the value is generally 
calculated as a mean residue concentration.  Another commonly used unit for circular 
dichroism is molar ellipicity ([θ]), which is directly related to the molar circular dichroism 
(Δε) (Equation 4.1).  
 
∆ 
 	 *+, − .+, 

[0]
3298.2
 
Equation 4.1 Relationship between molar circular dichroism and molar ellipticity. 
 
 It is important to determine the effect of introducing modified nucleotides has on the 
secondary structure, and circular dichroism is an important tool for this.  The different 
nucleic acid secondary structures, A-form, B-form and Z-form, each have characteristic 
circular dichroism spectra.  CD spectra of oligonucleotides have contributions from two 
effects: the base-sugar interaction (dependent on the sugar conformation), and base-base 
interactions (dependent on stacking effects).   
 
The key circular dichroism features of B-form DNA can be seen in a representative 
spectrum of calf thymus DNA (Figure 4.2).  Characteristically, B-form DNA exhibits a 
positive peak at 270-280 nm and a negative peak at 245 nm which can be clearly seen in 
this typical spectrum.  The positive peak at 220 nm is also characteristic, but closer to 200 
nm the voltage of the detector begins to increase, making this region less accurate. 
 
Figure 4.2 CD spectrum of calf thymus DNA. 
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4.1.3 Fluorescence quenching experiments 
 
Fluorescence quenching experiments can be used to investigate the local environment of a 
fluorophore, specifically to provide information about solvent accessibility or local charge.  
For example, quenching experiments are frequently used to determine the environment of 
tryptophan residues within a protein.166  There are a variety of mechanisms by which a 
quencher molecule can interact with fluorophores.  The mechanisms can be divided into 
two main categories: static quenching and dynamic quenching.  Static quenching involves 
formation of a non-fluorescent complex between the fluorophore and a quencher, whereas 
dynamic quenching requires a collision between the quencher and the fluorophore which 
quenches the excited state of the fluorophore in a non-radiative process.  The kinetics of 
quenching reactions can therefore help to distinguish the two types of quenching.  
Dynamic (collisional) quenching is described by the Stern-Volmer equation (Equation 
4.2).167 
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Equation 4.2 Stern Volmer equation for collisional quenching. 
F0 = Fluorescence intensity in the absence of a quencher; F = Fluorescence intensity in the presence of a 
quencher; kq = bimolecular quenching constant; τ0 = lifetime in the absence of quencher; τ = lifetime in the 
presence of quencher; [Q] = concentration of quencher; KSV = Stern-Volmer quenching constant. 
 
Therefore, for dynamic quenching, plots of F0/F against [Q] should give linear plots; 
however linear plots are also observed for static quenching.  The different mechanisms can 
be identified by looking at the effect of temperature on fluorescence quenching in the 
experimental system.  Generally, increasing the temperature will cause increased collisional 
(dynamic) quenching.  Static quenching is reduced at higher temperatures due to 
dissociation of the quencher-fluorophore complex.  Systems in which both static and 
dynamic quenching occur often display upward curving plots of F0/F against [Q].  This data 
can be described by the exponential function given in Equation 4.3.168 
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Equation 4.3 Stern-Volmer equation describing both static and dynamic quenching.   
V = static quenching constant. 
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A variety of quenchers can be used, depending on the application.  Compounds containing 
heavy atoms can quench fluorescence through spin-orbit coupling.  For these applications, 
caesium or iodine are often used.  Caesium is usually added as caesium chloride, which has 
been shown to be only a moderately efficient quencher of tryptophan (Table 4.1).  It is also 
very large, limiting its access to small solvent cavities.  As it is positively charged, it is not 
likely to quench fluorophores in positively charged or hydrophobic environments.  Iodide, 
usually as potassium iodide, has many of the same disadvantages as caesium when used as 
a quencher, although it has been shown to be more efficient for quenching tryptophan 
residues.  Potassium iodide is also light-sensitive, so is usually stabilised with 2-
mercaptoethanol or sodium thiosulfate.  In systems compatible with organic solvents, 
organoiodides such as iodobenzene can be used as neutral iodide quenchers. 
A highly efficient (and water-soluble) neutral fluorescence quencher for tryptophan is 
acrylamide (prop-2-enamide).  Acrylamide has very high permeability of hydrophobic 
pockets in proteins so can quench tryptophan residues not normally accessible to caesium 
chloride or potassium iodide.169 
 
Table 4.1 Efficiency of indole fluorescence quenching at pH 7.0 for several quenchers.166 
Quencher kq /10
-9
M
-1
s
-1
 V /M
-1
 
Cs+ 1.1 - 
I- 6.4 2.0 
acrylamide 7.1 2.5 
 
 
4.1.4 Application to detection of single-nucleotide polymorphisms 
 
The modified nucleotide contains a fluorophore which is in conjugation with the 
nucleobase.  This means it should be directly sensitive to formation of a Watson-Crick base-
pair (Figure 4.3).  Photophysical investigations with the nucleoside have shown that the 
fluorophore shows some environmental sensitivity, so it may be able to detect changes in 
local polarity and solvent accessibility.  Therefore, the nucleotide should be an ideal probe 
of base-pair mismatches.  As described in Chapter 1, base-pair mismatches arising from 
single nucleotide polymorphisms are associated with susceptibility to many diseases.  
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Therefore, simple fluorescence detection of the presence or absence of a SNP is a valuable 
tool for identifying genetic variations.  The effect of base-pair mismatches on the 
fluorescence properties of the oligonucleotides, as well as any structural or physical 
changes, are key to understanding base-pair discrimination.  This will dictate the usefulness 
of the modified nucleotide for assaying SNPs. 
 
 
Figure 4.3 Investigation of base-pair mismatches using the modified oligonucleotides. 
 
4.1.5 Oligonucleotide sequences 
 
The sequences of the modified oligonucleotides and their complementary strands used in 
this section are given below.  The sequences were chosen based on those used by Saito and 
co-workers for investigating base-pair mismatch discrimination.  The range of sequences 
chosen reflects a wide range of environments for the modified nucleotide.  The bases 
flanking the modified nucleotide are varied between C, T and G.  Adenine nucleotides are 
not used as flanking bases to avoid structural distortions which can be caused by runs of 
A.170  The bases in the rest of the sequence are also varied to give a range of sequence 
types, including G∙C rich and both purine-rich and pyrimidine-rich sequences.  Many base-
discriminating nucleotides are only tested in one or two different sequences, but 
examination of a variety of sequences is vital to determine any sequence dependency or 
specific quenching effects. 
 
For oligonucleotides C1, C2, C3, C4 and C5, sequences are as ODN1, ODN2, ODN3, ODN4 
and ODN5, with a = A. 
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ODN1 5′d(CGCTTGaGTTCGC)3’ 
1T 3′d(GCGAACTCAAGCG)5’ 
1C 3′d(GCGAACCCAAGCG)5’ 
1A 3′d(GCGAACACAAGCG)5’ 
1G 3′d(GCGAACGCAAGCG)5’ 
  
ODN2 5′d(CGCTTCaCTTCGC)3’ 
2T 3′d(GCGAAGTGAAGCG)5’ 
2C 3′d(GCGAAGCGAAGCG)5’ 
2A 3′d(GCGAAGAGAAGCG)5’ 
2G 3′d(GCGAAGGGAAGCG)5’ 
  
ODN3 5′d(CGCAAGaGAACGC)3’ 
3T 3′d(GCGTTCTCTTGCG)5’ 
3C 3′d(GCGTTCCCTTGCG)5’ 
3A 3′d(GCGTTCACTTGCG)5’ 
3G 3′d(GCGTTCGCTTGCG)5’ 
  
ODN4 5′d(CGCAACaCAACGC)3’ 
4T 3′d(GCGTTGTGTTGCG)5’ 
4C 3′d(GCGTTGCGTTGCG)5’ 
4A 3′d(GCGTTGAGTTGCG)5’ 
4G 3′d(GCGTTGGGTTGCG)5’ 
  
ODN5 5′d(CGCAATaTAACGC)3’ 
5T 3′d(GCGTTATATTGCG)5’ 
5C 3′d(GCGTTACATTGCG)5’ 
5A 3′d(GCGTTAAATTGCG)5’ 
5G 3′d(GCGTTAGATTGCG)5’ 
  
 
4.2 Spectroscopic properties of the modified oligonucleotides 
 
The UV-Vis and fluorescence properties of the single-stranded oligonucleotides were found 
to be significantly different from the nucleoside monomer.  The absorbance spectra for the 
oligonucleotides show a peak at 322 nm, a 20 nm bathochromic shift compared to the 
nucleoside in water.  The change in absorbance wavelength means that the absorbance 
spectrum is no longer obscured by the intrinsic absorbances of nucleic acids.  This change 
was observed for all the oligonucleotides synthesised (Figure 4.4).  The fluorescence 
emission maxima were also shifted, from 428 nm to ca. 400 nm, with only small variation 
between sequences (Table 4.2, Figure 4.5).  The molar absorbance coefficients were larger 
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than for the nucleoside, and the Stokes’ shifts were smaller, again with only small 
variations between sequences.  The quantum yields, however, varied from 0.024 (ODN2) to 
0.237 (ODN3), depending on the sequence.  The origins of this variation are not clear, as 
comparing ODN1 and ODN3, which both have the modified adenosine adjacent to guanine, 
differ in quantum yield by an order of magnitude (0.025 and 0.237, respectively).  ODN2 
and ODN4, which have the modified base adjacent to cytosine, also differ significantly 
(2.4% and 8.6% respectively). 
 
 
Figure 4.4 Absorbance spectra of modified oligonucleotides (5 μM). 
 
The fluorescence spectra change significantly upon formation of a duplex (Table 4.3).  In 
most cases, the emission maximum wavelength increases slightly (6-12 nm), however for 
ODN5, the emission wavelength decreases by 5 nm.  This will be discussed further in 
Section 4.4.1.  ODN1 and ODN2 show increases in quantum yield upon formation of the 
duplex, but ODN3, ODN4 and ODN5 show decreases in quantum yield compared to the 
single-strand oligonucleotides.  In the duplex, the quantum yields appear to have some 
dependency on the sequence.  ODN1 and ODN3 have the highest quantum yields (11.0% 
and 15.4 % respectively), and both have the modified nucleotide located between 
guanines.  The other oligonucleotides have significantly lower quantum yields, and all have 
the modified nucleotide adjacent to pyrimidines. 
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Table 4.2 UV and fluorescence properties of the single-strand oligonucleotides containing the modified base.   
 
Sequence λem
a
 /nm Stokes’ shift /cm-1 Φ  
ODN1 5′d(CGCTTGaGTTCGC)3′ 400 6056 0.025 
ODN2 5′d(CGCTTCaCTTCGC)3′ 400 6056 0.024 
ODN3 5′d(CGCAAGaGAACGC)3′ 405 6365 0.237 
ODN4 5′d(CGCAACaCAACGC)3′ 404 6303 0.086 
ODN5 5′d(CGCAATaTAACGC)3′ 405 6365 0.061 
a λex = 322 nm. 
 
 
Figure 4.5 Absorbance and emission spectra of modified oligonucleotides. 
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Table 4.3 Comparison of emission wavelength maxima and quantum yields between single-strand 
oligonucleotides and their duplexes. 
 
Sequence λem dsDNA
a
 /nm Δλem
b
 /nm Φ dsDNA ΔΦc 
ODN1 5′d(CGCTTGaGTTCGC)3′ 412 +12 0.110 +0.085 
ODN2 5′d(CGCTTCaCTTCGC)3′ 409 +9 0.035 +0.011 
ODN3 5′d(CGCAAGaGAACGC)3′ 412 +7 0.154 -0.083 
ODN4 5′d(CGCAACaCAACGC)3′ 410 +6 0.054 -0.034 
ODN5 5′d(CGCAATaTAACGC)3′ 400 -5 0.026 -0.035 
a λex = 322 nm, 
b Δλem = λem (dsDNA) - λem (ssDNA), 
c ΔΦ = Φ(dsDNA) – Φ(ssDNA) 
 
4.3 Oligonucleotide secondary structure 
 
4.3.1 Melting temperatures 
 
In order to assess the impact of the modified nucleobase on the stability of the synthesised 
oligonucleotides, their melting temperatures were measured and compared to the 
oligonucleotides containing the natural adenine base.  Melting temperatures for the 
modified base with its correct base pair were measured.  The base opposite the modified 
adenine was then changed to each of the other canonical bases to investigate the effect of 
base-pair mismatches on duplex stability. 
The melting temperatures were recorded by heating a 1:1 mixture of the oligonucleotide 
and its complementary strand in a buffered solution (50 mM sodium phosphate pH 7.0, 0.1 
M NaCl) from 20 °C to 90 °C at 1 °C/min, recording the absorbance at 260 nm.  The same 
process was then repeated for annealing the duplex (90 °C to 20 °C).  The data was 
differentiated, and the differentials fitted to Gaussian curves using OriginLab.   
Table 4.4 shows the melting temperatures for the modified base in each of the sequences, 
with each canonical base opposite (Tm); it also shows the difference between the melting 
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curve containing the modified base with the natural oligonucleotide (ΔTm)
‡.  This data is 
also shown graphically in Figure 4.6. 
For each of the synthesised sequences, some duplex destabilisation was observed when 
the modified adenine was base-paired with thymine compared to the unmodified sequence 
(average destabilisation 6.24 °C).  Although this is significant, it is less than the 
destabilisation associated with no base-pair being formed (average destabilisation 11.76 
°C§). 
  
                                                          
‡ Some of the melting temperatures of the unmodified duplexes were carried out by L. S. Griffin. 
§ Destabilisation calculated by averaging the differences between the base-paired (A-T) and non-
base-paired (A-C, A-G, A-A) melting temperatures of the unmodified oligonucleotides. 
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Table 4.4 Melting temperatures of the modified oligonucleotides. 
 
Sequences Opposite base (X) Tm (control) /°C Tm /°C ΔTm /°C 
ODN1 
1X 
5′
d(CGCTTGaGTTCGC)
3′ 
3′
d(GCGAACXCAAGCG)
5′
 
T 58.9 51.5 -7.5 
C 45.5 47.1 +1.6 
A 47.7 46.0 -1.7 
G 47.5 42.8 -4.7 
ODN2 
2X 
5′
d(CGCTTCaCTTCGC)
3′ 
3′
d(GCGAAGXGAAGCG)
5′
 
T 57.2 48.0 -9.2 
C 31.9 32.6 +0.7 
A 46.8 39.9 -6.9 
G 53.0 47.1 -5.9 
ODN3 
3X 
5′
d(CGCAAGaGAACGC)
3′ 
3′
d(GCGTTCXCTTGCG)
5′
 
T 55.7 49.5 -6.2 
C 42.7 44.4 +1.7 
A 45.8 46.7 +0.9 
G 46.9 40.3 -6.9 
ODN4 
4X 
5′
d(CGCAACaCAACGC)
3′ 
3′
d(GCGTTGXGTTGCG)
5′
 
T 58.5 52.6 -5.9 
C 41.1 46.0 +5.0 
A 48.7 40.7 -8.0 
G 50.7 47.0 -3.7 
ODN5 
5X 
5′
d(CGCAATaTAACGC)
3′ 
3′
d(GCGTTAXATTGCG)
5′
 
T 50.2 47.7 -2.4 
C 35.1 31.9 -3.2 
A 38.6 35.3 -3.3 
G 42.9 42.9 -0.1 
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Figure 4.6 Differences in Tm between modified and unmodified oligonucleotides. 
Error bars =  =>?@A1  ?@A2, for X =T, Tm1 and Tm2: n = 6; for X = C, A or G, Tm1: n = 2, Tm2, n = 6.  
 
It is also clear from Figure 4.6 that the base pair between the modified adenine and 
cytosine is significantly increased compared to the natural base (except in sequence 
ODN5).  The increased stability may be indicative of some additional stabilising interaction 
between the modified adenine and cytosine.  Looking at the difference between the 
modified adenine opposite T and the modified adenine opposite the other bases, however, 
shows no clear trend (Figure 4.7).  The base-pairs with cytosine do not appear to be 
particularly stabilised compared with the other mismatches. 
 
Figure 4.7 Difference between melting temperature of base-paired and mismatched base pairs in modified 
oligonucleotides. 
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4.3.2 Circular dichroism of the modified oligonucleotides 
 
The first observation that is apparent upon comparison of the UV spectrum with the CD 
spectrum is that the absorbance peak for modified adenosine analogue is not present in 
the CD spectrum.  This chromophore is planar and non-chiral, and chemically distant from 
the chiral centres of the molecule.  
The single-strand fluorescent oligonucleotides exhibit very different CD spectra (Figure 4.8).  
Characteristically, B-form DNA displays a positive band at 260-280 nm and a negative band 
at 245 nm.165  ODN2, ODN4 and ODN5 show CD spectra similar to that expected for B-form 
DNA.  This suggests that the nucleotides have adopted the 2′-endo (S) conformation in 
solution, and it is likely that the bases are stacked in a single-strand helix (like in a B-DNA 
helix).  Similar S-S stacked states have been previously observed for single-strand 
deoxyoligonucleotides which display B-form CD spectra.171  Stacking interactions of single-
strand oligonucleotides are thought to be favourable both enthalpically (due to the 
favourable van der Waals interactions) and entropically (due to the hydrophobic 
interactions).172  ODN3 has a strong positive peak at 280 nm, but only a weak negative peak 
at 245 nm.  This is indicative of an A-type structure (or a mixture of A-type and B-type).  It 
suggests that the nucleotides have adopted the 3′-endo (N) conformation, or a mixture of 
2′-endo and 3′-endo conformations (S-N stacked).  Oligonucleotides which form single-
strand helices in solution are not as conformationally locked as those in double helices.  In 
particular, the end nucleotides have greater conformational freedom and have been shown 
to adopt S-N stacked states at the terminal positions.171  ODN1 shows only an extremely 
weak CD spectrum, with a single peak at 280 nm.  This suggests that ODN1 does not have 
any specific secondary structure in solution.   
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Figure 4.8 CD spectra of single-strand oligonucleotides (mean nucleotide values). 
 
Circular dichroism spectra of the duplexes have a similar shape to the single-strand 
oligonucleotides, but with higher intensities.  All the duplexes exhibit CD spectra consistent 
with B-type DNA structures.  Most of the duplexes have CD spectra of comparable 
intensity; however the CD spectrum of ODN2-2T is much stronger than the other duplexes. 
Although its intensity is greater, it is very similar to that of the control duplex C2-2T.  It may 
be that the two runs of four purines enhance base-stacking, giving a larger CD signal.  
Importantly, the CD spectra of the modified duplexes were closely matched to the 
unmodified duplexes.  A representative comparison between the modified duplex and the 
control duplex is shown in Figure 4.10. 
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Figure 4.9 CD spectra of oligonucleotide duplexes (mean base-pair values) at 10 °C. 
 
 
Figure 4.10 Circular dichroism spectra of ODN1-1T and C1-1T at 10 °C. 
 
The circular dichroism spectra of the duplexes were measured at two temperatures, to give 
information for the annealed (10 °C) and melted (75 °C) oligonucleotides (Table 4.5).  In all 
cases the duplexes displayed positive CD bands at ca. 285 nm and 220 nm, and negative 
bands at ca. 250 nm.  The shape of the CD spectra generally stayed the same upon heating 
(Figure 4.11).  This can be seen from the small changes in absorbance maxima and minima; 
however the intensity of the bands decreased significantly in all cases.  This is consistent 
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with a decrease in secondary structure upon heating, although some secondary structure 
may still be present. 
 
 
Figure 4.11 CD spectra of ODN1-1T at 10 °C and 75 °C. 
 
Table 4.5 Major peaks in CD spectra of duplexes at 10 °C and 75 °C. 
 
Temperature 
/°C 
CD peaks 
λ /nm Δε /M-1cm-1 λ /nm Δε /M-1cm-1 λ /nm Δε /M-1cm-1 
ODN1-1T 
10 283 9.0 250 -7.7 221 3.1 
75 277 6.3 249 -2.1 219 2.4 
ODN2-2T 
10 279 36.3 254 -24.6 216 25.7 
75 279 12.6 253 -8.8 218 15.8 
ODN3-3T 
10 282 9.0 254 -7.2 221 3.9 
75 277 6.3 249 -2.0 218 2.2 
ODN4-4T 
10 285 7.0 255 -12.6 221 2.3 
75 282 4.9 250 -5.0 220 1.7 
ODN5-5T 
10 275 5.8 250 -8.2 219 6.3 
75 277 4.1 251 -5.3 220 2.4 
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4.3.3 Fluorescence quenching studies 
 
4.3.3.1 Quenching studies on single-strand oligonucleotides 
 
Potassium iodide, caesium chloride and acrylamide were all investigated as potential 
quenchers of the fluorescent nucleoside. 
 
 
Figure 4.12 Graph showing changes in fluorescence intensity of 35 on addition of quenchers. 
  
Caesium chloride was found to be the least efficient quencher, and acrylamide the most 
efficient for 35 (Figure 4.12).  When 0.25 M CsCl was added, the fluorescence intensity 
decreased by ca. 15%, and did not change significantly if more CsCl was added after this 
point.  Initially, addition of KI to 35 did not appear to give any quenching effect (at 0.1 M), 
but further additions showed some quenching effect.  As caesium was found to be a poor 
quencher for the fluorescent nucleoside, and iodide was expected to be repelled by 
negatively-charged oligonucleotides, acrylamide was chosen as the quencher for further 
study. 
Acrylamide solution was added portion-wise to the oligonucleotides and their duplexes in 
buffered solution at pH 7.0.  There is a large variation in the quenching effect of acrylamide 
on the single-stranded oligonucleotides (Figure 4.13), which may be partially responsible 
for the large differences observed in fluorescence intensities.  The plots of fluorescence 
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intensity against acrylamide concentration show broadly linear plots, although small 
variations due to static quenching are often difficult to observe if the static quenching 
constant is small.  For a single fluorophore system, such as this, the degree of fluorescence 
quenching can be used as a guide to the exposure of the fluorophore to the solvent.  From 
this it is clear that the different single stranded oligonucleotides have different exposures 
to solvent, suggesting perhaps that some secondary structure exists.  CD spectroscopy 
indicates that all the oligonucleotides except ODN1 have a helix-like secondary structure, 
which may shield the non-polar fluorophore from the aqueous solvent.  The efficiency with 
which it can do this will be dependent on the nature of the secondary structure.  The 
differences observed in the CD spectra are indicative of the range and type of secondary 
structures present.  It is clear that the oligonucleotide with the most solvent exposure is 
ODN3, which is also the sequence with the highest quantum yield and fluorescence 
intensity.  Additionally, ODN3 has a strong CD signal, more like A-type structure than the 
other oligonucleotides, which may make the fluorophore more solvent exposed.  ODN1 
shows no helical structure, which may mean that it is folded in such a way as to bury the 
non-polar fluorophore, meaning that it has little solvent exposure. 
 
 
Figure 4.13 Quenching of single-strand oligonucleotides by acrylamide at λ400. 
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Figure 4.14 Stern-Volmer plots for single-strand oligonucleotides 
 
There does appear to be some correlation between solvent accessibility and fluorescence 
intensity of the oligonucleotide, suggesting that this may be the origin of the variation in 
fluorescence observed for the single-strand oligonucleotides, rather than sequence 
dependent quenching (although the sequence may ultimately be responsible for the 
solvent exposure). 
To test whether the oligonucleotides were forming some secondary structure, the 
dependence of fluorescence intensity on temperature was investigated.  Fluorescence 
emission is also expected to vary with temperature as the number of collision events 
(which can cause non-radiative decay) increases with increased temperature.  Therefore 
the effect of temperature on the fluorescence intensity of the unincorporated nucleoside 
was measured as a comparison to the oligonucleotides (Figure 4.15). 
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Figure 4.15 Dependence of fluorescence intensity on temperature: normalised (top panel) and actual (bottom 
panel) data given.  Oligonucleotide fluorescence intensity measured at 400 nm, nucleoside fluorescence 
intensity measured at 365 nm. 
 
From the normalised data it does appear that some “unfolding” occurs upon heating – 
particularly ODN1 which shows a clear increase in fluorescence intensity upon heating.  As 
ODN3 has the highest fluorescence intensity and is the most quenched by acrylamide, it 
suggests that the more solvent-exposed fluorophores have higher emission intensities.  
Therefore, the increase in fluorescence intensity observed for ODN1 upon heating suggests 
that the fluorophore may be more exposed to solvent at higher temperatures.  As the 
curve is nearly straight (with a slight exponential curve), it suggests a non-cooperative 
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secondary structure unfolding.  This is consistent with the CD spectrum which shows very 
little secondary structure, possibly causing the oligonucleotide to fold randomly to bury the 
fluorophore.  However, alone this is clearly not enough to account for the differences in 
fluorescence intensity between the single strand oligonucleotides, and there is no 
correlation between the amount of quenching by acrylamide and the change in 
fluorescence intensity upon heating. 
 
4.3.3.2 Quenching studies on oligonucleotide duplexes 
 
In contrast to the single-strand oligonucleotides, the duplexes show little variation between 
their Stern-Volmer plots (Figure 4.16).  This suggests that the differences between the 
fluorescence intensities of the duplexes are not because they have different solvent 
accessibilities.  This supports the earlier suggestion that, once duplexed, the fluorescence 
intensities are dependent on the oligonucleotide sequence (specifically the neighbouring 
bases). 
   
 
Figure 4.16 Stern-Volmer plots of modified oligonucleotide duplexes. 
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The effects of acrylamide quenching on the mismatched duplexes was not investigated.  
However, it is likely that in mismatched sequences (particularly the purine mismatches), 
the variation in fluorescence intensity is at least partially due to the solvent accessibility of 
the fluorophore. 
 
4.4 Base-discriminating properties of the modified oligonucleotides 
 
4.4.1 Fluorescence titrations 
 
The changes in fluorescence spectroscopy on formation of a duplex were also examined.  
The complementary strand was titrated into a buffered solution of the modified 
oligonucleotide, and the fluorescence spectrum recorded after each addition.  In each case, 
both the emission maximum and the fluorescence intensity change as the duplex is formed, 
and both level out at a 1:1 mixture of modified oligonucleotide and complementary strand.  
Since only small changes are observed after complete duplexation, this suggests that a 
stable 1:1 duplex is formed.  Representative spectra are shown for ODN1 with its 
complementary strand (1T) in Figure 4.17. 
The changes in fluorescence intensity and emission maxima vary significantly between 
sequences, and depending on the base opposite the modified adenine (Figure 4.18).  
Because a wide range of sequences has been chosen to investigate these effects, trends 
have been identified in the fluorescence emission.  However, definitively detecting trends 
would need further investigation. 
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Figure 4.17 Top panel - Fluorescence emission spectra of ODN1 with sequential additions of 1T.  Bottom panel - 
Changes in fluorescence intensity and emission maximum on addition of 1T to ODN1. 
  
When the emission intensities of the correct base-paired (a∙T) duplexes is examined, it is 
clear that the fluorescence intensity is dependent on the bases adjacent to the 
fluorophore.  ODN1 and ODN3 have sequences where the modified base is between 
guanines, and both ODN1-1T and ODN3-3T have similar emission intensities.  Likewise, 
ODN2-2T and ODN4-4T, which both have the modified base adjacent to cytosine, have very 
similar (but lower) fluorescence intensities.  ODN5-5T, with the modified adenine next to 
thymine, has a lower intensity still.  This suggests that the pyrimidine bases have a 
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quenching effect on the fluorophore, and the two pyrimidine bases have different 
quenching effects.  As this neighbouring base-dependent fluorescence is only seen with the 
correctly base-paired sequences, it suggests that the effect is dependent on the formation 
of the A-T base pair.  For the base pair to be formed, the bases must be stacked in the 
duplex.  This base-stacking effect, and the π-π stacking interactions associated with it, must 
be responsible for the sequence-specific fluorescence. 
One trend that is clear from this data is that in each case, when the modified base is 
opposite cytosine, a quenching effect is observed.  All the sequences show very low 
fluorescence (between 5x105 and 1.5x106) when a c7A∙C pair is present.  The origins of this 
quenching effect will be discussed in subsequent sections. 
The differences in fluorescence intensity of the single-strand oligonucleotides suggest that 
more complex factors affect the fluorescence intensity when the nucleotide is not in a 
duplex.  The fluorescence intensity varies dramatically in the single stranded 
oligonucleotides, and this is reflected in the quantum yields (cf. Table 4.2).  In particular, 
ODN3 has much higher fluorescence than all of the other single-strand oligonucleotides.  As 
both ODN1 and ODN3 have the modified nucleobase adjacent to guanine, it is clear that 
this is not the effect of neighbouring bases.  The rest of the sequence in ODN3 is shared 
with ODN4, suggesting that the large difference in fluorescence intensity between ODN3 
and the other oligonucleotides is either not dependent on the primary structure of the 
oligonucleotide, or it is some subtle effect from the combination of that specific sequence 
(or both).  It therefore seems likely that some secondary structure (either helical or 
random) is responsible for at least some of the variation in intensity in the single strand 
oligonucleotides.  The mismatched purine-purine base pairs also show significant 
difference between the sequences.  Once again, there does not appear to be any clear 
pattern to these differences.  In these cases, as the rest of the duplex is expected to be 
base-paired, it may be dependent on the specific conformation that the mismatched base 
pair adopts, and the solvent accessibility and local polarity of these conformations. 
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Figure 4.18 Fluorescence intensities of the duplexes of the modified oligonucleotides. 
  
In order to better understand the variations in fluorescence emission of the single strand 
oligonucleotides which do not seem to be sequence specific, some further understanding 
of any non-specific secondary structure was required.  Aside from sequence, many other 
factors can affect fluorescence intensity.  The solvatochromic studies with the nucleoside 
show strong (if often non-specific) solvent dependence – although it was difficult to see 
patterns in the solvent dependence of the nucleoside, it is clear that the environment 
around the fluorophore has a pronounced effect on the fluorescent properties.  Therefore, 
changes in fluorescence intensity may be indicative of changes in local polarity associated 
with duplex formation, and therefore be dependent on the position of the fluorophore 
relative to the duplex. 
 
4.4.2 pH titrations 
 
In order to understand the variation in fluorescence intensity between the matched and 
mismatched duplexes, the effect of pH on the fluorescence intensity was investigated.  It 
has been previously observed by Seela and co-workers that 7-deazapurine-containing 
oligonucleotides show pH-dependent melting temperatures when mismatch base-pairs 
with cytosine are present.173  Seela proposed that a wobble pair with cytosine could be 
formed if the 7-deazapurine is protonated (Figure 4.19).  They had previously observed that 
the 7-deazaadenine heterocycle is considerably more basic than adenine (c7dA pKa = 5.3; 
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dA pKa = 3.5).  Using 
15N NMR studies, they determined that protonation occurs on the N1 
position.174  A∙C mismatches can be formed with one hydrogen bond between the exocyclic 
amine of the adenosine and the N-3 position of the cytosine.  Protonated adenosine-
cytosine (A+∙C) wobble pairs were proposed by Patel and co-workers for specific 
deoxyoligonucleotides, characterised using 1D 175  and 2D 176  NMR spectroscopy.  The 
structure of the wobble pair wasn’t clear until a crystal structure of a duplex containing an 
A∙C pair was published by Brown and co-workers (Figure 4.20).177  However, neither of 
these techniques gives definitive proof of protonation at N1.  Generally, the protonated 
wobble pair forms only under acidic conditions, and is highly dependent on context within 
the sequence.178  Wobble pairs are more often observed in RNA due to the wide range of 
RNA secondary structures, and indeed A+∙C wobble pairs have been observed in RNA 
hairpin loops.179  Protonation of adenosine is also required for the formation of some 
Hoogsteen base-pairs.  The C∙G*A+ base-pair contains adenosine protonated at N1, and has 
been proposed for pH-dependent triplexes formed under acidic conditions.180 
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Figure 4.19 c7A+∙C wobble pair proposed by Seela and co-workers. 
 
Figure 4.20 Crystal structure of the A+∙C base-pair mismatches in the sequence d(CGCAAATTCGCG) reported by 
Brown and co-workers (PDB ID: 1D99).177 
 115 
 
 
Investigation into the effect of pH variation on the nucleoside emission spectrum showed 
that protonation led to fluorescence quenching (vide supra).  As base-pairs with cytosine 
also led to fluorescence quenching this suggests that a protonated A+∙C wobble pair may be 
the origin of this quenching effect.  
To investigate the effect of pH on the fluorescence of the oligonucleotides, the 
fluorescence emission spectra were measured in buffered solutions with varying pH.  The 
spectra of ODN1 and its duplexes with T and C opposite the modified base are shown in 
Figure 4.21.  From the data collated for all the modified oligonucleotides (Table 4.6), it is 
clear that irrespective of the sequence, the pKas of the oligonucleotides are broadly the 
same.  The single-strand oligonucleotides have pKas around 5.3, significantly higher than 
the pKa of the unincorporated nucleoside (cf. Figure 3.10) negatively charged phosphate 
backbone is known to increase the pKa of nucleobases.
172  Upon formation of the correct 
base-pair with thymine, the pKa decreases to ca. 4.6.  This is expected, as protonation 
would destabilise the base-pair between the modified base and thymine.  The base-pairs 
with cytosine show the opposite trend; the pKa of the modified base increases to around 
7.5.  This means that the nucleotide is 100 times more basic when opposite cytosine.  The 
increase in pKa is consistent with stabilisation by formation of a base-pair.  The 2006 Seela 
paper suggested that incorporation of the nucleobase into oligonucleotides will increase 
the pKa of the heterocycle.  However, these results suggest that the increase in pKa is due 
to the formation of the base-pair; in effect, the base-pair acts as a template for the proton.  
It is also explains the origins of the base-discrimination between thymine and cytosine.  As 
the fluorescence titration experiments were carried out at a pH close to the pKa of the 
nucleotide in the A∙C mismatch, approximately 50% of the base will be protonated.  As it 
has been found that protonation causes fluorescence quenching, this gives rise to selective 
quenching of cytosine at pH 7.0.  At pH 9.0, discrimination between the pyrimidine bases is 
sequence specific (Figure 4.22). 
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Figure 4.21 Effect of varying pH on the fluorescence emission spectra of ODN1 and its duplexes at 400 nm. 
 
 
Table 4.6  pKa values for the modified oligonucleotides and their duplexes, measured from their fluorescence 
spectra. 
 Sequence ODNX pKa ODNX-XT pKa ODNX-XC pKa 
ODN1 5′d(CGCTTGaGTTCGC)3′ 5.25 4.49 7.85 
ODN2 
5′
d(CGCTTCaCTTCGC)
3′
 5.59 4.62 7.71 
ODN3 5′d(CGCAAGaGAACGC)3′ 5.24 4.50 6.49 
ODN4 
5′
d(CGCAACaCAACGC)
3′
 5.18 4.41 7.88 
ODN5 
5′
d(CGCAATaTAACGC)
3′
 5.10 4.94 7.59 
35 - 4.35 - - 
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Figure 4.22 Fluorescence intensity of oligonucleotide duplexes at pH 9.0. 
 
Consequently, this modified nucleotide (and potentially other related 7-deazaadenine 
systems) has useful base-discriminating properties over a relatively small pH range.  This 
work has implications for many other reported 7-deazaadenine fluorescent probes, which 
may form mismatched base pairs below pH 7.0.  This could give misleading results if used in 
an assay for SNP detection.  Very few examples of base-discriminating nucleotides have 
been tested for their tolerance to variations in pH, so it is not known if they may produce 
inaccurate results if at basic or acidic pH.  For example, base-discriminating 7-
deazaadenosine nucleotides which rely on the formation or absence of a base pair causing 
conformational changes (such as the Saito pyrene-labelled nucleotides) may give a false 
positive at slightly acidic pH if and c7A+∙C base-pair is formed.  Likewise, base-discriminating 
7-deazaadenosine nucleotides like the ones described here, which rely on protonated 
c7A+∙C base-pairs causing fluorescence quenching, may give false negative results under 
slightly basic conditions. 
 
4.5 Conclusions 
 
UV/Vis and fluorescence spectroscopy of the fluorescence nucleotide in a variety of 
oligonucleotide 13mers showed that the fluorescence properties are dependent on the 
sequence context, whilst the UV/Vis spectra show little variation.  The fluorescence 
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emission intensities of the single-strand oligonucleotides vary greatly, but with no clear 
relationship to the sequence.  The fluorescence emission intensities of the duplexes, 
however, show a clearer correlation with the sequence.  The duplexes containing the 
modified nucleotide flanked by guanosine (ODN1 and ODN3) have the highest fluorescence 
emission intensity, followed by those duplexes where the fluorescent nucleotide flanked by 
cytidine (ODN2 and ODN4).  Comparing ODN4 and ODN5 it is clear that thymidine has a 
greater quenching effect than cytidine.  The small differences between ODN1 and ODN3, 
and ODN2 and ODN4, which have the same flanking nucleotides but vary between purines 
and pyrimidines in the a±2 and a±3 positions, shows that the differences observed 
between sequences are primarily due to the adjacent nucleotides and not because of 
longer-range effects.  
Melting temperatures of all the fully paired duplexes show significant destabilisation 
compared to the unmodified duplexes.  The base-pair mismatches also show 
destabilisation, except in the case of cytidine mismatches, which mostly show an increase 
in stability compared to the control duplex.   
Comparison of the circular dichroism spectra of the matched duplexes with the unmodified 
duplex spectra shows that they are extremely similar, with all duplexes displaying spectra 
typical of B-form DNA.  CD spectra of the single-strand oligonucleotides reveal variations in 
secondary structure – this could be the cause of the differences observed between the 
fluorescence emission spectra.  This is supported by fluorescence quenching experiments 
with acrylamide which show different solvent accessibility across the sequences, and 
temperature dependence of the fluorescence spectra where increasing the temperature 
can cause either an increase or decrease in fluorescence emission depending on the 
sequence.  Notably, the circular dichroism spectrum of ODN1 shows little secondary 
structure.  ODN1 is also only slightly quenched by acrylamide, and shows an increase in 
fluorescence intensity upon heating (consistent with greater solvent accessibly).  This may 
indicate that ODN1 is folded so as to bury the fluorophore, unfolding upon heating to 
increase its solvent accessibility.   
Fluorescence emission of the mismatched base pairs with adenosine and guanosine were 
found not to be sequence dependent – there appears to be no clear pattern to the 
fluorescence intensities observed for the mismatched base-pairs.  It is likely that subtle 
variation in conformation arising from base-pair mismatches changes the solvent-exposure 
of the nucleotide, and therefore the fluorescence properties.  This could be further 
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investigated by fluorescence quenching studies on the mismatched duplexes.  In every 
case, fluorescence emission arising from cytidine mismatches shows significant quenching. 
The unusual results observed for the cytidine mismatches led to further investigation of 
their dependence on pH.  It has been previously observed that adenosine is capable of 
forming A+∙C mismatched pairs under specific conditions (generally acidic conditions).  This 
has also been indicated for 7-deazaadenosines, which are significantly more basic than 
adenosines.  We measured pKa values for the single-strand oligonucleotides, their matched 
duplexes, and the A∙C mismatches, and found that formation of c7A+∙C mismatches 
increases the pKa of the protonated species from ca. 5.3 (in the single-strand 
oligonucleotide) to ca. 7.5.  The 7-deazaadenosine-cytidine mismatch acts as a template for 
protonation of the nucleobase.  Protonation causes fluorescence quenching, giving rise to 
the observed base-discriminating properties. 
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5 Direct arylation of 2′-deoxyadenosine 
 
5.1 Introduction 
 
As previously described, direct arylation methodology is a useful tool for biaryl synthesis 
without the need for pre-functionalisation of one or both of the substrates (Section 1.4.3).  
It is particularly useful for heterocycles, where the heteroatoms often act as directing 
groups, helping to differentiate between C-H bonds.  The regioselectivity can often be 
further enhanced by the addition of other metal salts, as described for the Pd/Cu-catalysed 
arylation of imidazole reported by Miura and co-workers.  The addition of excess CuI biases 
reactivity towards arylation at C2, rather than C5 of 1-methylimidazole.87  The amount of 
CuI required, however, is dependent on the type of heterocycle (Scheme 5.1).   
 
 
Scheme 5.1 Requirement for CuI additives in the direct arylation of a variety of heterocycles. 
 
This raises questions about the role of CuI in the direct arylation reactions.  The mechanism 
proposed for the direct arylation of adenosine reported by our group (and that of others) 
does not adequately account for the requirement of excess CuI (Scheme 5.2).  However, it 
is clear that CuI can form relatively stable CuI complexes with 2’-deoxyadenosine, therefore 
excess CuI is needed for forming any organocuprate species.  It was found that 2′-
deoxyadenosine forms relatively stable complexes with CuI, coordinated through the 
exocyclic amine and N7 positions.  When the complex [Cu(N6,N7-dA)2]I is subjected to the 
reaction conditions (Pd(OAc)2, PhI, Cs2CO3, piperidine, DMF, 80 °C), only a trace of product 
is formed.  However, when the complex [Cu(N6,N7-dA)2]I.CuI (with Cu:dA = 1:1) is 
subjected to the same conditions, the 8-arylated product is formed in 41% yield.  The 
additional CuI is thought to be destabilising the complex, forming monoligated (and 
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therefore more reactive) Cu species.  Sonogashira reactions with 8-bromoadenosine are 
known to proceed with very low loadings of CuI (2 mol%), suggesting that coordination to 
CuI is not necessarily problematic, although the reaction conditions are different in this 
case (other competing ligands such as alkynes and amines are present). 
 
 
Scheme 5.2 Proposed mechanism for the direct arylation of adenosine. 
 
Bellina, Rossi and co-workers proposed that the requirement for excess CuI in these 
reactions was due to reversible cupration of the heterocycle.  However, it seems unlikely in 
the presence of excess base that the deprotonation reaction will be reversible. 
More recently, a system which employs both palladium and copper in sub-stoichiometric 
amounts has been reported by Huang and co-workers.181  Their system uses PXPd (0.25 
mol%) and Cu(Xantphos)I (1 mol%), and was successful for the arylation of a variety of 
heterocycles affording products in good to excellent yields (Scheme 5.3).  However, these 
conditions were not found to be suitable for the arylation of nucleosides. 
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Scheme 5.3 Co-catalytic Pd/Cu arylation of heterocycles. 
 
It seems that the nature of the copper source, as well as the identity of the substrate, may 
dictate whether excess copper salts are required.  However this area is not fully 
understood, and more work must be done to determine the role of CuI in this reaction.   
One of the great advantages of the direct arylation methodology is that it potentially allows 
for the functionalisation of biological molecules, specifically biopolymers, without the need 
for incorporation of a modified monomer.  In order to apply the chemistry to more 
complex biological molecules, milder conditions must be developed because of the 
temperature-sensitive nature of biomolecules.  Understanding the reaction mechanism is 
key to development of improved, milder reaction conditions. 
 
5.2 Low temperature direct arylation of 2′-deoxyadenosine 
 
A new major challenge in this area is the direct arylation of unmodified oligonucleotides.  A 
major advantage of the methodology developed within our group is the relatively mild 
conditions employed; the direct arylation of 2′-deoxyadenosine can be carried out at 80 °C.  
This is in stark contrast to many analogous arylation procedures, which generally employ 
temperatures between 100 and 160 °C.  However, to be applied to nucleotides or 
oligonucleotides the conditions must be even milder, at most 50-60 °C.  To this end, some 
optimisation of the reaction at lower temperatures has been carried out and is reported 
here.   
Work carried out by T. E. Storr (York) indicated that the role of piperidine in the reaction at 
80 °C was to reduce the PdII pre-catalyst to the Pd0 active catalyst as previously observed by 
Buchwald and others. 182   Therefore, the use of Pd0 catalysts in this reaction was 
investigated (Scheme 5.4).  Initial results showed excellent conversion after 24 h at 60 °C 
using Pd2(dba-4-OMe,4′-CF3)3, a catalyst developed in our group (unpublished),
183 however 
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these results were not found to be repeatable.  It is thought that the catalyst was 
contaminated with Pd0 nanoparticles, and that these may be positively influencing the 
reaction.  Results from a screen of Pd0 catalysts are shown in Table 5.1. 
A variety of Pd0 catalysts (Table 5.1, entries 2-4) showed similar activity.  The increased 
yield when Pd(PPh3)4 was used as the catalyst under air (phosphine oxidation leads to 
release of Pd0 atoms which aggregate via Ostwald ripening processes), the irreproducible 
yield (entry 1) and our suspicions about nanoparticle contamination with this catalyst also 
led to Pd0 nanoparticles being tested in the reaction (entries 6-8).  The low activity 
observed with Pd0 nanoparticles stabilised by polystyrene is thought to be partially due to 
the low solubility of these nanoparticles in DMF.  Pd0 nanoparticles stabilised by PVP (poly-
N-vinyl-pyrrolidone) have been shown within our group to act as an effective catalyst 
source for heterogeneous Suzuki coupling.184  The particles can be reliably synthesised from 
H2[PdCl4] with small particle size distributions (Figure 5.2).  The Pd
0-PVP particles were 
found to give a moderate yield in the direct arylation of 2′-deoxyadenosine at 60 °C (entry 
8).  This catalyst had previously been tested as a palladium source in the direct arylation of 
adenosine at 120 °C.  It was found that much lower catalyst loadings could be used in this 
reaction when Pd0-PVP was the catalyst source.  However, when the direct arylation at 60 
°C was carried out with this palladium source at 0.7 mol%, a significant drop off in yield was 
observed (entry 7).  These conditions are not fully optimised; therefore an ideal catalyst 
loading may lie between these two values.  As catalysis is thought to occur on defect 
positions on the nanoparticle surface, the number of active Pd centres is significantly lower 
than the catalyst loading suggests. 
 
 
Scheme 5.4 Screening reaction for Pd catalysts for the low temperature direct arylation of 2′-deoxyadenosine. 
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Table 5.1 Screening of palladium catalysts in direct arylation of 2′-deoxyadenosine at 60 °C. 
 Palladium catalyst Loading /mol% Yield /% 
1 Pd2(dba-4-OMe,4′-CF3)3 (original sample)
a
 5 81 
2 Pd2(dba-4-OMe,4′-CF3)3 (pure by microanalysis) 5 24 
3 Pd2(dba-4-,4′-OMe)3 5 20 
4 Pd(PPh3)4 5 19 
5 Pd(PPh3)4
b 5 30 
6 Pd0/polystyrene nanoparticles 5 23 
7 Pd0/PVP nanoparticles 0.7 (11 wt% Pd) 20 
8 Pd0/PVP nanoparticles 5 (11 wt% Pd) 52 
a Complex likely contaminated by Pd nanoparticles (formed in the synthesis of the complex or by degradation); b 
Reaction carried out under air 
 
 
Figure 5.1 Representation of Pd nanoparticles supported by PVP. 
Modelled using computational approaches by Prof. A. Lee (Cardiff) 
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Figure 5.2 Histogram showing size-distribution of synthesised Pd(PVP) nanoparticles (measured using the PSA 
macro for ImageJ, minimum particle size set to 1.5 nm).  Inset – TEM image of the Pd(PVP) nanoparticles. 
 
A small variety of phosphine ligands, including both electron-withdrawing and electron-
donating phosphines were also tested in the reaction, using Pd2(dba)3 as the palladium pre-
catalyst and a 2:1 ratio of phosphine:Pd (Table 5.2).  In all cases, a decrease in yield was 
observed when a phosphine was added to the reaction mixture.  This is another indicator of 
Pd nanoparticle involvement.  Coordination of the Pd catalyst by phosphine can slow the 
formation of Pd nanoparticles by stabilising the mononuclear species (especially under 
rigorously inert reaction conditions). 
 
Table 5.2 Screening of phosphine ligands in direct arylation of 2′-deoxyadenosine at 60 °C 
Phosphine Yield /% 
XPhos 31 
P(C
6
F
5
)
3
 9 
PCy
3
 7 
none 42 
Pd2(dba)3.dba (2.5 mol%), phosphine (10 mol%), other conditions as Scheme 5.4. 
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To investigate whether Pd nanoparticles could be the active species in the direct arylation 
reaction at 80 °C with Pd(OAc)2 and piperidine, aliquots were removed from the reaction 
mixture and added to PVP, (Mw = 29000), before the solvent was removed.  Addition of PVP 
stabilises any nanoparticles in solution, so particle growth does not occur just through 
removal of the solvent.  TEM images of the samples showed small particles, ca. 2 nm.  
Higher resolution TEM would be necessary to fully assess the size and shape of the particles 
observed, but the size distribution is very similar to that observed for the pre-synthesised 
Pd(PVP) particles (Figure 5.2).  The group had previously observed Pd nanoparticles in the 
direct arylation reaction of adenosine at 120 °C with Pd(OAc)2.
83 
 
 
Figure 5.3 TEM images Histogram showing size-distribution of samples taken from Pd(OAc)2 with piperidine 
reaction.  Lower image shows an expanded region metal-containing nanoparticles (measured using the PSA 
macro for ImageJ, minimum particle size set to 1.5 nm).  Inset – TEM image of the metal-containing 
nanoparticles. 
 
A small library of aryl iodides was tested in this reaction at lower temperature to 
investigate the substrate scope at this temperature with the Pd0-PVP catalyst (Table 5.3, 
Scheme 5.5).  The reactions were carried out over 48 h to maximise the conversion 
however this did not lead to any enhancement in the product yields. 
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Table 5.3 Investigation of substrate scope at 60 °C over 48 h with Pd0(PVP). 
Ar- Yield /% 
Ph- 50 
4-MeO-C6H4- 55 
3-CF3-C6H4- 25* 
4-F-C6H4- 53 
4-Tol- 38 
*contaminated with N-arylated product. 
 
 
Scheme 5.5 Investigation of substrate scope in direct arylation of 2′-deoxyadenosine at 60 °C. 
 
The significant variation in the yield, dependent on the aryl iodide used, suggests the 
dependency of the conversion on the palladium catalytic cycle.  The rough trend seen here 
is in contrast to the yields observed for the direct arylation at 80 °C with Pd(OAc)2 and 
piperidine, which gave the m-CF3 product in 99% isolated yield.
86
   It may be that cupration 
or transmetallation steps are slower at 60 °C, meaning that the Pd complexes resulting 
from rapid oxidative addition of aryl iodides may be present in solution longer, increasing 
the likelihood of homocoupling or protonation (Scheme 5.6).  It is important that the rates 
of both catalytic cycles are closely matched in order to achieve the optimum yield. 
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Scheme 5.6 Some deactivation pathways of Pd oxidative addition products. 
 
5.3 Role of Cu
I
 salts 
 
As alluded to previously, the role of the stoichiometric CuI additive in these reactions is not 
fully understood.  Understanding the reaction mechanism and identifying the rate-
determining step is crucial to the development of milder conditions.  Changing the 
temperature might also cause a change in the rate-determining step.  Deuteration studies 
were carried out in order to determine the efficiency of the deprotonation step at lower 
temperatures (Scheme 5.7 and Table 5.4). 
 
 
Scheme 5.7 Deuteration of 2′-deoxyadenosine. 
 
Table 5.4 Deuteration of 2′-deoxyadenosine at 60 °C. 
Base % Deuteration 
Cs2CO3 (80 °C) 96
86 
Cs2CO3 75 
Cs2CO3 (extrafine) 84 
Rb2CO3 19 
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Rb2CO3 was considered as an alternative to Cs2CO3, as the change in rate of 
transmetallation may increase the overall rate of reaction.185  2′-Deoxyadenosine was 
deuterated much less efficiently with rubidium carbonate than with caesium carbonate, as 
expected.  Although it still seemed viable as a base, albeit much weaker, when it was used 
in the direct arylation reaction under the standard conditions, no product formation was 
seen.  It is expected that coordination of CuI to the N7 position of the nucleoside will lower 
the pKa of the C8 proton, and aid deprotonation.  However, attempts to test this using 
Rb2CO3 and CuI failed, as coordination of copper to the substrate lead to broad NMR signals 
which could not be integrated.  Substitution of Cs2CO3 with Rb2CO3 in the direct arylation 
reaction led to oxidation of the CuI to a CuII species, and only a trace formation of product. 
It was proposed that the need for excess CuI could be due to a reaction of CuI with Cs2CO3 
to form Cu2CO3, an unreported and presumably highly reactive species (Scheme 5.8).  The 
copper carbonate formed could be responsible for an intramolecular deprotonation-
cupration of the adenosine heterocycle.  If the equilibrium for formation of this copper 
carbonate intermediate lies towards copper iodide then high concentrations of CuI would 
be required for small amounts of copper carbonates to be formed. 
 
 
Scheme 5.8 Proposed reaction of Cs2CO3 with CuI. 
 
To test this hypothesis, the reaction of Cs2CO3 with CuI was examined by in situ IR 
spectroscopic analysis (“ReactIR”).  When Cs2CO3 was mixed with CuI at the same 
concentrations as in the direct arylation reaction, as expected a new IR band, 
corresponding to a metal carbonate was observed at 1652 cm-1 (Figure 5.5 and Figure 5.6).  
The solution also changed colour from colourless (with the Cs2CO3 as a white precipitate) to 
dark yellow (also with precipitate present) (Figure 5.7).  No IR band is observed for the 
Cs2CO3 alone, probably due to its extremely low solubility in DMF.  This seemed to confirm 
the theory of formation of a soluble copper carbonate species.  However, a second new IR 
band was also observed upon addition of the CuI.  The second IR band appeared at 2350 
cm-1, which corresponds directly to carbon dioxide.  Both IR bands quickly level-off, possibly 
due to saturation of the solution.  This suggests that the new carbonate species may be 
decomposing to CO2, which could be a pathway leading to formation of a possibly inactive 
copper species leading to the requirement for excess CuI (Scheme 5.9).  When CuI was 
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replaced with Cu2O in the direct arylation reaction, no product was formed.  This provides 
evidence for a deactivation pathway.  However, it has not been possible to prove if Cu2CO3 
is the active copper species, or merely a step on the deactivation pathway, as it is a 
previously unknown and highly reactive complex.  It is possible that the cupration 
mechanism could be similar to the AMLA-6 (Ambiphilic Metal Ligand Activation) and CMD 
(concerted metalation-deprotonation) transition states proposed by Davies and 
Macgregor186 and Fagnou187 (Figure 5.5).  Despite the unanswered questions, it seems 
highly likely that this is a significant step within the overall context of the arylation 
chemistry. 
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H
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Cu
Cs Cs
Initial coordination mode AMLA-6 or CMD intermediate  
Figure 5.4 Proposed concerted deprotonation-cupration by Cu2CO3 (in DMF). 
 
Cs2CO3 + 2CuI
DMF
Cu2CO3
- 2CsI
Cu2O + CO2 (g)
 
Scheme 5.9 Evolution of CO2 (g) from CuI and Cs2CO3. 
 
Figure 5.5 ReactIR spectra following the reaction of CuI with Cs2CO3 in DMF over time at rt.  The addition of CuI 
was made at 05:50 mins. 
CO2 
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Figure 5.6 Change over time of selected IR bands.  The addition of CuI was made at 05:50 mins. 
 
 
Figure 5.7 Reaction mixture containing CuI and Cs2CO3 in DMF (the reaction monitored by ReactIR). 
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5.4 Conclusions 
 
It has been shown that the direct arylation of 2′-deoxyadenosine can be successfully carried 
out using Pd nanoparticles supported by PVP at 60 °C.  The yields are moderate, however 
direct arylation chemistry at this temperature is rare, so even moderate yields are useful, 
particularly in more structurally complex systems that could be tested in the future (e.g. 
oligonucleotides).  Evidence suggests that Pd nanoparticles play an important role in the 
catalysis, although it is not clear whether the catalysis takes place on the surface of the 
particle, or if the nanoparticles act as a reservoir of mononuclear Pd - this requires a 
comprehensive study in its own right, akin to that conducted for Suzuki-Miyaura cross-
coupling catalysed by Pd(PVP).184  Some insight has also been gained into the role of excess 
CuI.  CuI was found to react with Cs2CO3 to form a species consistent with a metal 
carbonate, as well as CO2 (g).  This is a deactivation pathway, which forms the inactive 
copper salt Cu2O.  The formation of Cu2CO3 could be vital to the success of the reaction.  
DFT studies on the copper-catalysed arylation of related heterocycles such as benzoxazoles 
suugests that the reaction proceeds via a four-membered transition state, and the 
deprotonation is mediated by an alcohol.188  Protection of the nucleoside sugar would 
indicate whether the sugar hydroxyls are acting as the alcohol mediating this reaction. 
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6 Conclusions and Future Work 
 
An overall summary of the thesis is given below, divided into four sections, with a summary 
and perspective on future directions for the research in the final section.  
 
6.1 Design and synthesis of novel fluorescent 7-deazaadenosine 
nucleosides 
 
A novel class of 7-modified-7-deazaadenosine nucleosides containing a diarylacetylene 
fluorophore at the 7-position was proposed (Figure 6.1).  The fluorescent nucleosides were 
designed to be sensitive to their local chemical environment, specifically to DNA 
hybridisation, thus allowing the detection of base-pair formation.  Such fluorescent 
nucleosides are suitable for identification of single-nucleotide polymorphisms (SNPs).   
 
 
Figure 6.1 Novel Rigid-rod fluorescent labels for 7-deazapurine nucleosides. 
 
The 7-deazaadenosine nucleosides were synthesised from the corresponding 7-iodo-7-
deazaadenine nucleoside by Pd-catalysed cross-coupling chemistry with 4-
(arylethynyl)phenylboronic acid derivatives.  The diarylacetylene boron reagents were also 
synthesised by Pd-catalysed cross-coupling of a 4-bromophenyl boronic acid derivative.  
Two different organoboronic acid protecting strategies were tested – the boronic acid 
functionality could be converted to a trifluoroborate salt,189 or protected as a boronate 
ester by condensation of the boronic acid with neopentyl glycol.  The boronate ester 
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protecting group strategy was found to be more useful as the products were more easily 
purified (organotrifluoroborate salts are unstable to silica gel).110  The boronate ester 
products were coupled to 7-iodo-7-deazaadenine nucleosides by aqueous Pd-catalysed 
Suzuki-Miyaura coupling, employing the water-soluble ligand TPPTS (Scheme 6.1).  The 
nucleoside products were isolated in good yields. 
 
 
Scheme 6.1 Cross-coupling of 7-modified-7-deazaadenosines with organoboronate esters. 
 
6.2 Characterisation of the 7-deazaadenosine analogues by UV-Vis 
absorption and fluorescence spectroscopy 
 
Photophysical characterisation of the C-modified nucleosides exhibited promising UV-vis 
and fluorescence properties.  In DMSO, the 7-(4-(arylethynyl)phenyl)-7-deazaadenosines 
had high quantum yields (up to 0.78), and absorbance maxima shifted away from the 
intrinsic absorbances associated with proteins and nucleic acids.  These quantum yields are 
a significant improvement on other reported fluorescent 7-deazadenine nucleosides.  The 
nucleosides with smaller π-systems, such as phenyl and phenylethynyl substituents, were 
found to be only very weakly fluorescent, with low quantum yields (<0.02).  The 4-CF3-
substituted analogue (20e) has a larger Stokes’ shift than the other analogues, which could 
be due to the ‘push-pull’ effect of the electron-withdrawing CF3 group and the electron-rich 
heterocycle.  Investigation of nucleosides with a wider range of substitutions would be 
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required to confirm this.  Solvatochromic studies showed a correlation between solvent 
polarity and Stokes’ shift for the parent compound.  Significant fluorescence quenching was 
observed for the parent compound in water, as was expected for these compounds, with 
the quantum yield decreasing from 0.74 to 0.15.  Although the quantum yield in water is 
significantly lower, this is still a significant improvement on the fluorescent 7-
deazaadenosines developed by Seela and others.27  During the preparation of this work, 
Hocek and co-workers reported a similar system employing biaryl substituents with similar 
photophysical properties to the diarylacetylene compounds (including the observed 
decrease in quantum yield in water).58  There is also a significant change in the fluorescence 
lifetime.  In both DMSO and water the compound shows a double exponential decay, 
however in DMSO the major component (92%) is longer at 2.2 ns.  In water, the ratio of the 
two components changes, and the lifetimes are decreased (0.4 ns (62%), 0.9 ns (38%)).  The 
solvent-dependency of the fluorescence lifetimes could be further investigated in order to 
determine any correlation between polarity and the observed lifetimes.  The changes in 
lifetime may provide a useful probe of chemical environment. 
 
6.3 Characterisation of the modified oligonucleotides by fluorescence and 
CD spectroscopy 
 
The parent nucleoside 20a was incorporated into a series of short deoxyoligonucleotides 
(13mers) using solid-phase synthesis.  The photophysical properties were found to be 
significantly different in the oligonucleotides, with the absorbance maximum at 322 nm 
and the emission maximum at ca. 400 nm, irrespective of sequence.  The quantum yields, 
however, vary from 0.024 to 0.237, depending on the sequence (Table 6.1) but with no 
direct correlation to the neighbouring nucleotides.  Many fluorescent nucleotides are 
quenched upon incorporation into oligonucleotides,164 so the conservation of the quantum 
yields in this case is highly beneficial.  Acrylamide quenching experiments were used to 
probe the structure of the single-strand oligonucleotides further, and in combination with 
examination of the temperature-dependency of the fluorescence spectra, indicated that 
the nature of the secondary structure of the oligonucleotides varied between sequences.  
Some correlation was observed between solvent accessibility (as measured by Stern-
Volmer plots) and quantum yield, with the most solvent-accessible fluorescent nucleotide 
(ODN3) having the highest quantum yield.  Circular dichroism spectroscopy also suggested 
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variation in the secondary structure of the single-strand oligonucleotides, with ODN1 (the 
least solvent accessible fluorophore) showing very little ordered structure, meaning that it 
may be randomly coiled in such that the fluorophore is buried.  This is supported by the 
changes in fluorescence intensity observed upon heating – ODN1 shows an increase in 
fluorescence intensity as the temperature increased.  The other oligonucleotides, however, 
show significant helical structure consistent with the formation of an ordered structure 
similar to B-form DNA, except ODN3, which is more consistent with an A-type structure.  
Further comparison of the CD spectra of the unmodified single-strand oligonucleotides 
with those recorded for the modified oligonucleotides would help elucidate whether the 
differences in secondary structure are due to the presence of the modified nucleotide. 
 
Table 6.1 Summary of the fluorescence properties of the single- and double-stranded oligonucleotides. 
 Sequence 
λem ssDNA
a
 
/nm 
λem dsDNA
a
 
/nm 
Φ ssDNA  Φ dsDNA 
ODN1 5′d(CGCTTGaGTTCGC)3′ 400 412 0.025 0.110 
ODN2 5′d(CGCTTCaCTTCGC)3′ 400 409 0.024 0.035 
ODN3 5′d(CGCAAGaGAACGC)3′ 405 412 0.237 0.154 
ODN4 5′d(CGCAACaCAACGC)3′ 404 410 0.086 0.054 
ODN5 5′d(CGCAATaTAACGC)3′ 405 400 0.061 0.026 
a λex = 322 nm. 
 
The single-strand oligonucleotides were hybridised with their complementary strands, and 
the effect of the modified nucleotide was measured by comparison of the melting 
temperatures with those of the unmodified duplexes.  Significant destabilisation was 
observed for the modified duplexes, although not enough to suggest the absence of a base-
pair.  Unlike the single-strand oligonucleotides, the fluorescence properties of the duplexes 
have a clearer correlation with the sequence.  The emission maximum and quantum yield 
(as well as the fluorescence intensities) are dependent on the bases neighbouring the 
fluorescent nucleotide.  Those sequences with neighbouring guanosines have the highest 
fluorescence.  When the C-modified nucleotide is between pyrimidine bases, some 
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fluorescence quenching is observed, with greater quenching observed for the sequence 
with thymidines (ODN5).  Examination of differences between the single-strand and 
duplexed oligonucleotides was not found to be informative, most likely because the single-
strand oligonucleotides do not have comparable secondary structures (see above).  CD 
spectroscopy of the duplexes showed them to be consistent with B-form DNA, and very 
similar to the unmodified duplexes.  Single-crystal X-ray diffraction of the duplexes would 
be invaluable for identification of any conformational or structural changes caused by 
introduction of the modified nucleotide. 
 
6.4 Characterisation of 7-deazaadenosine analogue as a base-
discriminating fluorescent probe 
 
The application of the fluorescent nucleotide as a probe of hybridisation (base-pair 
formation) was also investigated.  Complementary strands with different bases opposite 
the fluorescent nucleotide were used to examine the effect of base-pair mismatches.  
Comparison with the correctly matched duplex indicated that cytidine mismatches cause 
significant fluorescence quenching.  No clear pattern was observed for purine mismatched 
pairs.  Further work into the origins of the mismatch discrimination between thymidine and 
cytidine led to investigation of the effect of pH on the oligonucleotides.  It was found that 
the mismatch discrimination is due to formation of a protonated A+∙C mismatch base-pair 
as previously proposed by Seela and co-workers (Figure 6.2).173  When a 7-deazaadenosine-
cytidine mismatch is present, the pKa of the 7-deazaadenosine is increased, so that the 
adenosine analogue is partially protonated at pH 7 (Figure 6.3).  As observed for the free 
nucleotide, protonation of the nucleotide heterocycle caused fluorescence quenching.  
Examination of the fluorescence lifetimes across the range of pH values would add further 
understanding to the quenching effect. 
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Figure 6.2 c7A+∙C wobble pair proposed by Seela and co-workers. 
 
 
Figure 6.3 Effect of varying pH on the fluorescence emission at 400 nm of ODN1 and its duplexes (2.5 μM). 
 
Further work could examine the optimum pH for mismatch discrimination, which may be 
lower than pH 7.  As discussed above, there is no clear pattern to the fluorescence 
intensities observed for the purine mismatches.  There are two most likely reasons for the 
variation observed: (a) it is possible that the mismatches cause subtle conformational 
changes which change the solvent exposure of the residues (this could be further 
investigated by acrylamide quenching studies of all the duplexes with purine mismatches); 
(b) slight changes in the pKa of the nucleotides could partially protonate the heterocycle, 
causing some fluorescence quenching.  Examination of the pH dependence of the 
fluorescence spectra, and calculation of the pKa of the nucleotide in each example would 
confirm or disprove this possibility. 
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6.5 Development of milder conditions for the direct arylation of 2′-
deoxyadenosine 
 
In this second strand to the project, efforts were made to improve the direct arylation of 2′-
deoxyadenosine, so that it could be used under milder conditions that in the future would 
be more compatible with more complex oligonucleotide systems.  After screening a variety 
of Pd0 catalysts in the reaction at 60 °C, optimum yields were obtained when Pd(PVP) 
nanoparticles (ca. 2 nm) were used as the catalyst.  The yield of 52% is lower than the 
reaction yield at 80 °C, but still respectable.  Pd clusters or nanoparticles appear to play a 
key role in this reaction, but it is not clear whether they are acting as a reservoir of 
molecular Pd, or if the reaction takes place on the surface of the particle.  More detailed 
studies, similar to those conducted for Suzuki-Miyaura couplings,184 could help identify the 
catalytic species present (work that will continue in York over the coming years).  This 
temperature is extremely low for this class of C-H functionalisation reaction, as most 
chemistry of this type is carried out at extremely high temperatures (120-160 °C).  This 
lower temperature is unusual and emerging as a compatible system for use with more 
complex biomolecules.  Unfortunately this is beyond the scope of this PhD project, but this 
would be the next step.   
Further information about the role of excess CuI in these reactions has also been 
elucidated.  It appears that CuI reacts with Cs2CO3 to release CO2.  This presumably 
proceeds via a CuI carbonate species.  It is not clear with the current information if this is a 
catalytically active intermediate, or a decomposition pathway.  Kinetic studies would help 
explain the mechanism of this reaction, however due to the low solubility of CuI and Cs2CO3 
in the reaction solvent, as well as difficulties in accurate determination of the amount of 
starting material or product (the nucleosides bind to CuI), this is non-trivial. 
 
6.6 Future research perspectives 
 
A novel class of fluorescent base-discriminating 7-deazaadenine nucleosides has been 
synthesised using Pd-catalysed cross-coupling chemistry.  The fluorescent nucleosides were 
incorporated into a series of oligonucleotides, and found to show promising base 
discrimination between pyrimidine match (T) and mismatch (C) base-pairs.  Investigation of 
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the mechanism of the mismatch discrimination showed that protonation of the fluorescent 
nucleotide and formation of a wobble pair was the cause of the fluorescence quenching 
observed.  The highly-pH dependent wobble pair means that mismatch discrimination is 
very pH sensitive.  This has implications for other base-discriminating nucleotides reported 
in the literature, and more generally for the use of 7-deazaadenosines as adenosine 
analogues.  Formation of non-Watson-Crick base-pairs may cause errors in transcription or 
replication of nucleic acids containing these residues.  Further investigation into the 
application of these analogues in sequences associated with SNPs should assess the 
usefulness of these modified nucleotides for biomedical diagnostic applications.  Due to the 
highly pH-sensitive nature of the fluorescent nucleotides, they could also have applications 
as pH-sensitive probes.  The range of analogues synthesised could be expanded to include a 
wider range of substituents, particularly those with more polar (and therefore solubilising) 
properties.  This may also simplify phosphorylation of the nucleotides, and allow 
investigations into their compatibility with nucleic acid polymerase enzymes.  Another area 
for expansion would be the inclusion of 7-deazaguanine nucleosides containing the same 4-
(arylethynyl)phenyl fluorophores.  Studies into the direct arylation of 2′-deoxyadenosine 
has shed light on some key mechanistic details, but further studies would be required to 
fully understand the reaction mechanism.  Application of this methodology to mismatch 
discrimination will be further investigated within our laboratories. 
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7 Experimental 
 
General details 
Dry, N2-saturated solvents were collected from a Grubbs-type solvent system
190 in flame 
and vacuum-dried glassware.  Extra Dry DMF was purchased from Acros and deoxygenated 
by bubbling with N2 for 30 min.  Methanol was dried according to the procedure outlined 
by Williams et al.191  Pd(OAc)2 was purchased from Precious Metals Online.  6-Chloro-7-
deazapurine was purchased from Chemos GmbH.  All other chemicals were purchased from 
Sigma-Aldrich or Alfa Aesar.  Proton (1H), carbon (13C), phosphorus (31P), fluorine (19F) and 
boron (11B) NMR were recorded using a Jeol ECX400, ECS400 or Bruker AMX500 
spectrometer.  1H NMR were referenced to undeuterated solvent according to Fulmer et 
al.192  13C spectra were referenced to deuterated solvent.  31P, 11B and 19F NMR were proton 
decoupled and reported relative to to 85% H3PO4, BF3.OEt2 and CFCl3 respectively.  In all 
cases, the ipso carbon of boron-containing compounds was not observed due to 
quadrupolar coupling.  Mass spectrometry was recorded using ESI on a Bruker Daltronics 
micrOTOF machine, or EI on a Waters GCT Premier.  Mass spectrometry of oligonucleotides 
was carried out using MALDI on a solariX FTMS 9.4T by dissolving the samples in water (ca. 
500 μM) and mixing 1:1 with a solution of 3-hydroxypicolinc acid (0.5 M, 1:1 MeCN/H2O).  
Melting points (Mp) were recorded using a Stuart digital SMP3 machine.  UV/Vis spectra 
were recorded using a Jasco V-550 or a Jasco V-560 spectrophotometer.  Oligonucleotide 
melting curves were measured with a Jasco V-550 fitted with a Jasco PTC-423 Peltier 
device.  Fluorescence spectra were recorded using a Spectromax 3 fluorimeter.  Quantum 
yields were measured using an integrating sphere.  Circular dichroism spectra were run on 
a Jasco J810 CD Spectrophotometer fitted with a Jasco PTC-423 Peltier device.  High 
Performance Liquid Chromatography (HPLC) was carried out using an Agilent 1100 system 
with DAD (diode array detector).  Analytical HPLC was carried out on a Zorbax Eclipse XDB-
C18 5 μm reverse-phase column, monitoring absorbance at 254 nm and semi-preparative 
HPLC was carried out on a Luna 5 μm C18(2) 100 Å  column. 
 
4-Chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine 13 
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Based on the procedure reported by Wilulski et al.104 
4-Chloro-7H-pyrrolo[2,3-d]pyrimidine (2.61 g, 17.1 mmol, 1.0 eq) and KOH (2.39 g, 42.7 
mmol, 2.5 eq) were dissolved in DMF (30 ml).  Iodine (4.39 g, 17.3 mmol, 1.01 eq) in DMF 
(30 ml) was added slowly, and the reaction was stirred at room temperature for 30 min.  
The reaction mixture was then poured onto water and ice (ca. 800 ml) containing 0.5 % 
ammonia and 0.1 % sodium metabisulfite.  A white precipitate formed slowly, and this was 
filtered off.  The precipitate was dissolved in EtOAc, dried over sodium sulfate and filtered.  
The volatiles were removed in vacuo to yield the product as a white solid (3.53 g, 12.7 
mmol, 74 %).  Spectroscopic characterisation was consistent with that previously 
reported.103  1H NMR (400 MHz, DMSO-d6) δ 12.95 (br s, 1H, NH), 8.60 (s, 1H, C2-H), 7.93 (d, 
J = 2.5, 1H, C6-H); 13C NMR (101 MHz, DMSO-d6) δ 151.54, 150.77, 150.52, 133.91, 115.81, 
51.75; ESI HRMS [MH]+ 279.9134 (Calcd. for C6H4ClIN3 279.9133). 
 
4-Chloro-5-iodo-7-[(2,3,5-tri-O-benzoyl)-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidine 
14 
 
 
 
Based on the procedure reported by Seela and Ming.103 
4-Chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine (729 mg, 2.61 mmol, 1.0 eq) was stirred with 
BSA (0.77 ml, 3.1 mmol, 0.5 eq) in dry acetonirile (20 ml) at room temperature for 15 min.  
1-O-Acetyl-2,3,5-O-benzoyl-β-D-ribofuranose (1.45 g, 2.87 mmol, 1.1 eq) and TMSOTf (0.20 
ml, 3.1 mmol, 0.5 eq) were added and the reaction mixture was stirred for a further 10 min 
at rt, followed by 1.5 h at 80 °C.  The reaction mixture was allowed to cool to rt, then 
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diluted with EtOAc (40 ml).  The reaction mixture was then washed with sat. aq. NaHCO3 (2 
x 30 ml) and brine (2 x 30 ml), dried over Na2SO4 and filtered.  The volatiles were removed 
in vacuo to yield the crude product as a yellow gum.  This was redissolved in 
cyclohexane/EtOAc (20 ml 1:1 v/v) and absorbed on to silica.  It was purified by column 
chromatography on silica gel, eluting with cylcohexane/EtOAc (10:1 v/v) to yield the title 
compound as a white solid (1.20 g, 1.66 mmol, 71 %).  Spectroscopic characterisation was 
consistent with that previously reported.103  1H NMR (400 MHz, DMSO-d6) δ 8.60 (s, 1H, C2-
H), 8.30 (s, 1H, C6-H), 7.99 (dd, J = 8.4, 1.3 Hz, 2H, ArH), 7.94 (dd, J = 8.4, 1.3 Hz, 2H, Ar-H), 
7.85 (dd, J = 8.4, 1.3 Hz, 2H, Ar-H), 7.71 – 7.61 (m, 3H, Ar-H), 7.57 – 7.39 (m, 6H, Ar-H), 6.71 
(d, J = 5.1 Hz, 1H, C1′-H), 6.29 (dd, J = 6.1, 5.1 Hz, 1H, C2′-H), 6.13 (app t, J = 5.8 Hz, 1H, C3′-
H), 4.86 (ddd, J = 5.8, 5.0, 3.9 Hz, 1H, C4′-H), 4.80 (dd, J = 12.1, 3.9 Hz, 1H, C5′-Ha), 4.68 (dd, 
J = 12.1, 5.0 Hz, 1H, C5′-Hb); 13C NMR (101 MHz, DMSO-d6) δ 166.0, 165.2, 165.0, 152.2, 
151.5, 151.2, 134.8, 134.5, 134.5, 134.1, 130.0, 129.9, 129.9, 129.9, 129.8, 129.7, 129.7, 
129.4, 129.3, 129.2, 129.2, 129.1, 128.8, 87.0, 79.8, 74.0, 71.2, 63.9, 55.1 (29 of 32 
resonances observed); ESI HRMS [MH]+ 724.0336 (Calcd. for C32H24ClIN3O7 724.0342). 
 
4-Amino-5-iodo-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 15 
 
 
 
Based on the procedure reported by Seela and Ming.103 
4-Chloro-5-iodo-7-[(2′,3′,5′-tri-O-benzoyl)-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidine 
(362 mg, 0.500 mmol) was added to a sealed tube and dissolved in aq. NH3 (5 ml, 25 %) and 
dioxane (5 ml).  The reaction was stirred at 60 °C for 3 days.  The volatiles were removed in 
vacuo and the crude product was redissolved in methanol and absorbed on to silica.  The 
product was then purified by column chromatography on silica gel eluting with 
CH2Cl2/MeOH/Et3N (95:4:1).  The product was dried in vacuo to yield 4-amino-5-iodo-7-(β-
D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine as a white solid (171 mg, 0.436 mmol, 87 %).  
Spectroscopic characterisation was consistent with that previously reported.103  1H NMR 
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(400 MHz, DMSO-d6) δ 8.10 (s, 1H, C2-H), 7.67 (s, 1H, C6-H), 6.67 (br s, 2H, NH2), 6.02 (d, J = 
6.4 Hz, 1H, C1′-H), 5.31 (d, J = 6.4 Hz, 1H, C2′-OH), 5.16 (app t, J = 6.0 Hz, 1H, C5′-OH), 5.12 
(d, J = 5.0 Hz, 1H, C3′-OH), 4.35 (app dt, J = 6.4, 5.0 Hz, 1H, C2′-H), 4.06 (app dt, J = 5.0, 3.1 
Hz, 1H, C3′-H), 3.88 (app q, J = 3.8 Hz, 1H, C4′-H), 3.61 (ddd, J = 12.0, 5.0, 4.0 Hz, 1H, C5′-
Ha), 3.52 (ddd, J = 12.0, 6.0, 3.9 Hz, 1H, C5′-Hb); 13C NMR (101 MHz, DMSO-d6) δ 157.2, 
151.9, 150.2, 127.2, 103.3, 86.8, 85.2, 73.9, 70.5, 61.6, 51.9; ESI HRMS [MH]+ 393.0058 
(Calcd. for C11H14IN4O4 393.0054). 
 
4-Amino-5-phenylethynyl-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 16 
 
 
 
4-Amino-5-iodo-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine (55 mg, 0.14 mmol), 
PdCl2(PPh3)2 (0.9 mg, 1 μmol, 1 mol%), CuI (0.5 mg,3 μmol, 2 mol%) and were added to a 
Schlenk tube under a N2 atmosphere.  Triethylamine (59 μl, 0.42 mmol, 3 eq) and DMF (3 
ml) were added and the reaction was then stirred at room temperature for 5 min.  
Phenylacetylene (19 μl, 0.17 mmol, 1.2 eq) was then added and the reaction was stirred for 
4 hours at room temperature.  The solvent was removed in vacuo and the resulting crude 
product was absorbed on to silica and purified by column chromatography (eluting with 
CH2Cl2/MeOH, 98:2 → 9:1 v/v).  The product was dried in vacuo to give the product as a 
pale yellow solid (42 mg, 0.115 mmol, 83 %).  Mp 149-150 °C (decomp.); 1H NMR (400 MHz, 
DMSO-d6) δ 8.15 (s, 1H, C2-H), 7.90 (s, 1H, C6-H), 7.64 – 7.55 (m, 2H, Ar-H), 7.48 – 7.38 (m, 
3H, Ar-H), 6.73 (br s, 2H, NH2), 6.06 (d, J = 6.1 Hz, 1H, C1′-H), 5.27 (br s, 3H, OH), 4.40 (app t, 
J = 5.6 Hz, 1H, C2′-H), 4.10 (dd, J = 4.9, 3.4 Hz, 1H, C3′-H), 3.91 (app q, J = 3.5 Hz, 1H, C4′-H), 
3.65 (dd, J = 11.9, 3.7 Hz, 1H, C5′-Ha), 3.55 (dd, J = 11.9, 3.7 Hz, 1H, C5′-Hb); 13C NMR (101 
MHz, DMSO-d6) δ 157.8, 152.8, 149.8, 131.1, 128.7, 128.5, 127.2, 122.5, 102.2, 94.7, 86.3, 
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83.0, 76.7, 74.1, 72.1, 70.5, 61.6; ESI HRMS [MH]+ 367.1393 (Calcd. for C19H19N4O4 
367.1401). 
 
4-Amino-5-[(1-naphthyl)ethynyl]-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 17 
 
 
 
4-Amino-5-iodo-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine (42 mg, 0.11 mmol), 
PdCl2(PPh3)2 (0.7 mg, 1 μmol, 1 mol%) and CuI (0.4 mg, 2 μmol, 2 mol%) were added to a 
Schlenk tube under a N2 atmosphere.  Triethylamine (46 μl, 0.32 mmol, 3 eq), and DMF (2.5 
ml) were added and the reaction was stirred at room temperature for 5 min.  1-
Naphthylacetylene (19 μl, 0.13 mmol, 1.2 eq) was then added and the reaction was stirred 
overnight at room temperature.  The solvent was removed in vacuo and the resulting crude 
product was absorbed on to silica and purified by column chromatography (eluting with 
CH2Cl2/MeOH, 98:2 → 9:1 v/v).  The product was dried under reduced pressure to give the 
product as a pale yellow solid (40 mg, 0.095 mmol, 89 %). Mp 123-125 °C (decomp.); 1H 
NMR (400 MHz, DMSO-d6) δ 8.33 – 8.28 (d, J = 8.4, 1H, Ar-H), 8.16 (s, 1H, C2-H), 8.03 (s, 1H, 
C6-H), 8.02-7.95 (m, 2H, Ar-H), 7.88-7.84 (m, 1H, Ar-H), 7.68-7.63 (m, 1H, Ar-H), 7.62-7.57 
(m, 1H, Ar-H), 7.56-7.51 (m, 1H, Ar-H), 6.79 (br s, 2H, NH2), 6.06 (d, J = 6.1 Hz, 1H, C1′-H), 
5.38 (d, J = 6.4 Hz, 1H, C2′-OH), 5.21 (app t, J = 5.5 Hz, 1H, C5′-OH), 5.15 (d, J = 4.8 Hz, 1H, 
C3′-OH), 4.41 (app q, J = 5.8 Hz, 1H, C2′-H), 4.11-4.07 (m, 1H, C3′-H), 3.90 (app q, J = 5.3 Hz, 
1H, C4′-H), 3.64 (app dt, J = 11.7, 4.5 Hz, 1H, C5′-Ha), 3.54 (ddd, J = 11.7, 6.0, 3.9 Hz, 1H, C5′-
Hb); 13C NMR (101 MHz, DMSO-d6) δ 157.6, 152.8, 149.9, 132.8, 132.3, 130.2, 128.8, 128.5, 
127.5, 127.2, 126.7, 125.6, 125.3, 119.9, 102.1, 94.7, 89.0, 87.8, 87.1, 85.3, 73.9, 70.4, 61.5; 
ESI HRMS [MH]+ 417.1543 (Calcd. for C23H21N4O4 417.1557). 
4-Amino-5-phenyl-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 18 
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4-Amino-5-iodo-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine (39.2 mg, 0.100 mmol, 1 
eq), palladium acetate (1.2 mg, 5.0 μmol, 5 mol%), TPPTS (14.2 mg, 25.0 μmol, 25 mol%), 
phenylboronic acid (15.8 mg, 0.130 mmol, 1.3 eq) and sodium carbonate (32 mg, 0.30 
mmol, 3 eq) were added to a Schlenk tube under a N2 atmosphere.  Water/acetonitrile (2:1, 
1.2 ml) was added and the reaction mixture was stirred at 100 °C for 1.5 h.  The reaction 
mixture was allowed to cool to room temperature, and the volatiles were removed in 
vacuo.  The crude product was absorbed on to silica and purified by column 
chromatography, eluting with MeOH/CH2Cl2 (2:98 → 1:9 v/v).  The product was obtained as 
a white solid (24.5 mg, 0.0720 mmol, 72 %). 1H NMR (400 MHz, DMSO-d6) δ 8.15 (s, 1H, C2-
H), 7.55 (s, 1H, C6-H), 7.51 – 7.43 (m, 3H, Ar-H), 7.41 – 7.33 (m, 2H, Ar-H), 6.12 (d, J = 6.2 
Hz, 1H, C1′-H), 5.35 (d, J = 6.4 Hz, 1H, C2′-OH), 5.20 (dd, J = 6.2, 5.0 Hz, 1H, C5′-OH), 5.14 (d, 
J = 4.8 Hz, 1H, C3′-OH), 4.49 – 4.43 (m, 1H, C2′-H), 4.18 – 4.03 (m, 1H, C3′-H), 3.90 (app q, J = 
3.5 Hz, 1H, C4′-H), 3.63 (app dt, J = 11.9, 4.5 Hz, 1H, C5′-Ha), 3.53 (ddd, J = 11.9, 6.2, 3.7 Hz, 
1H, C5′-Hb); 13C NMR (101 MHz, DMSO-d6) δ 157.3, 151.7, 150.9, 129.0, 128.5, 127.0, 121.2, 
116.3, 100.5, 87.0, 85.1, 73.8, 70.6, 61.7; ESI HRMS [MH]+ 343.1403 (Calcd. for C17H19N4O4 
343.1401). 
 
Potassium 4-bromophenyltrifluoroborate
109
 21 
 
 
 
Prepared according to Molander et al.109 
4-Bromophenylboronic acid (1.00 g, 5.00 mmol) was dissolved in THF (40 ml).  Potassium 
hydrogen fluoride (2.30 g, 30.0 mmol, 6.0 eq) was dissolved in water (12.5 ml), and this was 
added slowly to the solution of boronic acid.  The reaction mixture was stirred for 24 h at 
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room temperature.  The solvents were then removed in vacuo, and the crude mixture was 
suspended in acetone (ca. 30ml).  The inorganic salts were removed by filtration and 
washed with hot acetone (5 ml).  The filtrate was collected and the solvent removed in 
vacuo to yield the product as a white solid (1.24 g, 4.73 mmol, 95 %).  Spectroscopic 
characterisation was consistent with that previously reported.  1H NMR (400 MHz, acetone-
d6) δ 7.40 (d, J = 7.8 Hz, 2H, Ar-H), 7.23 (d, J = 7.8 Hz, 2H, Ar-H); 
13C NMR (101 MHz, 
acetone-d6) δ 134.7 (q, J = 1.7 Hz), 129.9, 119.7 (q, J = 0.9 Hz); 
11B NMR (128 MHz, acetone-
d6) δ 2.22 (br q, JF-B = 50.4 Hz);
 19F NMR (376 MHz, acetone-d6) δ -143.09 (q, JB-F = 50.4 Hz); 
ESI MS m/z (%) 224 (99) [11B81BrM-K+]-, 223 (29) [10B81BrM-K+]-, 222 (100) [11B79BrM-K+]-, 221 
(24) [10B79BrM-K+]-; HRMS [M-K+]- 222.9549 (Calcd. for C6H4BBrF3 222.9548); Anal. calcd. for 
C6H4BF3BrK: C 27.41, H 1.53; found: C 26.72, H 1.47. 
 
Potassium 4-(phenylethynyl)phenyltrifluoroborate
108
 22a 
 
 
 
Prepared according to Kim et al.108 
4-Bromophenyltrifluoroborate potassium (131 mg, 0.500 mmol), Pd(OAc)2 (3.4 mg, 3 mol%) 
and XPhos (14.3 mg, 6 mol%) were added to a dry Schlenk tube under a N2 atmosphere.  
DMSO (1 ml) and piperidine 74 μl, 0.75 mmol, 1.5 eq) were added, followed by 
phenylacetylene (82 μl, 0.75 mmol, 1.5 eq).  The reaction was then stirred at 80 °C for 1 h.  
The volatiles were then removed under vacuum at 60 °C.  The crude mixture was then 
resuspended in toluene (5 ml) by sonication and filtered.  The precipitate formed was dried 
on the sinter, then washed into a clean flask with acetone.  This second filtrate was 
collected and the solvent removed in vacuo to give a crude product.  This was used without 
further purification.  Spectroscopic characterisation was consistent with that previously 
reported.  1H NMR (400 MHz, acetone-d6) δ 7.56 – 7.47 (m, 4H, Ar-H), 7.41 – 7.34 (m, 3H, 
Ar-H), 7.30 (d, J = 7.5 Hz, 2H, Ar-H); 13C NMR (101 MHz, acetone-d6) 132.6 (br), 132.1 (br), 
130.4 (br), 129.4 (br), 128.8 (br), 124.9, 120.2, 91.9, 88.1; 11B NMR (128 MHz, acetone-d6) δ 
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2.37 (br s); 19F NMR (376 MHz, acetone-d6) δ -139.54 (br s); ESI
- HRMS [M-K+]- 245.0757 
(Calcd. for C14H9BF3 245.0757). 
 
Potassium 4-[(4-methoxyphenyl)ethynyl]phenyltrifluoroborate
108
 22b 
 
 
 
Prepared according to Kim et al.108 
Potassium 4-bromophenyltrifluoroborate (39.3 mg, 0.150 mmol, 1.0 eq), Pd(OAc)2 (1.0 mg, 
3 mol%) and XPhos (4.3 mg, 6 mol%) were added to a dry Schlenk tube under a N2 
atmosphere.  DMSO (0.3 ml) and piperidine (22 μl, 0.23 mmol, 1.5 eq) were added, 
followed by 4-ethynylanisole (29 μl, 0.23 mmol, 1.5 eq).  The reaction was then stirred at 
80 °C for 1 h.  The volatiles were then removed under vacuum at 60 °C.  The crude mixture 
was then resuspended in toluene (5 ml) by sonication and filtered.  The precipitate formed 
was dried on the sinter, then washed into a clean flask with acetone.  This second filtrate 
was collected and the solvent removed in vacuo to give a crude product.  This was used 
without further purification.  Spectroscopic characterisation was consistent with that 
previously reported.  1H NMR (400 MHz, acetone-d6) δ 7.50 (d, J = 7.7 Hz, 2H, Ar-H), 7.44 (d, 
J = 8.9 Hz, 2H, Ar-H), 7.26 (d, J = 7.7 Hz, 2H, Ar-H), 6.94 (d, J = 8.9 Hz, 2H, Ar-H), 3.83 (s, 3H, 
OCH3); 
13C NMR (101 MHz, acetone-d6) δ 160.5, 133.5, 132.6, 130.2, 120.6, 116.9, 115.0, 
90.4, 88.1, 55.7 11B NMR (128 MHz, acetone-d6) δ 2.41 (br s);
 19F NMR (376 MHz, acetone-
d6) δ -142.36 (br s); ESI
- MS m/z  (%) 275 (100) [11BM-K+]-; 274 (23) [10BM-K+]-; HRMS [M-K+]- 
275.0865 (Calcd. for C15H11BF3O 275.0865). 
 
(4-Methylsulfanylphenylethynyl)trimethylsilane 
 
 
 149 
 
 
Prepared according to Sun et al.193  
4-Bromothioanisole (508 mg, 2.50 mmol), [Pd(PPh3)2Cl2] (17.5 mg, 1 mol%) and CuI (4.8 mg, 
1 mol%) were dissolved in toluene in a flame-dried Schlenk tube.  Triethylamine (25 ml) 
was added, followed by TMS-acetylene (1.24 ml, 3.00 mmol, 1.2 eq).  The reaction mixture 
was stirred at 80 °C for 18 h.  Water (20 ml) was added to the reaction mixture and the 
organic layer was separated.  The aqueous layer was extracted with Et2O (5 x 20 ml).  The 
organic layers were combined, dried over MgSO4, filtered and the solvent removed in 
vacuo.  The crude oil was purified by column chromatography on silica gel eluting with Pet 
Ether 40-60 to give the product as a yellow oil (198 mg, 0.89 mmol, 36%).  Spectroscopic 
characterisation was consistent with that previously reported.  1H NMR (400 MHz, CDCl3) δ 
7.37 (d, J = 8.7 Hz, 2H, Ar-H), 7.15 (d, J = 8.7 Hz, 2H, Ar-H), 2.48 (s, 3H, SCH3), 0.24 (s, 9H, 
Si(CH3)3); 
13C NMR (101 MHz, CDCl3) δ 139.7, 132.4, 125.8, 119.5, 105.0, 94.3, 15.5, 0.1; EI 
HRMS [M]+ 220.0752 (Calcd. for C12H16SSi 220.0742). 
 
4-Methylsulfanylphenylacetylene 
 
 
 
Prepared according to Tour et al. 194 
(4-Methylsulfanylphenylethynyl)trimethylsilane (290 mg, 1.33 mmol) was dissolved in 
MeOH/CH2Cl2 (40 ml, 1:1 v/v) under a N2 atmosphere.  K2CO3 (920 mg, 6.63 mmol) was 
added and the reaction was stirred at rt for 2 h.  The reaction mixture was then poured 
onto water (40 ml) and extracted with Et2O (4x40 ml).  The volatiles were removed in vacuo 
to give the product as a yellow oil (146 mg, 0.989 mmol, 74%).  Spectroscopic 
characterisation was consistent with that previously reported.  1H NMR (400 MHz, CDCl3) δ 
7.40 (d, J = 8.5 Hz, 2H, Ar-H), 7.17 (d, J = 8.9 Hz, 2H, Ar-H), 3.07 (s, 1H, CCH), 2.48 (s, 3H, 
SCH3);  
13C NMR (101 MHz, CDCl3) δ 140.2, 132.5, 125.9, 118.5, 83.6, 77.3, 15.5; APCI MS 
m/z (%) 133.0 (100) [MH]+, 118.0 (1) [MH-Me]+. 
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Potassium 4-[(4-methylsulfanylphenyl)ethynyl]phenyltrifluoroborate 22c 
 
 
 
Potassium 4-bromophenyltrifluoroborate (39.3 mg, 0.150 mmol), Pd(OAc)2 (1.0 mg, 3 
mol%) and XPhos (4.3 mg, 6 mol%) were added to a dry Schlenk tube under a N2 
atmosphere.  DMSO (0.3 ml) and piperidine (22 μl, 0.23 mmol, 1.5 eq) were added, 
followed by 4-ethynylthioanisole (33.4 mg, 0.225 mmol, 1.5 eq).  The reaction was then 
stirred at 80 °C for 1 h.  The volatiles were then removed under vacuum at 60 °C.  The crude 
mixture was then resuspended in acetone (5 ml) and filtered through Celite.  The filtrate 
was collected and the solvent removed in vacuo.  The crude product was then resuspended 
in Et2O and filtered.  The precipitate was dried under vacuum to give the crude product.  
This was used without further purification.  1H NMR (400 MHz, acetone-d6) δ 7.51 (d, J = 8.1 
Hz, 2H, Ar-H), 7.43 (d, J = 8.6 Hz, 2H, Ar-H), 7.28 (d, J = 8.1 Hz, 2H, Ar-H) 7.27 (d, J = 8.6 Hz, 
2H, Ar-H) 2.52 (s, 3H, SCH3); 
13C NMR (101 MHz, acetone-d6) δ 132.7, 132.7, 132.5, 130.2, 
126.7, 100.8, 92.7, 15.1 (8 of 11 resonances observed); 11B NMR (128 MHz, acetone-d6) δ 
2.25 (br s); 19F NMR (376 MHz, acetone-d6) δ -147.17 (br s); ESI
- MS m/z (%) 291 (100) 
[11BMH]+, 290 (24) [10BMH]+,  HRMS [M-K
+]- 291.0639 (Calcd. for C15H11BF3S 291.0635). 
 
4-Bromophenylboronic acid neopentyl glycol ester {IUPAC name: 2-(4-Bromophenyl)-5,5-
dimethyl-1,3,2-dioxaborinane} 26 
 
 
 
Prepared according to Zheng et al.111 
4-Bromophenylboronic acid (1.00 g, 5.00 mmol, 1.0 eq) and 2,2,-dimethylpropanediol (573 
mg, 5.50 mmol, 1.1 eq) were dissolved in toluene (50 ml) and heated to reflux in a Dean-
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Stark apparatus for 16 h (or until production of water ceased).  The toluene was removed in 
vacuo.  The product was purified by column chromatography on silica gel, eluting with 
EtOAc/Pet Ether 40-60 (1:4 v/v).  The product was isolated as a white solid (1.31 g, 4.87 
mmol, 97%). Spectroscopic characterisation was consistent with that previously reported.  
Mp 107-110 °C (lit. 109-111 °C195); 1H NMR (400 MHz, acetone-d6) δ 7.67 (d, J = 8.4 Hz, 2H, 
Ar-H), 7.53 (d, J = 8.4 Hz, 2H, Ar-H), 3.80 (s, 4H, (CH2)2), 1.01 (s, 6H, (CH3)2); 
13C NMR (101 
MHz, acetone-d6) δ 136.5, 131.5, 125.8, 72.8, 32.4, 21.8; 
11B NMR (128 MHz, acetone-d6) δ 
25.6 (s); EI MS m/z (%) 267 (16) [10B79BrM]+; 268 (100) [11B79BrM]+; 269 (33) [10B81BrM]+; 270 
(97); 271 (12) [10B81BrM]+; HRMS [M]+ 268.0276 (Calcd. For C11H14O2BBr 268.0272); Anal. 
calcd. for C11H14O2BBr: C 49.13, H 5.25; found: C 48.88, H 5.21. 
 
4-(Trimethylsilylethynyl)phenylboronic acid neopentyl glycol ester {IUPAC name: 2-(4-
{Trimethylsilylethynyl}phenyl)-5,5-dimethyl-1,3,2-dioxaborinane} 28 
 
 
 
Prepared according to Zheng et al.111 
4-Bromophenylboronic acid neopentyl glycol ester (1.08 g, 4.00 mmol, 1.0 eq), PdCl2(PPh3)2 
(140 mg, 5 mol%), CuI (38.0 mg, 5 mol%) and PPh3 (210 mg, 20 mol%) were added to a 
microwave vial which was sealed with a septum and flushed with argon.  DMF (2.2 ml) and 
Et2NH (6.5 ml were added and the mixture was sparged with argon and stirred to produce a 
dark orange solution.  Trimethylsilylacetylene (630 μl, 4.4 mmol, 1.1 eq) was added and the 
reaction mixture formed a pale yellow solution.  After <2 min, a white precipitate 
(presumably Et2NH2I) was formed.  The septum was replaced with a microwave vial cap and 
the mixture was heated to 120 °C in a microwave for 20 min.  The dark orange/brown 
reaction mixture was then allowed to cool to room temperature and the volatiles removed 
in vacuo.  The crude product was then suspended in water (25 ml) and extracted with 
CH2Cl2 (4x25 ml).  The combined organic fractions were washed with brine (15 ml) and 
dried over Na2SO4, filtered and the solvent removed in vacuo.  This crude material was 
purified by column chromatography on silica gel, eluting with Pet Ether 40-60, followed by 
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Et2O/Pet Ether 40-60 (1:49 v/v) to yield the product as a white solid (804 mg, 2.80 mmol, 
70%).  Spectroscopic characterisation was consistent with that previously reported.  Mp 94-
98 °C; 1H NMR (400 MHz, CDCl3) δ 7.72 (d, J = 8.1 Hz, 2H, Ar-H), 7.4 (d, J = 8.1 Hz, 2H, Ar-H), 
3.76 (s, 4H, (CH2)2), 1.02 (s, 6H, (CH3)2), 0.25 (s, 9H, Si(CH3)3); 
13C NMR (101 MHz, CDCl3) δ 
133.7, 131.2, 125.2, 105.6, 100.1, 95.2, 72.5, 32.0, 22.1, 0.1; 11B NMR (128 MHz, CDCl3) δ 
26.4 (br s); EI MS m/z (%) 270 (36) [10BM-Me]+; 271 (100) [11BM-Me]+; 285 (7) [10BM]+; 286 
(25) [11BM]+; HRMS [M]+ 286.1564 (Calcd. For C16H23O2SiB 286.1558); Anal. calcd. for 
C16H23O2SiB: C 66.13, H 8.10; found: C 66.17, H 8.31. 
 
4-Ethynylphenylboronic acid neopentyl glycol ester {IUPAC name: 2-(4-Ethynylphenyl)-5,5-
dimethyl-1,3,2-dioxaborinane} 29 
 
 
 
Prepared according to Zheng et al.111 
4-(Trimethylsilylethynyl)phenylboronic acid neopentyl glycol ester (301 mg, 1.05 mmol, 1.0 
eq) was dissolved in THF (10.5 ml) and cooled to 0 °C.  TBAF (1.05 ml, 1.0 M in THF, 1.0 eq) 
was added and the reaction mixture stirred at 0 °C for 1 h.  The mixture was then allowed 
to warm to r.t. and stirred for a further 2 h.  Saturated NaHCO3 solution (10 ml) was added 
and the mixture extracted with Et2O (3x10 ml).  The organic fractions were dried over 
Na2SO4, and the solvent removed in vacuo.  The crude mixture could be used without 
further purification, or filtered through a short silica plug (ca. 2 cm) eluting with EtOAc/Pet 
Ether 40-60 (1:4 v/v) to give the title compound quantitatively as a white solid.  
Spectroscopic characterisation was consistent with that previously reported.  Mp 75-77 °C 
(lit. 73-75 °C196) 1H NMR (400 MHz, CDCl3) δ 7.75 (d, J = 8.2 Hz, 2H, Ar-H), 7.48 (d, J = 8.2 Hz, 
2H, Ar-H), 3.77 (s, 4H, (CH2)2), 3.13 (s, 1H, CCH), 1.02 (s, 6H, (CH3)3); 
13C NMR (101 MHz, 
CDCl3) 133.8, 131.3, 124.2, 72.5, 32.0, 22.0; 
11B NMR (128 MHz, CDCl3) δ 25.8 (br s); EI MS 
m/z (%) 213.1143 (18) [10BM]+; 213.1794 (73) [11BM-H]+; 214 (100) [11BM]+; HRMS [M]+ 
214.1163 (Calcd. For C13H15O2B 214.1168); Anal. calcd. for C13H15O2B: C 72.94, H 7.06; 
found: C 72.94, H 7.17. 
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4-(Phenylethynyl)phenylboronic acid neopentyl glycol ester {IUPAC name: 2-(4-
{Phenylethynyl}phenyl)-5,5-dimethyl-1,3,2-dioxaborinane} 27a 
 
 
 
Prepared according to Zheng et al.111 
4-Bromophenyl boronic acid neopentyl glycol ester (538 mg, 2.00 mmol, 1 eq), PdCl2(PPh3)2 
(70.2 mg, 5 mol%), CuI (19.0 mg, 5 mol%) and PPh3 (105 mg, 20 mol%) were added to a 
microwave tube.  A septum was used to seal the tube and it was flushed with argon.  
Diethylamine (3.2 ml) and DMF (1.1 ml) were added, followed by phenylacetylene (264 μl, 
2.40 mmol, 1.2 eq).  The septum was replaced by a lid and the reaction heated to 120 °C in 
a microwave (150 W) for 20 min.  The solvent was then removed in vacuo to give the crude 
product, which was purified by column chromatography on silica gel eluting with Pet Ether 
40-60, followed by EtOAc/Pet Ether 40-60 (1:4 v/v) to give the product as a pale yellow 
solid (508.3 mg, 88%).  Spectroscopic characterisation was consistent with that previously 
reported.  Mp 125-127 °C; 1H NMR (400 MHz, CDCl3) δ 7.78 (d, J = 7.8 Hz, 2H, Ar-H), 7.57 – 
7.48 (m, 4H, Ar-H), 7.39-7.31 (m, 3H, Ar-H), 3.78 (s, 4H, (CH2)2), 1.03 (s, 6H, (CH3)2); 
13C NMR 
(101 MHz, CDCl3) δ 133.8, 131.8, 130.8, 128.5, 128.4, 125.4, 123.4, 90.5, 89.9, 72.5, 32.1, 
22.1; 11B NMR (128 MHz, CDCl3) δ 21.5 (br s); EI MS m/z (%) 178 (100) [M-BO2C5H16+H]
+ 289 
(5) [10BM]+; 290 (42) [11BM]+; HRMS [M]+ 290.1443 (Calcd. For C19H19BO2 290.1482) ); IR 
(ATR) ṽ (cm-1) = 2901 (br w), 2503 (br), 2159 (br), 2029 (br), 1975, 1603, 1477, 1420, 1305, 
1249, 1141, 1124. 
 
4-([4-Methoxyphenyl]ethynyl)phenylboronic acid neopentyl glycol ester {IUPAC name: 2-
(4-{[4-Methoxyphenyl]ethynyl}phenyl)-5,5-dimethyl-1,3,2-dioxaborinane} 27b 
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The title compound was prepared as described for 27a from 4-bromophenyl boronic acid 
neopentyl glycol ester (40.3 mg, 0.150 mmol) and 4-ethynylanisole (23 μl, 0.18 mmol, 1.2 
eq) and isolated as a yellow solid (29.8 mg, 0.0931 mmol, 62%).  Mp 116-118 °C (decomp.); 
1H NMR (400 MHz, CDCl3) δ 7.76 (d, J = 8.3 Hz, 2H, Ar-H), 7.51 – 7.45 (m, 4H, Ar-H), 6.88 (d, 
J = 8.8 Hz, 1H, Ar-H), 3.83 (s, 3H, OCH3), 3.77 (s, 4H, (CH2)2), 1.03 (s, 6H, (CH3)2); 
13C NMR 
(101 MHz, CDCl3) δ 159.8, 133.8, 133.2, 130.7, 125.8, 115.6, 114.1, 90.5, 88.6, 72.5, 55.5, 
32.1, 22.1; 11B NMR (128 MHz, CDCl3) δ 26.7 (br s); EI MS m/z (%) 319 (24) [
10BM]+; 320 
(100) [11BM]+; HRMS [M]+ 320.1599 (Calcd. For C20H21BO3 320.1588); IR (ATR) ṽ (cm
-1) = 
2959, 2918, 2211, 1599, 1476, 1419, 1305, 1245, 1141, 1089. 
 
4-(3-Thienylethynyl)phenylboronic acid neopentyl glycol ester {IUPAC name: 2-(4-[3-
Thienylethynyl]phenyl)-5,5-dimethyl-1,3,2-dioxaborinane} 27d 
 
 
 
The title compound was prepared as described for 27a from 4-bromophenyl boronic acid 
neopentyl glycol ester (107 mg, 0.500 mmol) and 3-ethynylthiophene (74 μl, 1.5 eq) and 
isolated as an off-white solid (101 mg, 0.341 mmol, 68%).  Mp 139-142 °C (decomp.); 1H 
NMR (400 MHz, CDCl3) δ 7.77 (d, J = 8.3 Hz, 2H, Ar-H), 7.52 (dd, J = 3.0, 1.2 Hz, 1H, Ar-H), 
7.50 (d, J = 8.3 Hz, 2H, Ar-H), 7.30 (dd, J = 5.0, 3.0 Hz, 1H, Ar-H), 7.20 (dd, J = 5.0, 1.2 Hz, 1H, 
Ar-H), 3.77 (s, 4H, (CH2)2), 1.03 (s, 6H, (CH3)2); 
13C NMR (101 MHz, CDCl3) δ 133.8, 130.7, 
130.0, 128.8, 125.5, 125.4, 122.5, 89.4, 85.6, 72.5, 32.0, 22.1; 11B NMR (128 MHz, CDCl3) δ 
26.4 (br s); EI MS m/z (%) 209 (13) [10BM-CHCHMe2O]
+; 210 (50) [11BM-CHCHMe2O]
+; 295 
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(21) [10BM]+; 296 (100) [11BM]+; HRMS [M]+ 296.1050 (Calcd. For C17H17SO2B 296.1046); IR 
(ATR) ṽ (cm-1) = 3095, 2949, 2897, 2160 (br), 2031 (br), 1976 (br), 1602, 1474, 1418, 1336, 
1303, 1246, 1134, 1018. 
 
4-([4-Trifluoromethylphenyl]ethynyl)phenylboronic acid neopentyl glycol ester {IUPAC 
name: 2-(4-{[4-Trifluoromethylphenyl]ethynyl}phenyl)-5,5-dimethyl-1,3,2-dioxaborinane} 
27e 
 
 
 
4-Ethynylphenyl boronic acid neopentyl glycol ester (107 mg, 0.500 mmol, 1 eq), 
PdCl2(PPh3)2 (17.5 mg, 5 mol%), CuI (4.8 mg, 5 mol%) and PPh3 (23.6 mg, 20 mol%) were 
added to a microwave tube.  A septum was used to seal the tube and it was flushed with 
Ar.  Diethylamine (1.5 ml) was added, followed by 4-iodobenzotrifluoride (110 μl, 0.750 
mmol, 1.5 eq).  The septum was replaced by a lid and the reaction heated to 120 °C in a 
microwave (150 W) for 25 min.  The solvent was then removed in vacuo to give the crude 
product.  The resulting solid was then  purified by column chromatography on silica gel 
eluting with Et2O/Pet Ether 40-60 (5:95 v/v) to give the product as a pale yellow solid (165 
mg, 0.460 mmol, 92%).  Mp 156-159 °C; 1H NMR (400 MHz, CDCl3) δ 7.80 (d, J = 8.1 Hz, 2H, 
Ar-H), 7.63 (d, J = 9.0 Hz, 2H, Ar-H), 7.60 (d, J = 9.0 Hz, 2H, Ar-H), 7.53 (d, J = 8.1 Hz, 2H, Ar-
H), 3.78 (s, 4H, (CH2)2), 1.03 (s, 6H, (CH3)2); 
13C NMR (101 MHz, CDCl3) 133.9, 132.0, 131.0, 
129.9 (q, J = 33 Hz), 127.3 (central peaks of q observed, J = 1.4 Hz), 125.4 (q, J = 4 Hz), 124.7 
(central peaks of q observed, J = 272 Hz), 124.7, 122.7, 92.3, 89.0, 72.5, 32.1, 22.0; 11B NMR 
(128 MHz, CDCl3) δ 25.9 (br s); 
19F NMR (376 MHz, CDCl3) δ -62.66 (s); EI MS m/z (%) 271 
(21); 272 (88); 357 (21) [10BM]+; 358 (100) [11BM]+; HRMS [M]+ 358.1301 (Calcd. For 
C20H18BO2F3 358.1356); IR (ATR) ṽ (cm
-1) = 2954, 2916, 2214, 1739, 1608, 1477, 1422, 1316, 
1249, 1104, 1064. 
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4-([4-Methylsulfanylphenyl]ethynyl)phenylboronic acid neopentyl glycol ester {IUPAC 
name: 2-(4-{[4-Methylsulfanylphenyl]ethynyl}phenyl)-5,5-dimethyl-1,3,2-dioxaborinane} 
27c 
 
 
 
The title compound was prepared as described for 27e from 4-ethynylphenyl boronic acid 
neopentyl glycol ester (32.1 mg, 0.150 mmol) and 4-bromothioanisole (45.7 mg, 1.5 eq) 
and isolated as a pale yellow solid (32.0 mg, 0.0952 mmol, 63%).  Mp 148-150 °C; 1H NMR 
(400 MHz, CDCl3) δ 7.77 (d, J = 8.1 Hz, 1H, Ar-H), 7.50 (d, J = 8.1 Hz, 2H, Ar-H), 7.44 (d, J = 
8.4 Hz, 2H, Ar-H), 7.21 (d, J = 8.4 Hz, 2H, Ar-H), 3.78 (s, 4H, (CH2)2), 2.50 (s, 3H, SCH3), 1.03 
(s, 6H, (CH3)2); 
13C NMR (101 MHz, CDCl3) δ 139.5, 133.8, 132.1, 130.8, 126.0, 125.5, 119.72, 
119.71, 90.3, 90.0, 72.5, 32.1, 22.1, 15.5; 11B NMR (128 MHz, CDCl3) δ 26.7 (br s);  EI MS 
m/z (%) 355 (21) [10BM]+; 356 (100) [11BM]+; HRMS [M]+ 336.1359 (Calcd. For C20H21SO2B 
336.1359); IR (ATR) ṽ (cm-1) = 2925 (br), 1730, 1603, 1477, 1421, 1342, 1309, 1250, 1128. 
 
1-O-Methyl-2-deoxy-(α,β)-D-ribofuranose 31 
 
 
 
Prepared according to Adamo et al.197 
2′-Deoxy-(α,β)-D-ribose (5.00 g, 37.2 mmol) was stirred in dry MeOH (50 ml) under a N2 
atmosphere.  Acetyl chloride (265 μl, 10 mol%) was added and the reaction was stirred at 
ambient temperature for 1 h.  The reaction was then quenched by addition of NaHCO3 (2 
g), and stirred for a further 5 min.  The mixture was filtered through Celite, and the filtrate 
concentrated in vacuo to yield the product quantitatively as a yellow oil.  The crude product 
was used without further purification.  α:β 1:0.8 1H NMR (400 MHz, DMSO-d6) δ 5.0 (br s), 
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4.97 (dd, J = 5.4, 2.5 Hz, H1β), 4.89 (dd, J = 5.7, 2.3 Hz, H1α), 4.65 (br s), 4.12 (br s), 4.09 
(ddd, J = 10.1, 6.3, 4.6 Hz, H3β), 3.91 (app dt, J = 8.2, 5.0 Hz, H3α), 3.71-3.64 (m, H4α and 
H4β), 3.58-3.31 (m, H5α and H5β, partially obscured by H2O), 3.23 (s, OMeα), 3.20 (s, 
OMeβ), 2.26 (ddd, J = 13.7, 8.2, 5.7 Hz, H2aα), 1.98 (ddd, J = 13.4, 6.3, 2.6 Hz, H2aβ), 1.87 
(app dt, J = 13.4, 5.4 Hz, H2bβ), 1.63 (ddd, J = 13.7, 5.0, 2.3 Hz, H2aα); 
13C NMR (101 MHz, 
DMSO-d6) δ 104.6, 104.1, 87.0, 85.0, 70.9, 70.1, 63.2, 61.4, 54.3, 54.3, 41.1, 41.0; ESI HRMS 
[MNa]+ 171.0627 (Calcd. For C6H12O4Na 171.0628). 
 
1-O-Methyl-2-deoxy-3,5,-di-O-p-toluoyl-(α,β)-D-ribofuranose 32 
 
 
 
Prepared according to Rolland et al.115 
1-O-Methyl-2-deoxy-(α,β)-D-ribofuranose was dissolved in dry pyridine (30 ml) under a N2 
atmosphere and cooled to 0 °C.  p-Toluoyl chloride (11 ml, 2.6 eq) was added dropwise to 
the reaction at 0 °C with stirring.  The reaction mixture was allowed to warm up to room 
temperature and stirred overnight.  The pyridine was removed in vacuo.  Water (75 ml) was 
added to the crude mixture, and the product was extracted with CH2Cl2 (3 x 75 ml).  The 
organic layers were washed with sat. aq. NaHCO3 (2 x 30 ml), HCl solution (2 M, 30 ml) and 
water (30 ml), then dried over NaHCO3, filtered and the solvent removed in vacuo.  The 
crude product could be used without further purification or purified by column 
chromatography on silica gel, eluting with EtOAc/Pet Ether 40-60 (1:9), to yield the product 
as a yellow gum (237 mg, 0.620 mmol, 83%).  1H NMR (400 MHz, CDCl3) δ 8.01-7.88 (m, Ar-
H), 7.22 (t, J = 7.6 Hz, Ar-H), 5.62-5.57 (m, H1β), 5.41 (ddd, J = 8.3, 3.6, 2.2 Hz, H1α), 5.23 
(dd, J = 5.5, 2.1 Hz, H4), 5.19 (d, J = 5.1 Hz, H4), 4.63-4.45 (m, H3α, H3β, H5α, H5β), 3.42 (s, 
OMe), 3.36 (s, OMe), 2.60-2.51 (m, C2α and C2β), 2.42 (s, ArMe), 2.41 (s, ArMe), 2.401 (s, 
ArMe), 2.397 (s, ArMe), 2.31 (app dt, J = 10.9, 5.8 Hz, H2), 2.19 (d, J = 13.8 Hz, H2); 13C NMR 
(101 MHz, CDCl3) δ 166.6, 166.4, 166.4, 166.2, 144.1, 144.0, 143.89, 143.8, 129.9, 129.9, 
129.8, 129.8, 129.2, 129.2, 129.2, 129.2, 127.3, 127.2, 127.1, 127.0, 105.7, 105.1, 82.0, 
81.0, 75.5, 74.7, 65.2, 64.4, 55.3, 55.2, 39.4, 39.4, 21.8, 21.8; ESI HRMS [MNa]+ 407.1462 
(Calcd. For C22H24O6Na 407.1465). 
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1-Chloro-2-deoxy-3,5,-di-O-p-toluoyl-α-D-ribofuranose 6 
 
 
 
Prepared according to Rolland et al.115 
Saturated HCl in acetic acid (ca. 2.3 M) was prepared according to the procedure by Kotera 
and co-workers.198  1-O-Methyl-2-deoxy-3,5,-di-O-p-toluoyl-(α,β)-D-ribofuranose (1.55 g, 
4.03 mmol) was dissolved in acetic acid (11 ml).  The resulting mixture was cooled to ca. 10 
°C, and sat. HCl in AcOH (9 ml) was added.  The mixture was stirred vigorously for a further 
15 min, and a white precipitate was produced.  The precipitate was collected by filtration 
and washed with cold Et2O (50 ml) to yield the α-chloro sugar as a white solid (730 mg, 2.02 
mmol, 50%). **   Spectroscopic characterisation was consistent with that previously 
reported.  1H NMR (400 MHz, CDCl3) δ  7.99 (d, J = 8.1 Hz, 2H, Ar-H), 7.89 (d, J = 8.1 Hz, 2H, 
Ar-H), 7.26 (d, J = 8.0 Hz, partially obscured by CHCl3 peak, Ar-H), 7.24 (d, J = 8.4 Hz, 2H, Ar-
H), 6.48 (app d, J = 5.3 Hz, 1H, C1′-H), 5.56 (ddd, J = 7.5, 3.0, 1.1 Hz, 1H, C3′-H), 4.86 (app dt, 
J = 4.2, 3.0 Hz, 1H, C′-H), 4.68 (dd, J = 12.1, 3.1 Hz, 1H, C5′-Ha), 4.59 (dd, J = 12.1, 4.2 Hz, 1H, 
C5′-Hb), 2.87 (ddd, J = 15.0, 7.4, 5.3 Hz, 1H, C2′-Ha), 2.75 (app dd, J = 15.1, 0.9 Hz, 1H, C2′-
Hb), 2.42 (s, 3H, CH3), 2.41 (s, 3H, CH3), 2.0 (br s, 2H); 
13C NMR (101 MHz, CDCl3) δ 166.5, 
166.2, 144.4, 144.2, 130.0, 129.8, 129.3, 129.3, 126.9, 126.7, 95.4, 84.8, 73.6, 63.6, 44.6, 
21.82, 21.78; ESI HRMS [M-Cl]+ 353.1382 (Calcd. For C21H21O5 353.1384). 
 
4-Chloro-5-iodo-7-[(3,5-di-O-p-toluoyl)-2-deoxy-β-D-ribofuranosyl]-7H-pyrrolo[2,3-
d]pyrimidine
121
 33 
 
 
                                                          
** Product isomerises in the presence of atmospheric water and in solution to give a mixture of α- 
and β-anomers.  Stored in a vacuum desiccator over MgSO4. 
 159 
 
 
Prepared according to Seela et al.121  
Finely powdered KOH (94.1 mg, 1.68 mmol, 2.1 eq) was stirred in dry MeCN (5 ml) under a 
N2 atmosphere.  TDA-1 (10 μl, 4 mol%) was added and the mixture was stirred for 5 min at 
rt.  6-Chloro-7-iodo-7-deazapurine (223 mg, 0.800 mmol, 1 eq) was added and the mixture 
was stirred for a further 5 min.  1-Chloro-2-deoxy-3,5,-di-O-p-toluoyl-α-D-ribofuranose (346 
mg, 0.960 mmol, 1.2 eq) was added and the reaction was stirred for 20 min at rt.  The 
crude mixture was absorbed on to silica gel and purified by column chromatography on 
silica gel, eluting with CH2Cl2/EtOAc (20:1) to yield the product as a yellow solid (370 mg, 
0.580 mmol, 73%).  Spectroscopic characterisation was consistent with that previously 
reported.  1H NMR (400 MHz, DMSO-d6) δ 8.64 (s, 1H, C2-H), 8.18 (s, 1H, C6-H), 7.94 (d, J = 
8.2 Hz, 2H, Ar-H), 7.84 (d, J = 8.2 Hz, 2H, Ar-H), 7.35 (d, J = 8.2 Hz, 2H, Ar-H), 7.30 (d, J = 8.2 
Hz, 2H, Ar-H), 6.75 (dd, J = 7.8, 6.5 Hz, 1H, C1′-H), 5.77 – 5.73 (m, 1H, C3′-H), 4.64 (app td, J 
= 8.1, 5.8 Hz, 1H, C4′-H), 4.58 – 4.50 (m, 2H, C5′-H), 3.09 (app dt, J = 14.3, 6.5 Hz, 1H, C2′-
Ha), 2.76 (ddd, J = 14.3, 6.5, 2.6 Hz, 1H, C2′-Hb), 2.39 (s, 3H, CH3), 2.37 (s, 3H, CH3); 
13C NMR 
(101 MHz, DMSO-d6) δ 165.5, 165.2, 151.3, 150.8, 150.6, 144.1, 143.8, 133.3, 129.5, 129.4, 
129.3, 129.3, 126.5, 126.5, 116.8, 83.7, 81.6, 74.7, 64.0, 54.1, 36.2, 21.22, 21.20; ESI HRMS 
[MH]+ 632.0438 (Calcd. For C27H24ClIN3O5 632.0444). 
 
4-Amino-5-iodo-7-(2-deoxy-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 34 
 
 
 
Prepared according to Seela et al.199 
Compound 33 (2.00 g, 3.17 mmol) was suspended in an aqueous ammonia (25%)/dioxane 
mixture (1:1, 160 ml) and stirred in a sealed flask for 48 h at 110 °C.  During this time the 
compound dissolved.  The solvent was then removed in vacuo and the resulting mixture 
dissolved in MeOH/CH2Cl2 and absorbed onto silica gel.  The product was purified by 
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column chromatography on silica gel eluting with CH2Cl2/MeOH (95:5 → 90:10) and 
isolated quantitatively as a white solid.  Spectroscopic characterisation was consistent with 
that previously reported.  1H NMR (400 MHz, DMSO-d6) δ 8.10 (s, 1H, C2-H), 7.66 (s, 1H, C6-
H), 6.67 (br s, 2H, NH2), 6.48 (dd, J = 8.2, 5.9 Hz, 1H, C1′-H), 4.32 (app td, J = 6.1, 2.6 Hz, 1H, 
C3′-H), 3.80 (app td, J = 4.4, 2.6 Hz, 1H, C4′-H), 3.56 (app dt, J = 11.7, 5.0 Hz, 1H, C5′-Ha), 
3.49 (ddd, J = 11.7, 5.7, 4.4 Hz, 1H, C5′-Hb), 2.45 (ddd, partially obscured by CD3SOCD2H, J = 
13.1, 8.2, 5.7 Hz, 1H, C2′-Ha), 2.15 (ddd, J = 13.2, 5.9, 2.6 Hz, 1H, C2′-Hb); 13C NMR (101 
MHz, CDCl3) δ 157.2, 151.9, 149.7, 126.8, 103.1, 87.4, 82.9, 70.9, 62.8, 61.9, 51.8; ESI HRMS 
[MH]+ 377.0096 (Calcd. For C11H14IN4O3 377.0105). 
 
4-Amino-5-(4-bromophenyl)-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 19 
 
 
 
1H NMR (400 MHz, DMSO-d6) δ 8.11 (s, 1H, C2-H), 7.62 (d, J = 8.5 Hz, 2H, Ar-H), 7.55 (s, 1H, 
C6-H), 7.38 (d, J = 8.5 Hz, 2H, Ar-H), 6.20 (br s, 2H, NH2), 6.07 (d, J = 6.4 Hz, 1H, C1′-H), 5.31 
(d, J = 6.4 Hz, 1H, C2′-OH), 5.16 (dd, J = 6.1, 5.1 Hz, 1H, C5′-OH, 5.10 (d, J = 5.0 Hz, 1H, C3′-
OH), 4.41 (app td, J = 6.4, 4.9 Hz, 1H, C2′-H), 4.06 (app q, J = 4.5 Hz, 1H, C3′-H), 3.86 (app q, J 
= 3.8 Hz, 1H, C4′-H), 3.59 (ddd, J = 11.9, 5.1, 3.8 Hz, 1H, C5′-Ha), 3.49 (ddd, J = 11.9, 6.1, 3.8 
Hz, 1H, C5′-Hb); 13C NMR (101 MHz, DMSO-d6) δ 157.4, 151.8, 151.1, 133.7, 131.8, 130.4, 
121.5, 120.0, 115.2, 100.2, 87.0, 85.1, 73.8, 70.6; MS (ESI)  m/z  (%) 423 (96) [81BrMH]+, 421 
(100) [79BrMH]+, 291 (9) [81BrMH-ribose]+, 289 (10) [79BrMH-ribose]+;  ESI HRMS [MH]+ 
421.0497 (Calcd. for C17H18BrN4O4 421.0506). 
 
General Procedure for synthesis of fluorescent analogues from organotrifluoroborates 
4-Amino-5-iodo-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine (49.0 mg, 0.125 mmol, 
1.0 eq), Pd(OAc)2 (0.6 mg, 2 mol%), TPPTS (2.8 mg, 4 mol%), sodium carbonate (66.3 mg, 
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0.625 mmol, 5.0 eq)  and the potassium organotrifluoroborate (0.150 mmol, 1.2 eq)† were 
added to a Schlenk tube under a N2 atmosphere.  Water/acetonitrile (2:1, 3 ml) was added 
and the reaction mixture was stirred at 70 °C for 4 h.  The reaction mixture was then 
neutralised with HCl (1 M), and the volatiles were removed in vacuo.  The crude product 
was absorbed on to silica gel and purified by column chromatography on silica gel, eluting 
with AcOH/MeOH/CH2Cl2 (0.5:2.5:97 v/v).  
 
General Procedure for synthesis of fluorescent analogues from organoboronate esters 
4-Amino-5-iodo-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine or  4-Amino-5-iodo-7-(2-
deoxy-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine (1.0 eq), Pd(OAc)2 (2 mol%), TPPTS (5 
mol%), caesium carbonate (3.0 eq)  and the organoboronate ester (1.2 eq) were added to a 
Schlenk tube under a N2 atmosphere.  Water/acetonitrile (2:1, v/v, 0.1 mM) was added and 
the reaction mixture was stirred at 100 °C for 3 h.  The crude product was absorbed on to 
silica gel and purified by column chromatography, eluting with MeOH/CH2Cl2 (0:100 → 1:9 
v/v)  Small-scale reactions (0.050 mmol) were isolated by preparative TLC, eluting with 9:1 
CH2Cl2/MeOH. 
 
4-Amino-5-(4-[phenylethynyl]phenyl)-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 
20a 
 
N
NN
NH2
O
OHOH
HO
 
 
From organotrifluoroborate:  The title compound was synthesised from 7-iodo-7-
deazaadenosine (49.0 mg, 0.125 mmol) and potassium 4-
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(phenylethynyl)phenyltrifluoroborate (0.15 mmol, 1.2 eq).  The product was isolated as a 
white solid (31.0 mg, 0.070 mmol, 56%).  
From organoboronate ester:  The title compound was synthesised from 7-iodo-7-
deazaadenosine (196 mg, 0.500 mmol) and 4-(phenylethynyl)phenylboronic acid neopentyl 
glycol ester (174 mg, 0.600 mmol, 1.2 eq).  The product was isolated as a white solid (164 
mg, 0.371 mmol, 74%). 
1H NMR (400 MHz, DMSO-d6) δ 8.19 (br s, 1H, C2-H), 7.66 (d, J = 9.4 Hz, 3H, Ar-H), 7.61 – 
7.50 (m, 4H, Ar-H), 7.46 – 7.42 (m, 3H, Ar-H), 6.28 (br s, 2H, NH2), 6.13 (d, J = 6.2 Hz, 1H, 
C1′-H), 5.35 (d, J = 6.2 Hz, 1H, C2′-OH), 5.20 (t, J = 5.6 Hz, 1H, C5′-OH), 5.14 (d, J = 4.8 Hz, 1H, 
C3′-OH), 4.46 (app q, J = 6.2 Hz, 1H, C2′-H), 4.11 (m, 1H, C3′-H), 3.91 (app q, J = 3.9 Hz, 1H, 
C4′-H), 3.64 (ddd, J = 11.8, 5.6, 3.9 Hz, 1H, C5′-Ha), 3.53 (ddd, J = 11.8, 5.6, 3.9 Hz, 1H, C5′-
Hb); ESI HRMS [MH]+ 443.1706 (Calcd. for C25H23N4O4 443.1714). 
1H NMR (400 MHz, CD3OD) δ 8.16 (s, 1H, C2-H), 7.63 (d, J = 8.4 Hz, 2H, C), 7.56 – 7.52 (m, 
3H), 7.50 (s, 1H), 7.41 – 7.35 (m, 3H), 6.11 (d, J = 6.4 Hz, 1H, C1′-H), 4.67 (dd, J = 6.4, 5.3 Hz, 
1H, C2′-H), 4.31 (dd, J = 5.3, 2.8 Hz, 1H, C3′-H), 4.13 (q, J = 2.8 Hz, 1H, C4′-H), 3.87 (dd, J = 
12.4, 2.8 Hz, 1H, C5′-Ha), 3.75 (dd, J = 12.4, 2.8 Hz, 1H, C5′-Hb);  13C NMR (101 MHz, CD3OD) 
δ 159.0, 152.4, 151.57, 135.8, 133.2, 132.5, 129.9, 129.59, 129.55, 124.5, 123.8, 123.5, 
118.04, 102.9, 91.03, 90.99, 89.9, 87.3, 75.6, 72.5, 63.4. 
 
4-Amino-5-(4-[{4-Methoxyphenyl}ethynyl]phenyl)-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-
d]pyrimidine 20b 
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From organotrifluoroborate:  The title compound was synthesised from 7-iodo-7-
deazaadenosine (49.0 mg, 0.125 mmol) and potassium 4-[(4-
methoxyphenyl)ethynyl]phenyltrifluoroborate (0.15 mmol, 1.2 eq).  The product was 
obtained as a white solid (42.5 mg, 0.0900 mmol, 72 %).   
From organoboronate ester:  The title compound was synthesised from 7-iodo-7-
deazaadenosine (19.6 mg, 0.0500 mmol) and 4-([4-methoxyphenyl]ethynyl)phenylboronic 
acid neopentyl glycol ester (19.2 mg, 0.600 mmol, 1.2 eq).  The product was obtained as a 
white solid (23.5 mg, 0.050 mmol, quant.).   
1H NMR (400 MHz, CD3OD) δ 8.16 (s, 1H, C2-H), 7.60 (d, J = 8.5 Hz, 2H, Ar-H), 7.52 (d, J = 8.5 
Hz, 2H, Ar-H), 7.49 (s, 1H, C6-H), 7.46 (d, J = 9.0 Hz, 2H, Ar-H), 6.95 (d, J = 9.0 Hz, 2H, Ar-H), 
6.11 (d, J = 6.3 Hz, 1H, C1′-H), 4.67 (dd, J = 6.3, 5.3 Hz, 1H, C2′-H), 4.30 (dd, J = 5.3, 2.9 Hz, 
1H, C3′-H), 4.13 (app q, J = 2.9 Hz, 1H, C4′-H), 3.87 (dd, J = 12.3, 2.9 Hz, 1H, C5′-Ha), 3.83 (s, 
3H, OCH3), 3.75 (dd, J = 12.3, 2.9 Hz, 1H, C5′-Hb); ESI HRMS [MH]
+ 473.1806 (Calcd. for 
C26H25N4O5 473.1819). 
1H NMR (500 MHz, DMSO-d6) δ 8.18 (s, 1H, C2-H), 7.66-7.62 (m, 3H, Ar-H), 7-55-7.47 (m, 
4H, Ar-H), 7.02 (d, J = 8.9 Hz, 2H, Ar-H), 6.24 (br s, 1H, NH2), 6.15 (d, J = 6.2 Hz, 1H, C1′-H), 
5.33 (d, J = 6.3 Hz, 1H, C2′-OH), 5.18 (app t, J = 5.6 Hz, 1H, C5′-OH), 5.12 (d, J = 4.9 Hz, 1H, 
C3′-OH), 4.48 (app dd, J = 11.6, 6.3 Hz, 1H, C2′-H), 4.13 (app dd, J = 8.2, 4.9 Hz, 1H, C3′-H), 
3.93 (app q, J = 3.7 Hz, 1H, C4′-H), 3.66 (app dt, J = 12.1, 4.0 Hz, 1H, C5′-Ha), 3.60-3.53 (m, 
1H, C5′-Hb);  13C NMR (126 MHz, DMSO-d6) δ 159.5, 157.3, 151.8, 151.1, 134.4, 132.9, 
131.7, 128.5, 121.6, 120.8, 115.8, 114.4, 114.2, 90.0, 88.0, 87.0, 85.1, 73.8, 70.6, 61.6, 55.3. 
 
4-Amino-5-(4-[{4-Methylsulfanylphenyl}ethynyl]phenyl)-7-(β-D-ribofuranosyl)-7H-
pyrrolo[2,3-d]pyrimidine 20c 
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From organotrifluoroborate:  The title compound was synthesised from 7-iodo-7-
deazaadenosine (49.0 mg, 0.125 mmol) and potassium 4-[(4-
methylsulfanylphenyl)ethynyl]phenyltrifluoroborate (0.15 mmol, 1.2 eq).  The product was 
obtained as a cream solid (42.6 mg, 0.0870 mmol, 70%).  
From organoboronate ester:  The title compound was synthesised from 7-iodo-7-
deazaadenosine (19.6 mg, 0.0500 mmol) and 4-([4-
methylsulfanylphenyl]ethynyl)phenylboronic acid neopentyl glycol ester (20.2 mg, 0.600 
mmol, 1.2 eq).  The product was obtained as a white solid (17.3 mg, 0.0350 mmol, 71%).   
1H NMR (400 MHz, DMSO-d6) δ 8.16 (s, 1H, C2-H), 7.62 (d, J = 8.1 Hz, 2H, Ar-H), 7.53 (d, J = 
8.1 Hz, 2H, Ar-H), 7.49 (s, 1H, C6-H), 7.45 (d, J = 8.3 Hz, 2H, Ar-H), 7.27 (d, J = 8.3 Hz, 2H, Ar-
H), 6.11 (d, J = 6.3 Hz, 1H, C1′-H), 4.67 (dd, J = 6.2, 5.3 Hz, 1H, C2′-H), 4.31 (dd, J = 5.3, 3.0 
Hz, 1H, C3′-H), 4.13 (app q, J = 3.0 Hz, 1H, C4′-H), 3.87 (dd, J = 12.4, 2.6 Hz, 1H, C5′-Ha), 3.75 
(dd, J = 12.4, 2.9 Hz, 1H, C5′-Hb); 13C NMR (126 MHz, DMSO-d6, selected peaks from HSQC) 
δ 152.2, 132.2, 122.1, 128.9, 132.2, 126.1, 87.5, 73.9, 71.1, 85.7, 62.1, 62.2; ESI HRMS 
[MH]+ 489.1587 (Calcd. For C26H25N4O4S 489.1581). 
 
4-Amino-5-(4-[{3-thienyl}ethynyl]phenyl)-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-
d]pyrimidine 20d 
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From organoboronate ester:  The title compound was synthesised from 7-iodo-7-
deazaadenosine (19.6 mg, 0.050 mmol) and 4-(3-thienylethynyl)phenylboronic acid 
neopentyl glycol ester (17.7 mg, 0.600 mmol, 1.2 eq).  The product was obtained as a white 
solid (17.3 mg, 0.0385 mmol, 77%).  1H NMR (400 MHz, CD3OD) δ 8.15 (s, 1H, C2-H), 7.65 
(dd, J = 3.0, 1.2 Hz, 1H, Ar-H), 7.61 (d, J = 8.5 Hz, 2H, Ar-H), 7.53 (d, J = 8.5 Hz, 2H, Ar-H), 
7.49 (s, 1H, C6-H), 7.46 (dd, J = 5.0, 3.0 Hz, 1H, Ar-H), 7.21 (dd, J = 5.0, 1.2 Hz, 1H, Ar-H), 
6.11 (d, J = 6.3 Hz, 1H, C1′-H), 4.67 (dd, J = 6.3, 5.4 Hz, C2′-H), 4.31 (dd, J = 5.4, 2.9 Hz, 1H, 
C3′-H), 4.13 (app dd, J = 5.5, 2.9 Hz, 1H, C4′-H), 3.87 (dd, J = 12.4 2.7 Hz, 1H, C5′-Ha), 3.75 
(dd, J = 12.4, 2.9 Hz, 1H, C5′-Hb); 13C NMR (126 MHz, CD3OD) 159.0, 152.4, 151.6, 135.6, 
133.1, 130.7, 129.93, 129.90, 126.9, 123.7, 123.6, 123.5, 118.1, 91.0, 89.2, 87.3, 86.3, 75.6, 
72.5, 63.4, 49.4. ESI HRMS [MH]+ 449.1264 (Calcd. for C23H21N4O4S 449.1278). 
 
4-Amino-5-(4-[{4-trifluoromethylphenyl}ethynyl]phenyl)-7-(β-D-ribofuranosyl)-7H-
pyrrolo[2,3-d]pyrimidine 20e 
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From organoboronate ester:  The title compound was synthesised from 7-iodo-7-
deazaadenosine (19.6 mg, 0.050 mmol) and 4-([4-
trifluoromethylphenyl]ethynyl)phenylboronic acid neopentyl glycol ester (21.4 mg, 0.600 
mmol, 1.2 eq).  The product was obtained as a white solid (17.4 mg, 0.0341 mmol, 68%).  1H 
NMR (400 MHz, CD3OD) δ 8.14 (s, 1H, C2-H), 7.70 (d, J = 8.8 Hz, 2H, Ar-H), 7.68 (d, J = 8.8 
Hz, 2H, Ar-H), 7.65 (d, J = 8.5 Hz, 2H, Ar-H), 7.55 (d, J = 8.5 Hz, 2H, Ar-H), 7.50 (s, 1H, C6-H), 
6.09 (d, J = 6.3 Hz, 1H, C1′-H), 4.64 (dd, J = 6.3, 5.3 Hz, 1H, C2′-H), 4.28 (dd, J = 5.3, 2.9 Hz, 
1H, C3′-H), 4.10 (app q, J = 2.8 Hz, 1H, C4′-H), 3.84 (dd, J = 12.4, 2.7 Hz, 1H, C5′-Ha), 3.73 
(dd, J = 12.4, 2.9 Hz, 1H, C5′-Hb); 13C NMR (101 MHz, CD3OD) 158.94, 152.37, 151.58, 
136.43, 133.43, 133.06, 130.87, 129.9 (q, J = 260 Hz, central two peaks of quartet 
observed), 129.97, 126.83, 126.5 (q, J = 3.8 Hz), 123.93, 122.63, 117.92, 92.50, 90.99, 89.41, 
87.28, 75.62, 72.50, 69.57, 63.42; ESI HRMS [MH]+ 511.1588 (Calcd. for C26H22F3N4O4 
511.1588). 
 
4-Amino-5-(4-[phenylethynyl]phenyl)-7-(2-deoxy-β-D-ribofuranosyl)-7H-pyrrolo[2,3-
d]pyrimidine 35 
 
 
 
From organoboronate ester:  The title compound was synthesised from 7-iodo-7-deaza-2′-
deoxyadenosine (188 mg, 0.500 mmol) and 4-(phenylethynyl)phenylboronic acid neopentyl 
glycol ester (174 mg, 0.600 mmol, 1.2 eq).  The product was isolated as a white solid (213 
mg, 0.500 mmol, quant.).  1H NMR (400 MHz, CD3OD) δ 8.16 (s, 1H, C2-H), 7.64 (d, J = 8.5 
Hz, 2H, Ar-H), 7.57 – 7.48 (m, 5H, Ar-H), 7.44 – 7.34 (m, 3H, Ar-H), 6.60 (dd, J = 8.2, 6.0 Hz, 
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1H, C1′-H), 4.55 (app dt, J = 5.5, 2.7 Hz, 1H, C3′-H), 4.03 (app q, J = 3.3 Hz 1H, C4′-H), 3.82 
(dd, J = 12.1, 3.3 Hz, 1H, C5′-Ha), 3.74 (dd, J = 12.1, 3.6 Hz, 1H, C5′-Hb), 2.72 (ddd, J = 13.4, 
8.2, 6.0 Hz, 1H, C2′-Ha), 2.36 (ddd, J = 13.4, 6.0, 2.7 Hz, 1H, C2′-Hb); 13C NMR (126 MHz, 
CD3OD) δ 158.8, 152.2, 151.3, 135.8, 133.2, 132.5, 129.9, 129.58, 129.55, 124.5, 123.5, 
123.1, 118.2, 102.5, 91.0, 89.9, 89.1, 86.5, 73.0, 63.7, 41.5; ESI HRMS [MH]+ 427.1746 
(Calcd. For C25H23N4O3 427.1765). 
 
4-{[(Dimethylamino)methylidene]amino}-5-(4-[phenylethynyl]phenyl)-7-(5-O-[{4,4′-di 
methoxytriphenyl}methyl]-(2-deoxy-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 36 
 
 
 
Based on the procedure reported by Seela et al.128 
Compound 35 (171 mg, 0.400 mmol) was stirred with DMF dimethylacetal (640 μl) in 
MeOH (5.7 ml) under a N2 atmosphere for 2 h at 40 °C.  The volatiles were then removed 
under vacuum.  Pyridine (2 ml) was then added, followed by DMTrCl (203 mg, 0.600 mmol, 
1.5 eq).  The reaction as then stirred at 50 °C for 1 h.  The reaction was then quenched with 
5% aq. NaHCO3 (7 ml) and extracted with CH2Cl2 (3 x 20 ml).  The organic layers were dried 
over Na2SO4 and the volatiles removed in vacuo.  The crude product was purified by column 
chromatography on silica gel, eluting with MeOH/Et3N/CH2Cl2 (0:0.5:99.5 → 5:0.5:94.5) to 
give the product as a white solid (229.2 mg, 73%).  1H NMR (500 MHz, CD2Cl2) δ 8.80 (s, 1H, 
C2-H), 8.45 (s, 1H, C6-H), 7.69 (d, J = 8.4 Hz, 2H, Ar-H), 7.60 (dd, J = 7.8, 1.6 Hz, 2H, Ar-H), 
7.50 – 7.38 (m, 8H, Ar-H), 7.35 (d, J = 8.9 Hz, 4H, Ar-H), 7.32 – 7.22 (m, 3H, Ar-H), 6.85 (app 
t, J = 6.9 Hz, 1H, C1′-H), 6.83 – 6.78 (m, 4H, Ar-H), 4.74 (app dt, J = 6.4, 3.3 Hz, 1H, C3′-H), 
4.14 (app q, J = 3.9 Hz, 1H, C4′-H), 3.782 (s, 3H, OCH3), 3.778 (s, 3H, OCH3), 3.44 (dd, J = 
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10.2, 4.2 Hz, 1H, C5′-Ha), 3.34 (dd, J = 10.2, 4.2 Hz, 1H, C5′-Hb), 3.16 (s, 3H, NCH3), 3.06 (s, 
3H, NCH3), 2.76 (ddd, J = 13.5, 7.5, 6.2 Hz, 1H, C2′-Ha), 2.53 (ddd, J = 13.5, 6.3, 3.5 Hz, 1H, 
C2′-Hb), 2.30 (br s, 1H); 13C NMR (126 MHz, CD2Cl2) δ 161.6, 159.0, 156.7, 153.3, 152.0, 
145.2, 136.2, 136.0, 135.4, 131.8, 130.9, 130.4, 130.2, 128.8, 128.6, 128.5, 128.3, 127.2, 
123.8, 121.7, 120.8, 118.7, 113.47, 113.46, 109.3, 90.2, 89.5, 86.9, 85.9, 83.4, 73.3, 64.5, 
55.6, 41.2, 41.1, 35.4; ESI HRMS [MH]+ 783.3420 (Calcd. for C49H45N5O5 783.3415). 
 
4-{[(Dimethylamino)methylidene]amino}-5-(4-[phenylethynyl]phenyl)-7-(3-O-[2-
cyanoethyl diisopropylphosphoramidite]-5-O-[{4,4′-dimethoxytriphenyl}methyl]-(2-
deoxy-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine
128
 37 
 
 
 
Based on the procedure reported by Seela et al.128 
Compound 36 (220 mg, 0.281 mmol) was dissolved in THF (1.2 ml).  Freshly distilled iPr2EtN 
(166 μl, 0.927 mmol, 3.3 eq) was added, followed by 2-cyanoethyl-N,N-
diisopropylchlorophosphoramidite (78 μl, 0.35 mmol, 1.25 eq).  The reaction was stirred at 
r.t. for 2 h.  The mixture was then filtered, diluted with EtOAc (15 ml) and washed with cold 
aq. Na2CO3 (1 M, 2 x 5 ml) and water (5 ml).  The organic layer was dried over Na2SO4 and 
the volatiles removed in vacuo.  The crude product was purified by column 
chromatography on silica gel, eluting with acetone/Pet Ether 40-60 (3:7) containing 0.5% 
Et3N.  The product was isolated as a low melting solid which contained an unknown 
impurity (impurity present in 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite starting 
material) Yield = 148 mg.  Selected NMR peaks given below.  1H NMR (400 MHz, CD2Cl2) δ  
8.76 (s), 8.41 (s), 8.40 (s), 7.71 (s), 7.64 (d, J = 8.2 Hz, Ar-H), 7.59-7.50 (m, Ar-H), 7.48-7.32 
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(m, Ar-H), 7.35-7.25 (m, Ar-H), 7.27-7.17 (m, Ar-H), 6.80 (t, J = 7.0 Hz, C1′-H), 6.79-6.69 (m, 
Ar-H), 6.11 (s), 4.91-4.67 (m), 4.29-4.19 (m), 3.73 (s), 3.73 (s), 3.72 (s), 3.39-3.28 (m), 3.11 
(s, NCH3), 3.02 (s, NCH3), 2.64 (t, J = 6.3 Hz, C2′-Ha), 2.49 (t, J = 6.3 Hz, C2′-Hb), 1.24-1.15 
(m); 13C NMR (126 MHz, CD2Cl2) δ 156.3, 151.9, 129.8, 130.4, 130.3, 130.0, 40.8, 35.1; 
31P 
NMR (212 MHz, CD2Cl2) δ 149.06, 149.05; ESI HRMS [MH]
+ 984.4541 (Calcd. for C58H63N7O6P  
984.4572). 
 
4-Amino-5-(4-[phenylethynyl]phenyl)-7-(5-triphosphate-β-D-ribofuranosyl)-7H-
pyrrolo[2,3-d]pyrimidine 43 
 
 
 
 
Preparation of tri-n-butylammonium pyrophosphate 
Tetrasodium diphosphate was treated with Dowex 50WX8 (H+ form) to give tri-n-
butylammonium pyrophosphate [Can. J. Chem. (1964) 42:599-604].  Tetrasodium 
diphosphate decahydrate (2.23 g, 5 mmol) was dissolved in water (50 ml) with sonication 
and applied to the Dowex column.  The column was washed with water and the eluate was 
dropped directly into a cooled (ice water) and stirred solution of nBu3N (2.38 ml, 10 mmol) 
in ethanol (20 ml).  The column was washed until the pH of the eluate increased to 5.0 (ca. 
70 ml of water).  The ethanol/water solution was evaporated to dryness.  The tri-n-
butylammonium pyrophosphate product was co-evaporated with 3x50 ml of methanol to 
remove water (< 40˚C to prevent decomposition).  The product was then dried under high 
vacuum overnight.  The residue was dissolved in anhydrous DMF (10 ml) and used within 
24 h. 
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Ludwig conditions
200
 
The nucleoside (88.4 mg, 0.2 mmol) was dissolved in dry trimethylphosphate (1 ml) under a 
N2 atmosphere and cooled to 0 °C.  Phosphoryl chloride (55.9 μL, 0.6 mmol, 3 eq) was 
added and the mixture stirred for 3 h at 0 °C.  Tri-n-butylammonium pyrophosphate in 
anhydrous DMF (2 mmol, 3 ml) was then added, followed by nBu3N (0.6 ml).  After stirring 
for 30 min, the reaction was quenched by addition of aqueous triethylammonium hydrogen 
carbonate buffer (20 ml, pH 7.5, 1 M).  After stirring at rt for 30 min, the solvent was 
removed in vacuo (< 40˚C) to yield an off-white solid. 
The product was resuspended in ca. 10 ml TEAB buffer (pH 7.5, 0.05 M) and filtered twice 
through 0.45 µm pore syringe filter cartridges.  The product was purified using fast protein 
liquid chromatography (FPLC) on a DEAE-Sephadex (A25-Chloride form, 20 ml) column and 
TEAB buffer (0.05 to 1.2 M linear gradient, pH 7.5).  The product was loaded onto the 
column through the pump, and washed through with 0.05 M TEAB buffer until the 
absorbance of the eluent stopped changing.   
The relevant fractions are pooled and concentrated under reduced pressure to ca. 10 ml. 
Methanol (50 ml) was added and the compound concentrated to ca. 10 ml.  This procedure 
was repeated three times.  The solution was then cooled to 0 °C and evaporated to dryness 
under high vacuum. 
The compound was then redissolved in a minimum amount of methanol, and a saturated 
solution of sodium iodide in acetone was added dropwise (0 °C, kept in dark), leading to 
precipitation of a solid.  The solid was filtered (sintered glass filter) and washed with 
acetone (10 ml), Et2O (10 ml) and allowed to air dry (alternatively, the solid could be 
isolated by centrifugation).  The solid was washed through the filter with water (10 ml) and 
dried overnight under high vacuum.  Mass spectrometry (ESI-) of the crude product found 
the mass ion corresponding to the triphosphate product, as well as diphoshpate and 
monophosphate products.  Attempts to isolate the product by semi-preparative RP-HPLC 
failed. 
 
Huang conditions
140
 
Salicyl chlorophosphite (40.5 mg, 0.2 mmol, 2 eq) dissolved in dry DMF (0.3 ml).  nBu3N 
(0.38 ml) was added to tri-n-butylammonium pyrophosphate in DMF (0.3 ml) in a separate 
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flask under a N2 atmosphere.  The pyrophosphate mixture was then added to the salicyl 
chlorophosphite and the mixture was stirred at rt for 30 min, and then cooled to 0 °C.  The 
mixture was then added to a Schlenk tube containing the nucleoside (44.2 mg, 0.1 mmol).  
The nucleoside phosphate mixture was stirred at 0 °C for 5 h and then allowed to reach rt.  
A solution of iodine (1.25 ml, 3% w/v in 9:1 pyridine/water) was added dropwise to the 
reaction mixture (until the reaction maintains the iodine colour).  The reaction was then 
stirred for 15 min.  Water (2.5 ml) was then added to hydrolyse the product, and the 
mixture stirred for 1.5 h.  The reaction mixture was then transferred to a 50 ml falcon tube.  
NaCl solution (0.7 ml, 3 M) was then added, followed by ice-cold EtOH (19 ml) to 
precipitate the product.  The precipitate was isolated by centrifugation (5000 g, 10 min, 5 
°C).  The supernatant was decanted and the precipitate allowed to air dry.  A mixture of 
products was identified by HPLC, but could not be separated.  31P NMR suggested the 
presence of a mixture of triphosphate products. 
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UV-Vis spectroscopy 
Extinction coefficients for nucleosides were measured in solvents as described by taking 
spectra over five concentrations (between 1 x 10-4 M and 1 x 10-6 M).  Solutions of 
nucleosides for UV-Vis spectra in DCM, EtOAc and water were made from a 2.5 x 10-3 M 
stock in DMSO.  UV-Vis spectra of oligonucleotides were measured in EB buffer at ca. 5 μM.  
All measurements were made in triplicate. 
 
Fluorescence quantum yields 
Fluorescence quantum yields were measured using an integrating sphere in a Horiba 
Fluoromax 3 fluorimeter using solutions with an absorbance of ca. 0.1 (for the nucleosides), 
or a molecular concentration of 2.5 μM (for the oligonucleotides), according to the 
manufacturer’s instructions.  The oligonucleotide quantum yields were measured in a 
buffered solution at pH 7.0 (50 mM sodium phosphate, 0.1 M NaCl). 
 
Melting temperatures 
The oligonucleotide and the complementary strand were dissolved in a buffered solution at 
pH 7.0 (50 mM sodium phosphate, 0.1 M NaCl) to give 850 μl of a solution containing the 
duplex (2.5 μM).  The solutions were then degassed for 10 min with stirring, and layered 
with 150 μl of mineral oil.  Absorbance vs temperature curves were measured at 260 nm 
ramping from 20 °C to 90 °C and then from 90 °C to 20 °C, at 1 °C/min with stirring at ca. 
800 rpm.  The raw data was differentiated over 6-point steps, and the first derivatives fitted 
to Gaussian curves using OriginLab to find the melting temperatures.  All measurements 
were repeated in triplicate. 
 
Fluorescence titration measurements 
850 μL of a solution of the oligonucleotide (2.5 μM) in pH 7.0 buffer (50 mM sodium 
phosphate, 0.1 M NaCl) was prepared.  The excitation spectrum (200-600 nm, emission 
measured at 450 nm) was measured to find the excitation maximum.  The emission 
spectrum was then measured (365-600 nm, λex = 322 nm, slit width = 1 nm) at 20 °C.  
Several additions of the complementary strand were then made, with thorough mixing of 
the sample after each addition (typically each addition was 0.25 eq with respect to the 
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oligonucleotide, to give a final ratio of 1:2 oligo:complementary strand).  The emission 
spectrum was remeasured (as above) after each addition. 
 
Fluorescence quenching experiments 
Fluorescence quenching experiments were carried out using 2.5 μM solutions of the 
oligonucleotides or duplexes in pH 7.0 buffer (as above) at 20 °C or 60 °C.  Acrylamide 
(Acrylagel, gas stabilised 30% w/v aqueous solution) was added portion-wise to give 
solutions with the specified acrylamide concentrations.  Fluorescence emission spectra 
were measured as above after each addition. 
 
Effect of pH on fluorescence 
The pH dependence of fluorescence spectra was investigated using 2.5 μM solutions of the 
oligonucleotides or duplexes in buffered solution at 20 °C.  Sodium phosphate buffer was 
used for pH 6, 7, 8 and 9.  Sodium citrate buffer was used for pH 3, 4, and 5.  Sodium borate 
buffer was used for pH 10 and 11.  pKa values were determined by fitting the data to a 
sigmoidal Boltzmann function using OriginLab according to the equation: 
B 
 	
 − 
1  %CDCE/GC
  
Where the pKa is equal to (A1+A2)/2. 
 
Circular dichroism 
Circular dichroism spectra were measured at 200 μM (base concentration, 7.69 μM duplex 
concentration) in pH 7.0 buffer (as above) in a cuvette with a path length of 0.1 cm.  The 
spectra were measured over 200-320 nm, scanning at 50 nm/min, at 10 °C and 75 °C. 
 
Fluorescence Lifetime Measurements
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Samples for fluorescence lifetime measurement were prepared so as to have an 
absorbance of ca. 0.1 at the absorbance maximum.  The fluorescence lifetimes were 
measured by time-correlated single photon counting (TCSPC). The excitation source used 
was the 3rd harmonic (300 nm) of a mode-locked (900 nm), cavity dumped (APE Pulse 
switch) Ti:sapphire laser (Coherent MIRA 900), pumped by the 2nd harmonic (532 nm) of a 
 174 
 
CW Nd:YAG laser (Coherent Verdi V6). The pulse characteristics were as follows: a temporal 
full width at half maximum (FWHM) of ~150 fs, average power 0.3 mW at a repetition rate 
of 4 MHz. The fluorescence emission was collected at right angles to the excitation source, 
with the emission wavelength selected by a monochromator (Jobin Yvon TRIAX 190) and 
detected by a cooled photomultiplier tube module (IBH TBX-04). The detector was linked to 
a time-to-amplitude converter (Ortec 567) and a pulse height analyser, PHA, (E.G. & G. 
Trump Card) controlled by the software  Maestro (ver 5.10). Fluorescence decays were 
recorded to a minimum of 10,000 counts in the peak channel of the PHA with a record 
length of 1000 channels. The band pass of the monochromator was adjusted to give a 
signal count rate of 5-20 KHz. The instrument response function (IRF) was measured using a 
dilute LUDOX® colloidal silica suspension as the scattering sample, giving an IRF of ~200 ps 
FWHM. Iterative reconvolution of the IRF with one or two decay functions and non-linear 
least-squares analysis were used to analyse the data in Microsoft Excel using the solver 
function. The quality of the fit was judged by the calculated value of the reduced χ2 and 
Durbin-Watson parameters and visual inspection of both the residual and the 
autocorrelated residuals.  
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General procedure for direct arylation of 2′-deoxyadenosine at 60 °C 
2′-Deoxyadenosine (251 mg, 1.0 mmol, 1.0 eq), CuI (571 mg, 3.0 mmol, 3 eq), caesium 
carbonate (815 mg, 2.5 mmol, 2.5 eq) and the palladium source (0.7-5 mol%) were added 
to a Schlenk tube under a N2 atmosphere.  DMF (5.3 ml) and the aryl iodide (2.0 mmol, 2.0 
eq) were added and the reaction was stirred at 60 °C for either 24 or 48 h.  The reaction 
was then cooled to room temperature, and HCl (5.3 ml, 1 M) was added to acidify the 
crude mixture.  The pH was tested, and NaOH (1 M) was added until the pH reached 6.5.  
The reaction mixture was then extracted with EtOAc/iPrOH (5 x 25 ml, 9:1 v/v), dried over 
MgSO4 and the solvent removed in vacuo.  The crude product was redissolved in 
MeOH/CH2Cl2 (1:1 v/v) and absorbed onto silica.  The product was then purified by column 
chromatography on silica gel, eluting with MeOH/CH2Cl2 (2:98 → 1:9 v/v).  The solvent was 
removed in vacuo to yield the pure product.  Characterisation as previously reported.86 
 
Pd2(dba-4-OMe,4′-CF3)3 
NaCl (133 mg, 2.27 mmol, 2.0 eq) was added to a solution of PdCl2 (200 mg, 1.13 mmol) in 
methanol (10 ml) and stirred at room temperature under an inert atmosphere for 24 h.  
The solution was then filtered through a plug of cotton wool.  The solution was warmed to 
60 °C and dba-4-OMe,4′-CF3 (1.16 g, 3.50 mmol, 3.1 eq) was added.  The warm mixture was 
stirred vigorously, and methanol added until the ligand was fully dissolved (ca. 60 ml).  
Sodium acetate (556 mg, 6.78 mmol, 6.0 eq) was then added to the solution.  The reaction 
mixture was removed from the heat and allowed to cool to ambient temperature (with no 
external cooling), and stirred for 2 h until a dark red/brown precipitate was formed.  The 
precipitate was filtered and washed with methanol (2 x 5 ml), water (2 x 2 ml), and cold 
acetone (2 x 0.5 ml).  The product was dried by suction to give the complex as a dark 
red/brown solid (848 mg, 97 %).  Mp 163-168 °C; Anal. calcd. for C57H45F9O6Pd2: C 56.59, H 
3.75; found: C, 56.48; H, 3.67. 
 
Pd(PVP) nanoparticles (ca. 2 nm)
  
Prepared according to Ellis et al.184 
PdCl2 (85.1 mg, 0.48 mmol) was stirred with HCl (aq., 0.20 M, 4.8 ml) in water (235 ml) and 
heated slightly until the PdCl2 dissolved (indicating formation of H2[PdCl4], 2.0 mM 
solution).  Water (224 ml) and EtOH (336 ml) were added, followed by PVP (Mw = 29000, 
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1.067 g).  The reaction mixture was heated to reflux for 3 h with vigorous stirring.  During 
this time the reaction mixture formed a dark brown solution.  The reaction mixture was 
allowed to cool to room temperature and the solvents removed in vacuo.  The 
nanoparticles were dried overnight under high vacuum, and then ground to a fine powder.  
The particles were characterised by TEM. 
 
Preparation of samples for TEM 
The direct arylation reaction was carried out as described above.  After 1.5 h, a 1 ml aliquot 
was removed and PVP (Mw = 29,000; 208 mg, 20 monomer equivalents with respect to Pd) 
was added and the mixture was stirred for 30 min.  The volatiles were then removed in 
vacuo.  The solid samples were suspended in ethanol and dropped onto a gold grid.  The 
nanoparticles were characterised using a FEI Tecnai 12 Biotwin High Contrast Electron 
Microscope operated at 120 keV.  The nanoparticles were measured using the PSA macro 
for ImageJ. 
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Appendix I – UV-Vis and Fluorescence Spectra 
4-Amino-5-phenylethynyl-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 16 
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4-Amino-5-[(1-naphthyl)ethynyl]-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 17 
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4-Amino-5-phenyl-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 18 
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4-Amino-5-(4-[phenylethynyl]phenyl)-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 
20a 
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4-Amino-5-(4-[{4-Methoxyphenyl}ethynyl]phenyl)-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-
d]pyrimidine 20b 
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4-Amino-5-(4-[{4-Methylsulfanylphenyl}ethynyl]phenyl)-7-(β-D-ribofuranosyl)-7H-
pyrrolo[2,3-d]pyrimidine 20c 
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4-Amino-5-(4-[{3-thienyl}ethynyl]phenyl)-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-
d]pyrimidine 20d 
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4-Amino-5-(4-[{4-trifluoromethylphenyl}ethynyl]phenyl)-7-(β-D-ribofuranosyl)-7H-
pyrrolo[2,3-d]pyrimidine 20e 
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Fluorescence Lifetime Measurements 
Compound 
Emission Wavelength 
/nm 
Fluorescence lifetime 
/ns 
Durbin-Watson 
parameter 
16 350 4.1 (87%), 0.5 (13%) 1.73 
17 430 1.5 (60%), 0.5 (40%) 1.74 
18 360 2.0 (37%), 0.2 (63%) 1.12 
20a 430 2.2 (92%), 0.5 (8%) 1.83 
20b 405 1.6 (90%), 0.5 (10%) 1.92 
20c 430 2.0 (92%), 0.5 (8%) 1.86 
20d 405 1.5 (88%), 0.5 (12%) 1.82 
20e 490 2.1 (87%), 0.8 (12%) 1.82 
35 430 2.3 (88%), 0.6 (12%) 1.92 
35 (water) 430 0.4 (62%), 0.9 (38%) 1.83 
35 (water) 500 0.4 (61%), 1.0 (39%) 1.83 
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Appendix II - Melting curves 
Melting curves are shown as the change in UV absorbance at 260 nm against temperature 
in °C.  The differentiated and fitted data is shown below the corresponding melting curves, 
where A (vertical axis) is the derivative and B (horizontal axis) is the temperature in °C. 
ODN1-1T 
ODN1-1C 
 187 
 
-0.02
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
0 50 100
A
b
so
rb
a
n
ce
Temperature
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
0.16
050100
A
b
so
rb
a
n
ce
Temperature
0
0.05
0.1
0.15
0.2
0 50 100
A
b
so
rb
a
n
ce
Temperature
0
0.05
0.1
0.15
0.2
050100
A
b
so
rb
a
n
ce
Temperature
ODN1-1A 
ODN1-1G 
 
 188 
 
-0.01
0
0.01
0.02
0.03
0.04
0.05
0.06
0 50 100
A
b
so
rb
a
n
ce
Temperature
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
050100
A
b
so
rb
a
n
ce
Temperature
-0.02
0
0.02
0.04
0.06
0.08
0.1
0 50 100
A
b
so
rb
a
n
ce
Temperature
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
0.16
050100
A
b
so
rb
a
n
ce
Temperature
ODN2-2T 
ODN1-2C 
 
 189 
 
-0.02
0
0.02
0.04
0.06
0.08
0.1
0.12
0 50 100
A
b
so
rb
a
n
ce
Temperature
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
0.16
050100
A
b
so
rb
a
n
ce
Temperature
-0.02
0
0.02
0.04
0.06
0.08
0.1
0.12
0 50 100
A
b
so
rb
a
n
ce
Temperature
0
0.02
0.04
0.06
0.08
0.1
0.12
050100
A
b
so
rb
a
n
ce
Temperature
ODN2-2A 
 
 
 
 
 
 
 
 
 
 
 
 
 
ODN2-2G 
 
 190 
 
-0.02
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
0 50 100
A
b
so
rb
a
n
ce
Temperature
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
050100
A
b
so
rb
a
n
ce
Temperature
0
0.02
0.04
0.06
0.08
0.1
0.12
0 50 100
A
b
so
rb
a
n
ce
Temperature
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
050100
A
b
so
rb
a
n
ce
Temperature
ODN3-3T 
ODN3-3C 
 
 191 
 
0
0.02
0.04
0.06
0.08
0.1
0.12
0 50 100
A
b
so
rb
a
n
ce
Temperature
0
0.02
0.04
0.06
0.08
0.1
0.12
050100
A
b
so
rb
a
n
ce
Temperature
-2.00E-02
0.00E+00
2.00E-02
4.00E-02
6.00E-02
8.00E-02
1.00E-01
1.20E-01
0 50 100
A
b
so
rb
a
n
ce
Temperature
0
0.05
0.1
0.15
050100
A
b
so
rb
a
n
ce
Temperature
ODN3-3A 
ODN3-3G 
 
 
 
 
 
 
 192 
 
-0.02
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
0 50 100
A
b
so
rb
a
n
ce
Temperature
0
0.05
0.1
0.15
0.2
050100
A
b
so
rb
a
n
ce
Temperature
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0 50 100
A
b
so
rb
a
n
ce
Temperature
0
0.02
0.04
0.06
0.08
0.1
050100
A
b
so
rb
a
n
ce
Temperature
ODN4-4T 
ODN4-4C 
 
 
 
 
 
 
 193 
 
-0.02
0
0.02
0.04
0.06
0.08
0.1
0 50 100
A
b
so
rb
a
n
ce
Temperature
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
0.16
050100
A
b
so
rb
a
n
ce
Temperature
-0.01
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0 50 100
A
b
so
rb
a
n
ce
Temperature
0
0.02
0.04
0.06
0.08
0.1
0.12
050100
A
b
so
rb
a
n
ce
Temperature
ODN4-4A 
ODN4-4G 
 
 
 
 
 
 
 194 
 
-0.02
0
0.02
0.04
0.06
0.08
0.1
0.12
0 50 100
A
b
so
rb
a
n
ce
Temperature
0
0.02
0.04
0.06
0.08
0.1
0.12
050100
A
b
so
rb
a
n
ce
Temperature
-0.01
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0 50 100
A
b
so
rb
a
n
ce
Temperature
0
0.05
0.1
0.15
0.2
0.25
050100
A
b
so
rb
a
n
ce
Temperature
ODN5-5T 
ODN5-5C 
 
 195 
 
-0.02
0
0.02
0.04
0.06
0.08
0.1
0 50 100
A
b
so
ra
b
a
n
ce
Temperature
0
0.02
0.04
0.06
0.08
0.1
050100
A
b
so
rb
a
n
ce
Temperature
-0.02
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
0 50 100
A
b
so
rb
a
n
ce
Temperature
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
0.16
050100
A
b
so
rb
a
n
ce
Temperature
ODN5-5A 
ODN5-5G 
 
 
 
 
 
  
 196 
 
Appendix III - Circular Dichroism Spectra 
ODN1-1T 
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ODN3-3T 
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ODN4-4T 
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Appendix IV – Fluorescence spectroscopy of the oligonucleotides 
Stern-Volmer plots 
Single-stranded oligonucleotides 
 
Double-stranded oligonucleotides 
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Fluorescence titrations (representative spectra) 
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Appendix V - pH dependence of oligonucleotides 
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Appendix VI - NMR Spectra 
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Abbreviations 
 
Ac    acetyl 
APCI    atmospheric pressure chemical ionisation 
Ar    aryl or heteroaryl 
ATP    adenosine triphosphate 
 
bp    boiling point 
BSA    (N,O)-bis(trimethylsilyl)acetamide 
Bu    butyl 
Bz    benzoyl 
 
c7A    7-deazaadenosine 
CD    circular dichroism 
COSY    correlation spectroscopy 
 
dba    dibenzylamine acetone 
DCE    dichloroethane 
DEAE    diethylaminoethyl cellulose 
DMA    (N,N)-dimethylacetamide 
DMF    (N,N)-dimethylformamide 
DMF-DMA   (N,N)-dimethylformamide dimethylacetal 
DMSO    dimethylsulfoxide 
DNA    deoxyribonucleic acid 
dATP    2′-deoxyadenosine triphosphate 
dCTP    2′-deoxycytidine triphosphate 
dUTP     2′-deoxyuridine triphosphate 
 
EI    electron impact 
ESI    electrospray ionization 
Et    ethyl 
eq    equivalents 
 
FPLC    fast protein liquid chromatography 
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GTP    guanosine triphosphate 
 
HIV    human immunodeficiency virus 
HMDS    hexamethyldisilazane 
HOMO    highest occupied molecular orbital 
HPLC    high performance liquid chromatography 
HRMS    high resolution mass spectrometry 
HSQC    heteronuclear single quantum coherence 
 
ICT    intramolecular charge transfer 
IMes    1,3-bis(2,4,6-trimethylphenyl)imidazolylidene 
IRF    instrument response function 
 
LUMO    lowest unoccupied molecular orbital 
 
Me    methyl 
mp    melting point 
MS    mass spectrometry 
Mw    weight average molecular mass 
 
NAD+    nicotinamide adenine dinucleotide 
n.d.    not determined 
NIS    (N)-iodosuccinimide 
NOESY    nuclear Overhauser effect spectroscopy 
NMR    nuclear magnetic resonance 
NTP    nucleoside triphosphate 
 
PCR    polymerase chain reaction 
Pet Ether 40-60   petroleum ether, bp 40-60 °C 
PEX    primer extension 
Ph    phenyl 
Piv    pivalyl, trimethylacetyl 
Pr    propyl 
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PVP    poly-(N)-vinyl-2-pyrrolidone 
PXPd    dichlorobis(chlorodi-tert-butylphosphine)palladium 
 
RNA    ribonucleic acid 
RNAP    ribonucleic acid polymerase 
rt    room temperature (ca. 12 – 25 °C) 
 
SNP    single nucleotide polymorphism 
 
TBDMS    tert-butyldimethylsilyl 
TCSPC    time correlated single photon counting 
TEAB    triethylammonium bicarbonate 
Tf    triflyl, trifluoromethylsulfonyl 
TFA    trifluoroacetate 
THF    tetrahydrofuran 
Tm    melting temperature (denaturation temperature) 
TMEDA    (N,N,N′,N′)-tetramethylethylenediamine 
TMS    trimethylsilyl 
Tol    para-toluoyl 
TPPTS    trisodium triphenylphosphine trisulfonate 
TRIP    2,4,6-triisopropylphenyl 
TXTPS trisodium tri(4,6-dimethyl-3-sulfonatophenyl)phosphine  
 
UTP uridine triphosphate 
UV-Vis ultraviolet-visible 
 
XPhos 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl 
 
ε molar absorption (or extinction) coefficient  
λ wavelength 
τ fluorescence lifetime 
Φ    fluorescence quantum yield  
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